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SUMMARY
The aim of the project was to develop an immunoassay 
for glucagon and to use it to investigate the possible role 
of glucagon in 2-deoxy-glucose (2DG) induced hyperglycaemia.
The radioimmunoassay work was directed to producing 
glucagon antiserum of sufficient quality for routine radio­
immunoassay . This was accomplished by immunising 6 rabbits,
one of which produced an antiserum with a final titre of
■ - . ■ ■ ■ 9 ■1/160,000 and an affinity constant [Ka] of 1.9 x 10 L/M
resulting in an assay with a sensitivity of 100 pg/ml.
The possible role of glucagon as mediator in 2DG- 
induced hyperglycaemia was studied under various experimental 
conditions in normal rats, and in normal and glucagon- 
immunised rabbits. Somatostatin which caused a fall in 
blood glucose concentration in control rats did not prevent 
the appearance of 2DG-induced hyperglycaemia. Glucagon- 
immunised rabbits showed only a very small rise in blood 
glucose and plasma insulin when given exogenous glucagon 
(5 pg/kg b.w.) but had a normal hyperglycaemia response to 
2DG, These data suggest that glucagon is not essential for 
the production of 2DG-induced hyperglycaemia.
The effect of a variety of adrenergic blocking agents 
on 2DG-induced hyperglycaemia was studied. At the dose 
levels used, none of the short term adrenergic blockers were 
effective in abolishing the rise in blood glucose, though 2 
of the blockers were effective in abolishing the hyperglycaemia
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effect of exogenous adrenaline. The possibility that 
direct innervation of the liver adrenergic nerves is resp­
onsible for the observed rise in blood glucose has not been 
excluded and indeed seems likely on the evidence available.
Finally, metabolic studies were carried out to 
investigate the fate of injected 2DG, in the rat, using 
tritiated 2DG. Over 50% of the administered dose was 
excreted unchanged in the urine within 24 hours; the rest 
was unaccounted for.
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CHAPTER 1 
GENERAL INTRODUCTION
1.1 GLUCOSE HOMEOSTASIS
The term homeostasis was first suggested by Cannon 
in 1929 (1) to describe the steady states maintained by 
co-ordinated physiological reactions. He extended this 
concept in his book "The Wisdom of the Body" (2) to cover 
the regulation of the blood "sugar" concentration. 
Homeostasis was defined by Gautier-Smith (3) as "self- 
regulating mechanisms that maintain the constancy of the 
internal environment despite great variations in the 
external environment".
Disturbances of glucose homeostasis can have serious 
metabolic consequences. Glucose is an essential nutrient 
for some tissues, in particularly the brain (3). Normally 
an adequate supply of glucose is provided by the hepatic 
glycogen. Food ingestion increases the glucose pool 
(i.e. the total amount of glucose in the circulation, 
gluconeogenic compounds and liver glycogen). This increase 
is counter-balanced by converting glucose into glycogen, 
triglycerides or utilisation as a fuel.
To study glucose homeostasis it is convenient to 
consider separately factors causing (i) a net reduction, 
and (ii) a net increase in the glucose pool. Each of 
these may be sub-divided into hormonal and non-hormonal 
factors.
1.1.1 Factors Causing a Net Reduction in the Glucose Pool
(a) Hormonal
(i) Insulin
Insulin is an important anabolic hormone in glucose 
homeostasis. Its rôle in glucose uptake by muscle and 
adipose tissue is well-documented (4,5). In this way 
insulin decreases the blood glucose concentration (6). It 
also reduces the glucose pool by stimulating lipogenesis 
and inhibiting gluconeogenesis (7).
Insulin release is known to be modified by the blood 
glucose concentration. It is also affected by several 
gastrointestinal hormones (8) when carbohydrates are taken 
orally.
(ii) Somatomedin
This polypeptide hormone may mediate the actions of 
growth hormone on skeletal muscle (9). As it exhibits 
insulin-like activities, which cannot be neutralized by 
insulin antibodies, it is named Non-Suppressible Insulin- 
Like Activity (NSILA) (10). NSILA possesses a hypoglycaemic 
activity both ini vivo and iui vitro (11) and causes inhibition 
of adenyl cyclase activity of many tissues (12).
Somatomedin consists of many molecular species with 
different physical properties (13). Recently, studies 
with diabetic rats indicated a close relationship between 
somatomedin and insulin both in growth and in the control 
of diabetes (14).
(iii) Somatostatin
This peptide hormone was first isolated in 1973 (5) 
from sheep hypothalami and was found to inhibit rat and 
human growth hormone release and was, therefore, called 
Somatotrophin-Release Inhibiting Factor (SRIF), The 
synthetic hormone was found to exhibit a similar effect (16). 
In 1974 SRIF was shown to inhibit the release of pancreatic 
glucagon and insulin in baboons (17). Blood glucose 
concentration was also found to be reduced.
Marked stimulation of glucagon release was noticed 
when anti-somatostatin serum was added to the incubated 
islets of Langerhans (18). Because of its anti-glucagon 
effect, somatostain has been successfully used, in conjunction 
with insulin, for the treatment of diabetes (19).
(b) Non-hormonal
Although most hypoglycaemic activities are hormonally 
mediated, there are a few non-hormonal hypoglycaemic agents. 
The following are some examples of these.
(1) Hypoglycin
This is the principal toxin found in the seeds and 
unripe fruits of the Jamaican ackee tree (Blighia sapida)
(20) which causes the hypoglycaemic disease "vomiting 
sickness". It is an amino acid derivative of propionic
acid (21) . Hypoglycin inhibits the oxidation of long
chain fatty acids making glucose the only source of fuel.
thus leading to severe hypoglycaemia (22). Hypoglycin 
may also stimulate insulin secretion (23).
(ii) Dichloroacetic acid (DCA)
This hypoglycaemic compound inhibits fatty acid 
oxidation and increases glucose oxidation in the muscle 
of diabetic, but not normal, rats (24). It also activates 
pyruvate dehydrogenase in perfused rat hearts (25) and in 
isolated hepatocytes (26) .
(iii) Biguanides
These oral hypoglycaemic agents include such compounds 
as phenformin and metformin. They inhibit lipolysis (27) 
and gluconeogenesis (28). Phenformin treatment for 
diabetes can lead to lactic acidosis (29). Holloway and 
Alberti (30) found that by combining phenformin and DCA to 
treat diabetic rats, lactic acidosis was reduced. It was 
suggested recently that phenformin may also suppress glucagon 
release in man (31).
1.1.2 Factors Causing a Net Increase in the Glucose Pool
(a) Hormonal
Many hormones increase the glucose pool. For 
example, cortisol and glucagon increase gluconeogenesis.
The following hormones are hyperglycaemic (6): 
catecholamines, glucagon, cortisol and growth hormone.
Others, such as thyroxine and prolactin (32) have a less 
important rôle. Because glucagon and adrenaline have
been particularly studied in this work, their rôle in 
glucose homeostasis is reviewed here.
(i) Adrenaline
Adrenaline has long been known to decrease muscle 
glycogen (33). Initially, it was thought to be due to 
stimulation of phosphorylase (34); however, a more complex 
system was later discovered. This will be discussed later.
(ii) Glucagon
In some species (e.g. fowl), glucagon is essential 
for life and pancreatectomy could lead to fatal hypoglycaemia 
(35). Glucagon is a potent glucose mobilizer and is an 
important factor in glucose homeostasis when glycogen is 
depleted (36).
(b) Non-hormonal
(i) Food ingestion
Food ingestion, especially carbohydrates, is the 
main factor which increases the glucose pool. However, 
this increment is not sustained for a long period (37).
(ii) Insulin antagonists
The presence of some factors in the plasma which
oppose insulin action was described by Vallance-Owen (38) .
(iii) Glucose - fatty acid cycle
This metabolic activity was described by Randle 
et al (39) and has recently been extended to include ketone
bodies (37). Newsholme suggests that the original cycle 
may represent a mechanism controlling both the rates of 
glucose utilisation and fatty acids mobilisation according 
to changes in the blood glucose concentration (37).
(iv) 2-Deoxy-d-glucose (2DG)
The hyperglycaemic effect of 2DG has been studied 
by many workers and conflicting results concerning hormonal 
involvement have been reported. This thesis seeks to 
elucidate the physiological and metabolic effect of this 
substance on glucose homeostasis.
1.2 2-DEOXY-GLUCOSE INDUCED HYPERGLYCAEMIA
1.2.1 General
The compound, 2-deoxy-glucose (2DG), can block 
glycolysis and so has been considered for use in the 
treatment of certain neoplasms. It was first examined 
by Cramer and Woodward in 1952 (40) in the course of their 
search for carcinostatic glucose analogues. They found 
that 2DG produces some regression of Walker carcinoma . 
and terminates embryonic development in rats. 2DG can 
inhibit glycolysis in normal and tumour tissues (41).
These observations led to this study of the effects of 2DG.
1.2.2 Metabolism and Interference of 2DG with Carbohydrate 
Metabolism
Wick et ^  (42) found that 2DG rapidly enters the 
cells of extrahepatic tissues and has a glucose-sparing
effect in eviscerated, nephrectorriised animals. 2DG is 
phosphorylated by hexokinase soon after its entry to the 
cell (43).
■ 14 ^Using C-labelled 2DG, Wick et ^  (44) localized
14the blocking effect on glycolysis. C-2DG could not be
14oxidized by extrahepatic tissue and no CO^ could be
detected. But 2DG did not affect the normal metabolism 
14of C-labelled acetate, and when given with glucose there 
was a marked reduction in the amount of CO2 produced.
These observations led Wick et al (44) to conclude that 
2-DG blocks glucose utilisation by competitive inhibition 
between 2DG-6-PO^ and glucose-6-PO^ for phosphoglucoiso- 
merase, Kipnis and Cori (43) did not find any enzyme 
system which could metabolize 2DG-6-PO^. However, 
primitive organisms (e.g. Aspergillus oryzae) can grow on 
2DG as their sole source of carbon but not as rapidly as 
on glucose (45). Therefore, it is not clear which pathway(s) 
2DG may disturb or its ultimate fate (apart from excretion in 
native form).
1.2.3 Possible Involvement of Catecholamines and the CNS 
in 2DG-Induced Hyperglycaemia
Lazio et ^  (46) showed that 2DG infusion causes 
a significant increase (up to ten-fold) of both adrenaline 
and noradrenaline. This may account for accompanying rise 
in plasma free fatty acids. A similar observation was made 
by HÔkfelt et ^  (47) in rats. These authors, however, 
suggested that 2DG stimulates the central nervous system
which then provokes adrenaline secretion resulting in 
hyperglycaemia. However, animals with denervated adrenals 
still developed hyperglycaemia which led Hükfelt et a^ (47) 
to conclude that other factors may also be involved. The 
involvement of the central nervous system is endorsed by 
the previous findings of Landau and Lubs (48), who found 
that rabbits injected with high doses of 2DG suffered a 
marked inco-ordination of extremities, dilation of the 
pupils, etc. and some animals died within 6-32 minutes. 
These findings suggest that 2DG probably induces cellular 
glucopenia in the nervous system, thereby increasing 
adrenaline output from the intact adrenal medulla,
Wegienka et ^  (49) used 2DG in a test for the estimation 
of the adrenomedullary reserve. Similarly, Sizonenko et 
a^ (50) assessed the function of the adrenal medulla in 
childhood hypoglycaemia using the 2DG test. The authors 
did not observe 2DG-induced hyperglycaemia in this group of 
patients. This was thought to be due to an absence of 
sensitivity of the autonomic nervous system to 2DG or to a 
blockade in either the different nervous pathways or in the 
adrenal medulla. Similar observations were made by Kruse 
and Bartels (51). Brodows et al (52) suggested that the 
integrity of the sympathoadrenomedullary axis is essential 
for the counter-regulatory response to 2DG-induced intra­
cellular glucopenia in man. Finally, it is suggested that 
the hyperinsulinaemic response to 2DG is mediated by the 
adrenergic receptors (53).
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1.2,4 Possible Involvement of Glucagon and the Pancreas
in the 2DG-Induced Hyperglycaemia
2DG increases the size of the nuclei of both alpha 
and beta cells of the rat pancreas (54). This may 
indicate increased activity of these cells and subsequently 
increased secretion of both insulin and glucagon.
Galansino et ^  (55) suggested that 2DG-induced 
hyperglycaemia is not mediated by glucagon. However, in 
conscious dogs, which previously have a T-catheter implanted 
in the superior pancreaticoduodenal vein, Müller et al (56) 
found a two-fold increase in glucagon concentration after 
2DG. An interesting finding is that insulin concentration 
rose markedly before the rise in glucose and started to 
fall while glucose was still high. Frohman et al (57) 
used rats previously implanted with a cannula in the lateral 
cerebral ventricle, and found that small doses of 2DG (which 
are not effective if administered systemically) injected via 
the cannula cause marked hyperglycaemia, but insulin was not 
affected. Also, the insulin response to glucose was significantly 
attenuated by 2DG injection via the cannula but not when 2DG 
was given systemically. These effects of 2DG were arrested 
by adrenalectomy. This suggested that the neurogenic 
control of insulin secretion in response to cellular 
glucopenia is mediated by the adrenal rather than by direct 
enervation of the g-cells. Recently, Frohman and Nagui (58) 
used dogs implanted with a stainless steel cannula in their 
lateral cerebral ventricle attached to the skull and a
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polyvinyl catheter inserted into their jugular vein at the 
same time. Using the two routes, strikingly different 
results were obtained.. Glucagon, insulin and glucose were 
much higher when 2DG was administered intraventricularly 
than intravenously. This suggests that stimulation of 
glucagon secretion as a consequence of alterations in 
glucose metabolism is enhanced when this alteration occurs 
in the central nervous system rather than elsewhere.
1.2.5 other Factors and Effects
Several workers reported other effects of 2DG.
For example, hyperglycaemia persisted after both ventro­
medial and ventrolateral hypothalamic destruction (59), 
which suggest lack of hypothalamic involvement. Both 
plasma cortisol and serum growth hormone were elevated 
following 2DG (60). A significant fall in the rectal 
temperature both in man and mice after 2DG infusion, despite 
the hyperglycaemia, was observed (61). Vagal stimulation by 
2DG was suggested by Gough and Keddie (62) who found 
increased acid output after 2DG in patients with duodenal 
ulcers.
Finally, on a cautionary note, many methods for 
measuring glucose subject to interference by 2DG such as 
0-toluidine (47), ferricyanide and glucose oxidase (61).
This must be taken into account when interpreting blood 
glucose fluctuations in the presence of 2DG;
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1.3 GLUCAGON
1.3.1 Historical Background
In 1921, Banting and Best (63) observed the action 
of glucagon when testing pancreatic extracts in depancreatised 
dogs. They noticed a mild hyperglycaemia before the 
hypoglycaemic effect. This hyperglycaemia was thought to 
be due to adrenaline release. Collip (64) and Murlin et 
al (65) correctly attributed the phenomenon to a glucogenic 
substance and called it "glucagon" - that is a glucose 
mobiliser. In 1935 evidence for the glycogenolytic action 
of glucagon was provided by Bürger and Brandt (66) who 
attempted to purify it.
Despite these observations it was still thought the 
initial hyperglycaemia induced by insulin, even after 1939, 
when Lundsgaard ejt aJL (67) showed that different preparations 
of insulin (with similar biological activities) did not cause 
similar degrees of transient hyperglycaemia. Doubts about 
the hormonal nature of glucagon and its physiological role 
were encouraged by the discovery of substances, in the 
gastrointestinal mucosa which may, or may not, have been 
glucagon (68).
However, these doubts were finally dispelled. In 
1950 Sutherland (69) demonstrated the glycogenolytic action 
of glucagon in liver slices, by monitoring the enzymes 
involved in glycogenolysis. In 1953 Staub et al (70,71) 
obtained crystalline porcine glucagon from a pancreatic
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fraction that was normally discarded during the commercial 
purification of insulin. In 1957 Bromer (72) found 
the amino acid sequence of porcine glucagon and later showed 
(73) that bovine glucagon has an identical sequence. It 
has now been shown that crystalline rat glucagon (74), 
rabbit glucagon (75) and human glucagon (76) have identical 
amino acid sequences.
1.3.2 Physical Properties and Structures
A summary of the physical properties of glucagon is 
shown in Table 1.1 (77) and the amino acid sequence is shown 
in Fig.1.1 (72). Glucagon is a polypeptide hormone 
containing 29 amino acids and has a molecular weight of 3485. 
The secondary and tertiary structures of glucagon are still 
not clear; considerable regions of alpha-helix was reported 
by Haugen and Lipscombe (78) to occur in the crystalline state,
Glucagon has a close structural similarity with the 
secretin family of gut hormones comprising: gastric 
inhibitory polypeptide (GIP), vasoactive intestinal poly­
peptide (VIP) as well as secretin (79).
Glucagon was synthesised by Weings et a_l (80) and • 
shown to have similar physiological properties to those 
of the naturally occurring hormone. Chemical or enzymatic 
modification of a particular part of the hormone can lead 
to loss of physiological functions (77). However, peptides 
resulting from the proteolytic actions of trypsin, 
chymotrypsin or subtilisin on glucagon retain hyperglycaemic 
activity (72).
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TABLE 1.1 Some Properties of Crystalline Glucagon (77)
Property Value
^l'cm (276 my, water, pH 1.0-8.0) 2.12 ±0.05
Isoelectric point ~ pH 7
Molecular weight 3,485
Solubility (aqueous)
pH 3.5-8.5 50 yg/ml or less
pH 2.0-3.0 and 9.0-10.0 >10 mg/ml
Solubility (nonaqueous)
Dimethylsulfoxide )
90% Formic acid ) 
90% Chloroethanol )
5 mg/ml or greater
70% Dimethyl formamide)
Stability (0.2-1.0 mg/ml)
Aqueous solutions, pH 2.5-3.0 3 months, 4°C
Aqueous solutions, pH 9.0-10.0 4 hours, 24^0; 50% after 
4 months, 4^C
^Extinction coefficient
15
TrpÏLeu
.Gin Asn
Thr
Val
COOPhe,
Asp,
Ala
Are
Ar;
Ser
Ser Lys Asp^
Thr
Phe
Thr
Gly
Gin
Ser
His
Fig. 1.1 Amino acid sequence of glucagon (72)
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1.3.3 Origin
In 1907, Lane (81) classified two kinds of cells in 
the islets of Langerhans, A-cells and B-cells. This 
classification was made according to the solubility of 
their secretory granules, the A-granules being precipitated 
by alcoholic fixatives, whilst the B-granules were dissolved 
It was generally known that the B-cells were those which 
secrete insulin (82).
A-cells were subjected to a histochemical reaction 
for indoles and showed the presence of tryptophan-rich 
protein. It was proposed (83) that the protein in the 
A-cells may be glucagon since the latter contains 5.8% 
tryptophan. Later, using an immunofluorescent technique, 
Baum ^t aT (84) located glucagon in the A-cells.
Glucagon has also been reported to be produced by 
the gastrointestinal mucosa (68) and considerable effort 
has been expended to identify cells of the gastrointestinal 
mucosa equivalent to the pancreatic A-cells. A-cells were 
identified in the gastrointestinal mucosa of cats by 
Vassallo e_t aJL (85) and in human duodenal mucosa by 
Kobayashi (86).
The hyperglycaemic material of the gut discovered 
by Sutherland and De Duve (68) was purified later by the 
same authors (87.) and shown to behave similarly to glucagon 
in many protein precipitation procedures. It was found in 
extracts of canine stomach and duodenum (88) and in the 
jejunum and ileum of many species (89). It has different
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immunological properties to those of the pancreatic glucagon 
(90) (hence the name gut-Glucagon-Like-Immunoreactivity: GLI). 
Gut-GLI was reported to consist of several molecular species 
(91,92,93) which became apparent upon fractionation. Murphy
et al (94,95) found two molecular species in gut-GLI• Gut-
GLI has been found in the blood after pancreatectomy (95,97,98) 
Recently, Jacobsen ef ^  (99) determined the amino acid 
sequence of their preparation of gut-GLI. They suggested 
that biosynthesis of gut-GLI and glucagon start with an 
identical primary gene product.
1.3.4 Glucagon Metabolism and Physiology
(a) Metabolism
Glucagon, after secretion from the pancreas is 
transported to the liver by the portal blood (100,101,102). 
This was confirmed by Assan (103) in man, by umbilical vein 
catheterisation, who found the concentration of glucagon 
was 0.3-5 ng/ml in portal blood. This concentration is 
compatible with physiologic binding to hepatic receptors 
(Km 4.5 ng/ml) (104). The variations of glucagon 
concentration after stimulation (e.g. arginine) are greater 
in the portal and pancreatic veins than in the peripheral 
veins (103) .
Glucagon has specific binding sites in the liver.
The amount of glucagon bound to these sites does not 
represent all the glucagon produced: some of it is 
destroyed in the blood and some is excreted in the urine 
and bile. Berson et al (105) showed extensive degradation
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of glucagon by liver homogenate. Anserge^t (106) , 
found that most of this degradation occurred in the cytosol. 
They suggested that more than one peptidase contributed to 
the destruction of glucagon.
Glucagon is transferred into the bile (101). A
131large amount of the injected I-glucagon was recovered 
from the bile (103).
Glucagon is removed quickly from the blood; hence, 
high level of the hormone in peripheral blood would not 
be expected. Alford e_t aJ^  (107) found the half life of, 
intravenous injection, glucagon in normal subjects was 
4-6 minutes and in diabetics was 6-8 minutes. Because 
of this rapid clearance rate, long acting preparation, 
such as zinc-glucagon and zinc-protamine-glucagon (108) 
are used therapeutically. The relative high potency of 
plasma to degrade glucagon (in relation to insulin) was 
shown (109) in human plasma as well as in plasma from other 
species (110). It is, therefore, necessary that glucagon 
has to be protected during its assay. The addition of 
Trasylol, a proteinase inhibitor (approtinin), minimises 
the degradation of glucagon (111).
Although the liver has been regarded as the first 
and major target organ for glucagon (104), extrahepatic 
receptors have been found in the adipose tissue (112) and 
in islet cell tumour in golden (Syrian) hamsters (113).
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(b) Physiology
I Effect of glucagon on metabolism
(i) Glucose
Perhaps the most important property of glucagon is 
that which led to its discovery - its hyperglycaemic activity. 
This activity may be the result of glucagon actions via 
several systems. These are either (a) increased glycogen- 
olysis, (b) increased gluconeogenesis, or (c) decreased 
glucose consumption.
(a) Glycogenolysis :
Glucagon stimulation of hepatic glycogenolysis was 
shown by Sutherland and Cori in 1948 (114) to cause hyper- 
glycaemia. This action subsequently led to the discovery 
of cyclic AMP, later to be known as the second messenger for 
glucagon and many other hormones as shown in Fig.1.2 (115). 
Glucagon and many other hormones activate adenyl cyclase, 
which is located in the plasma membrane (116), and convert 
ATP to cyclic AMP.
Fig.1.3 shows the enzyme system activated by cAMP 
(cyclic AMP) resulting in the production of glucose-1- 
phosphate from glycogen. Glucose-l-phosphate can then be 
used in several pathways. A bioassay for glucagon based 
on its stimulatory effect on adenyl cyclase will be discussed 
later (see 1.3.5).
Glucagon elevates the level of cAMP in the isolated 
perfused rat liver. The magnitude of this elevation was 
much greater than that of adrenaline.
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High activities of adenyl cyclase have been demon­
strated in the plasma membrane of liver and fat cells (119). 
This implies that glucagon acts extracellularly.
(b) Gluconeogenesis:
Glucagon has a direct catabolic action on the 
isolated perfused rat liver demonstrated by the stimulation 
of urea production (120,121). Glucagon enhanced gluconeo­
genesis from lactate and pyruvate in the perfused rat liver 
(122). This was mediated by cyclic AMP. Garcia et al 
(12 3) showed that glucagon encouraged gluconeogenesis from 
pyruvate, lactate and alanine and suggested that glucagon 
was stimulating, at the same time the activity of several 
enzymes directed towards gluconeogenesis.
(c) Inhibition of glycogenesis and glycolysis:
In liver perfusion, glucagon caused 30% reduction 
in glucose oxidation (120). Inhibition of glycogen synthesis 
by glucagon was shown by Bishop and Lamer (124), They 
found that while insulin enhanced the formation of uridine 
diphosphate glucose (UDPG), glucagon favoured its breakdown. 
They, therefore, concluded that this was the site at which 
glucagon inhibited glycogen synthesis. Furthermore, it 
was suggested that glucagon might inhibit glycogen synthesis 
by inactivating glycogen synthetase (125). This occurs by 
combining glycogen synthetase with ATP, thus forming the 
inactive glycogen synthetase phosphate (the conversion of 
synthase I to synthase D in Fig.1.3).
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In summary, glucagon maintains normoglycaemia by 
the following mechanisms:
(i) Activation of glycogenolysis
(ii) Activation of gluconeogenesis, and
(iii) Inhibition of glycogen synthesis
These actions are illustrated in the metabolic
pathway in Fig.1.4 (126).
(ii) Glucagon and lipids
Glucagon may be a lipolytic hormone. In several 
species, glucagon enhanced the in vitro release of glycerol 
and free fatty acids from pieces of adipose tissue or from 
isolated rat adipocytes (127,128). A similar lipolytic 
effect was recorded on avian (pigeon, chicken, etc.) adipose 
tissue (129).
In human adipose tissue, however, conflicting results 
have been obtained: no lipolytic effect of glucagon was 
found by some authors (130,131); and stimulation of lipolysis 
by others (132). Marks (133) attributed the difficulty in 
establishing the lipolytic effect of glucagon in mammals as 
due to the anti-lipolytic action of insulin on adipose 
tissue which does not exist in birds (hence the clear 
lipolytic action of glucagon). The lipolytic action of 
glucagon in vitro was diminished in the presence of glucagon 
antibodies (134).
The mechanism by which glucagon induces lipolysis is 
illustrated in Fig.1.5 (135) which is briefly summarised as 
follows.
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Glucagon binds to its specific protein receptors 
on the outer surface of the adipocytes plasma membrane.
The information is transmitted to the adenyl cyclase via 
a transducer. The activation of the adenyl cyclase causes 
increased production of cAMP. Cyclic AMP then reacts with 
the inactive protein kinase, combining with its regulatory 
subunit (R) and releasing the active catalytic subunit (C) (136)
which then activates the "hormone sensitive" triglyceride 
lipase (137). The activation of this enzyme in adipose 
tissue exposed to glucagon was shown by.Weings and Lôfler 
T138).
The major indicator of the degree of lipolysis is 
the amount of free fatty acids (FFA) or glycerol. Thus, 
an dm vivo study of the lipolytic effect of glucagon could 
be monitored by measuring either glycerol or FFA or both. 
Lefebvre and Luyckx (131) monitored the changes in the 
level of plasma FFA after injecting glucagon intravenously 
or intramuscularly in normal subjects and they noticed the 
following:
(a) A slight and very transient increase, occurring 
within a few minutes after the injection which may be due 
to the mobilisation of catecholamines by glucagon.
(b) A second phase, during which the plasma level 
of FFA falls. This may be caused by hyperglycaemia and 
hyperinsulinaemia induced by glucagon.
(c) After about two hours of the injection a marked 
increase of the level of FFA is noticed.
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However, Schade and Eaton (139) recently showed 
that glucagon could increase plasma FFA up to 200%, 
depending on the dose, within ten minutes and return to 
the base line after 20 minutes. The authors noted a 
160% increase in the level of plasma ketone bodies and 
suggested that glucagon has the capacity to enhance ketosis 
and reduce plasma triglyceride concentration in normal man, 
and may participate in the modulation of FFA into these 
metabolites.
(iii) Glucagon and amino acids
Glucagon causes 3-4 fold decrease in total plasma 
amino acids concentrations in man (140) and animals (141). 
This suggests that glucagon has a potential physiological 
role in regulating amino acid levels.
In the liver, glucagon affects the amino acid 
metabolism in three ways (142).
(a) Stimulation of membrane transport;
(b) Inhibition of net protein synthesis and 
accelerate of its metabolism; and
(c) Stimulation of gluconeogenesis. ’
Although glucagon is one of the hormones which 
increases adenyl cyclase activity in the liver, and the 
subsequent accumulation of cAMP, it is not clear whether 
this is a "second messenger" for all the effects of 
glucagon on the amino acids metabolism. The intracellular
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effect of glucagon on the amino acid metabolism has been 
studied by Mallette ejb ajL (143) . They showed that glucagon 
induces changes in the amino acids metabolism which encourages 
gluconeogenesis.
(ivj Glucagon and other hormones
(a) Insulin;
Samols ^t a_l, in 1965 (144) were the first to note 
the stimulatory effect of glucagon on the B-cells of the 
pancreas. Their conclusion was that glucagon has a direct 
stimulatory effect on insulin secretion long before the 
development of the hyperglycaemia caused by glucagon 
injection. Glucagon insulinogeni.c activity is increased 
with hyperglycaemia or feeding and reduced by hypoglycaemia 
or fasting (145). Severe fasting of 2-4 days may abolish 
this activity (146). Furthermore, adrenaline or nor­
adrenaline infusion and increased sympathetic nervous 
activity diminish the insulinotropic activity of glucagon 
(147). Despite this effect, adrenaline and noradrenaline 
have been shown to stimulate glucagon release (148).
Greater insulin release was achieved when both glucose and 
glucagon were infused simultaneously (149,150). Even the 
moderate increase of glucagon concentration produced by 
the arginine infusion tests is sufficient to stimulate 
insulin release (151).
The insulinotropic activity of glucagon is not yet 
fully understood. However, suggestions have been made 
that this could be due to intracellular accumulation of
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cAMP (152) which stimulates insulin release in the presence
of adequate amount of glucose (153). The mechanism of
■ +2 -insulin release by cAMP may involve Ca too. It v/as
suggested that the presence of insulinotropic agents (such
■ 45
as glucose and sulphonylurea) stimulate Ca uptake by B-
cells and inhibit outward calcium transport (154). These
agents might allow cAMP to cause a sustained increase in
■ ■ +2the cytosolic level of Ca which results in a sustained 
increase of insulin release (154).
(b) Catecholamines
It is well documented that glucagon stimulates the 
release of adrenaline and noradrenaline from the adrenal 
gland (155). Mulvehill e_t aj^  (156) found the presence of 
a glucagon-sensitive, adenyl cyclase in the adrenal medulla 
which may account for the glucagon effect.
In man a 35-185% rise in the circulating levels of 
catecholamines was observed after the intravenous 
in]ection of 1 mg glucagon (157). This effect has been 
used to diagnose pheochromocytoma (158,159).
II Factors affecting glucagon secretion
(i) Glucoses
Foâ _et aT (160) were the first to suggest that 
glucagon might be under the control of glucose concentration; 
they reported that the pancreatic duodenal venous effluent 
of hypoglycaemic dogs contained a factor which cause hyper­
glycaemia in recipient dogs. Orally given glucose also
30
stimulates glucagon secretion (161). Insulin-induced 
hypoglycaemia causes a rise in blood glucagon. The 
elevation of glucagon was significant at a glucose 
concentration below 50 mg/100 ml (100). Hypoglycaemia 
due to sulphonylurea also causes a rise in glucagon 
levels (101). On the other hand, a rise in glucose 
concentration is associated with a reciprocal decline 
in the glucagon level (100). The above data suggest 
that the A-cell is obligatorily stimulated at a glucose 
concentration of 50 mg/100 ml or less, and suppressed at 
a glucose concentration of 160 mg/100 ml (100). Müller 
et al confirmed this in healthy volunteers (162). They 
gave these subjects an average of 107 ± 11 (SEM) g of 
carbohydrate (Fig.1.6a). It can be seen that as plasma 
glucose levels go up, insulin levels follow suit; and 
glucagon levels go down.
(ii) Fatty acids
Edwards jet aj. (163) reported a marked inhibition 
of glucagon release by fatty acids and ketone bodies in 
vivo and concluded that A-cells are sensitive to variation 
of fatty acid concentration within physiological ranges 
(164). This could be interpreted as due to the lipolytrc 
action of glucagon. Since fatty acids are a product of the 
lipolytic action of glucagon, free fatty acids would be 
expected to act as negative feedback upon the secretion of 
glucagon. This was established by the studies of Madison
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ejb ajL (165) who made dogs hyperlipidaemic by infusion of 
cottonseed oil emulsion. They observed a small decline 
in plasma glucagon concentration accompanied by a small 
rise in insulin. This was later confirmed by Gross and 
Mialhe (166) in their work on ducks, using an oleic and 
linoleic acid infusion. They found that the pancreatectomised 
ducks did not show this decline. They concluded that the 
fatty acid-glucagon feedback mechanism may not be insulin- 
dependent.
(iii) Amino acids :
Many amino acids stimulate glucagon secretion when 
administered intravenously or orally (167). Rocha et al 
(168) studied the effect of 20 amino acids on glucagon 
secretion in dogs. They found that asparagine, glycine 
and phenylalanine were most effective. ; In man, however, 
arginine was the most effective stimulator of glucagon 
secretion, followed closely by alanine and glycine (169).
It may be expected from these data that a rise in glucagon 
level would occur after a protein meal. This was confirmed 
by Müller ejfc ^  (162). They gave healthy subjects a large 
protein meal consisting of an average 63 g of lean beef.
They noticed a gradual rise in the mean glucagon value to 
a maximum 35% rise after 150 minutes (Fig.1.6b). There 
was also a slight increase in the mean alpha-amino nitrogen 
level. Insulin also was noted to rise above the basal level.
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(iv) Hormones :
A-cells contain a high population of beta-adrenergic 
receptors. Isoproterenol (a synthetic beta-adrenergic 
agent) stimulates the release of glucagon and insulin.
This stimulation is, however, inhibited when propranolol 
(a specific beta-adrenergic antagonist) is administered (170).
The association of the sympathetic nervous system 
with the islet hormone secretions, whether by release of 
catecholamines or neurally, has been studied by Iverson (171), 
who found that catecholamines stimulate glucagon secretion 
in vitro. In vivo stimulation was shown by Gerich et al 
(172) who found that upon the infusion of adrenaline, the 
mean plasma glucagon level rises progressively. However, 
despite elevation of blood glucose level, they found no 
appreciable change in insulin. They suggested that 
adrenaline may affect A-cells only and not B-cells, which 
complies with the later evidence of the same group (170).
Pancreozymin stimulates the release of glucagon (173) 
while secretin suppresses the secretion of glucagon (174). 
Iverson (175), using isolated perfused canine pancreas, 
found that gastrin and pancreozymin stimulate glucagon 
secretion. Somatostatin, an inhibitor of the release of 
growth hormone, inhibits glucagon secretion by some agents 
(such as arginine) (175). An excessive glucagon release in 
response to arginine was found in acromegaly (177). This 
suggests a synergistic effect of growth hormone on 
arginine induced glucagon secretion. Thyroid hormones
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have been reported to have an inhibitory effect on glucagon 
release (178) whilst glucocorticoid has been shown to have 
a stimulatory effect on glucagon secretion (179).
1.3.5 Methods of Measurements
These include bioassays, radioreceptor assays 
and radioimmunoassay.
(a) Bioassays
Until the discovery of radioimmunoassay, glucagon 
could only be detected by its biological activity and 
considerable efforts were devoted to the development of 
useful bioassays for this hormone. The introduction of 
radioimmunoassay offered a greater sensitivity than bioassay, 
as well as being simpler and cheaper. However, bioassay is 
still useful for determining whether material measured as 
glucagon by radioimmunoassay is a biologically active 
hormone or not.
Bioassays are based on the action of glucagon in 
one or more of the following:
a. Activation of the adenyl cyclase system 
with the resulting increase of cyclic AMP.
b. Conversion of inactive phosphorylase to the 
active form by cyclic AMP.
c. Stimulation of glycogenolysis in liver cells, 
with the resulting release of glucose.
35
Bioassays are classified into the following procedures 
according to Sokal (180).
(i) In vivo assay
The principle of this assay is based on the glyco­
genolytic action of glucagon on cat liver, described by Staub and 
Behrens (181). Their procedure is based on comparison of 
the rises in blood glucose caused in individual animals by 
the test materials and by standard injections of pure 
glucagon. Staub and Behrens obtained optimal results when 
the rises in blood glucose after the sample injection were 
20-60 mg/loo ml, which corresponded in their system, to 
0.25-0.75 yg glucagon.
One major disadvantage of this assay (apart from 
its apparent lack of sensitivity) is that it lacks 
specificity since there are many agents, e.g. adrenaline, 
which cause hyperglycaemia.
(ii) In vitro assays using liver preparations
For this purpose, liver homogenates, liver slices
or subcellular fractions may be used. Vuylsteke and
De Duve (182) described the first assay using rabbits’
liver slices. Berthet et al (183) developed an assay
using dog liver homogenates. However, these methods
respond to adrenaline in lower concentrations than glucagon
and are affected by metallic ions and other materials
'
present in tissue extracts and plasma. ' An'improved 
technique was devised by Makmann and Sutherland (87) using 
the following procedure.
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A fraction of cat liver containing the adenyl 
cyclase system is incubated with thé material under test 
(cat liver was used due.to the low cyclic AMP produced 
in the absence of glucagon). If glucagon is present, 
cyclic AMP production will be stimulated. The cyclic 
AMP formed is then used for the preparation of the active 
form of phosphorylase, its activity being determined by 
the measurement of glucose residues added to primer glycogen.
These assays are more sensitive than the in vivo ones. 
Some can detect glucagon concentrations of 3 ng/ml and up to 
100 ng/ml.
(iii) In vitro assays using isolated perfused liver
In contrast to the previous assays, the isolated 
perfused liver functions in a similar manner to the organ 
in the intact animal. At physiological levels, all known 
effects of glucagon on liver can be reproduced in the 
isolated perfused livers. Hence, glucagon may be assayed 
by measuring one or more of these effects. Sokal (184) 
found the use of phosphorylase activation to be particularly 
convenient. Phosphorylase activity is determined by 
measuring phosphate release from glucose-l-phosphate in 
the perfusate. Sokal (180) found a significant increase 
in phosphorylase activity after glucagon additions of 5 ng 
to the blood reservoir, and maximal activation following 
additions of about 100 ng. •
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(b) Radioreceptor Assays
Assays using glucagon-specific receptors have been
developed in recent years. This assay requires isolation
of the receptors from the liver cells. Tomasi et al (18 5)
131reported a high binding of I-glucagon to the plasma 
membrane obtained from rat liver. Giorgio jet al. (186) 
characterised the glucagon binding protein as having a 
molecular weight of about 190,000 and as possessing two 
classes of binding sites, one of high affinity and one of 
low affinity. More recently, Freychet (187) described a 
sensitive receptor assay capable of detecting as little 
as 0.2 ng/ml glucagon. The system used by Freychet 
involved a highly purified liver plasma membrane. The 
principle of the radioreceptor assay is similar to that 
of other competitive binding assays Such as radioimmuno­
assay. . However, the receptors are used in place of the 
antibody which recognises the antigenic determinants of 
the molecules. Receptor assays, on the other hand, 
recognise the biologically active structure of the hormone 
(187) and may, therefore, give a better measurement of 
the biological activity of the hormone.
(c) Radi oimmunoassay
(i) History and general
In 1959 Yalow and Berson (188) published a radio­
logical method for assaying plasma insulin in humans.
These findings, however, are related to an earlier method
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by the same authors for insulin determination in animals 
using anti-insulin serum obtained from insulin-treated 
diabetic or schizophrenic patients (189). Almost at the 
same time Ekins, in 1960 (190), referred to a similar 
system for the determination of thyroxine using the 
naturally occurring protein, thyroxin-binding globulin, 
unlike Yalow and Berson who used a specific antiserum for 
determining insulin.
In radioimmunoassay the radioactively-labelled 
antigen and the naturally occurring form, compete, under 
certain conditions, for a limited number of specific 
antibody binding sites. The amount of the labelled 
antigen is kept fixed.
It is, therefore, important to have a means of 
preparing the substance to be assayed in a radioactively- 
labelled form. Greenwood, Hunter and Glover in 1963 (191) 
designed a simple method for the incorporation of radio­
active iodine into protein using chloramine-T as oxidant.
Generally a protein antigen is a substance which, 
upon injection into a suitable host, is capable of producing 
specific antibodies in the blood of that host. Serum 
separated from the blood of the host is screened, using 
the radioiodinated antigens for the presence of antibodies 
and their suitability for the radioimmunoassay of the 
native antigen. The radioimmunoassay can be presented as 
follows :
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Ag* Ag Ab Ag*Ab + AgAb
labelled + non-labelled + specific antigen-antibody
antigen antigen. antibody complexes
Where is the association constant and
is the dissociation constant
The equilibrium constant, K, thus is equal to, 
according to the law of mass action (192)
r ’(AGAb)
“ ÎÇ- - -lAG) -(Abj
K is a measure of the binding avidity of the 
antibody and (Ab) , (AG) , (AGAb) indicate the molar 
concentration of the antibody, antigen and antibody- 
antigen complex respectively.
This approach infers that there are single combining 
sites on both the antigen and antibody, that the reaction 
has reached equilibrium and that there is no difference in 
the reactivities of the labelled and unlabelled antigen in 
the assay system (193). Under these conditions the 
percentage of bound antigen (to the antibody) is directly 
proportional to the concentration of antibody present and 
will decrease as the concentration of antigen increases.
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By comparison, the percentage of- the bound labelled 
antigen to that of standard solutions containing known 
amounts of antigen, the concentration of an unlabelled 
antigen in the sample could be calculated from the standard 
curve. When performing radioimmunoassay, a means of 
separating the antigen-antibody complexes from the free 
antigens is necessary so that the distribution of radio­
activity can be calculated.
Thus, the following are essential for the radio­
immunoassay of an antigen.
a. Pure form of the antigen: for preparation of 
the. label and the standard;
b. A specific antiserum;
c. A means of separating the complexes 
from the unreacted antigens.
Provided that the above requirements are fulfilled, 
a titration curve of the antiserum against a fixed amount 
of radioactively labelled antigen should be constructed.
The aim of this curve is to establish the so-called "titre" 
of the antiserum for that particular preparation of the ; 
labelled antigen. The titre is an expression for the 
amount of antibodies to be used in the assay.
From the curve the titre.value can be obtained by 
calculating the dilution at which 40-60% of the labelled 
antigen is bound. If an excess amount of the antiserum
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is used, i.e. more than enough to give 40-60% of the 
labelled antigen, in subsequent studies a loss of 
sensitivity will result (194).
The next step is the setting-up of a standard curve 
which involves varying-"amounts of the standard and a fixed 
amount of both the antiserum and the labelled antigen. In 
such a reaction mixture the labelled and the unlabelled 
antigen are competing for the limited binding sites 
available for them. Thus, the more unlabelled antigen 
present in the mixture (e.g. highest standard), the less 
chance the labelled antigen has to capture sites for 
binding and subsequently the lower will be the percentage 
binding and vice versa. This means tha t the mixture 
which contains no standard would produce the highest 
percentage binding of radioactively labelled antigen (the 
zero point) followed by the lowest standard and so on.
The presentation of results could be expressed in many 
ways, such as: bound/free, free/bound, percentage bound of total 
activity or percentage bound of zero. Any of these 
expressions is plotted against the varying amounts of 
the standards added to the mixture.
Since its discovery, the radioimmunoassay 
technique has been expanding rapidly to enter many fields.
It has been used for assaying peptide hormones, steroid 
hormones, drugs, cyclic nucleotides, enzymes, viruses, 
tumour antigens, serum proteins, etc. (195)1
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(il) Glucagon radioimmunoassay
Glucagon was the second hormone to be measured by 
radioimmunoassay. The first radioimmunoassay for glucagon 
was reported by Unger et al in 1959 (196) soon after the 
Yalow and Berson method for insulin assay (188). This 
method (196) was based on the principle of the insulin 
radioimmunoassay.
Ever since its introduction, glucagon radioimmuno­
assay has been associated with certain problems. Faloona 
(197) summarised these problems as:
a. Difficulty in obtaining an antiserum of 
sufficient titre and sensitivity for radio­
immunoassay purposes;
b. Cross-reactivity of non-pancreatic glucagon­
like imraunoreactivity with most antisera; and
c. Incubation damage to both radioiodinated 
glucagon and endogenous glucagon from proteo­
lytic factors present in human plasma.
Eisentraut et al (111) showed that incubation of
125I-glucagon with human plasma for four days caused a 
60% loss of the immunoreactivity and even diluting the 
plasma did not prevent the damage completely. However, 
the addition of Trasylol (aprotinin, a proteolytic inhibitor) 
prevented the damage almost completely. Although the addition 
of Trasylol to a blood sample after the withdrawal from the 
subject did not affect glucagon levels, it was recommended.
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With the introduction of the use of Trasylol, the 
last problem has been resolved. Many antisera have been 
produced by many workers, but large numbers of these antisera 
have shown varying degrees of cross-reactivity with gut- 
glucagon-like immunoreactivity. To produce a high titre 
glucagon antiserum may also prove to be a difficult problem. 
However, Buchanan (198) found that by immunising with 
albumin-conjugated glucagon, emulsified in Freund's adjuvant, 
higher titre antisera were produced.
In an attempt to minimise the interference by other
plasma proteins or polypeptides, Heding (199) designed a
procedure for extracting glucagon from plasma using 96%
ethanol. The ethanol-plasma mixture was then centrifuged
and the supernatant collected and dried in a desiccator.
At the time of assay it was reconstituted with buffer. The
author has also reported that without Trasylol, the
addition of pork glucagon to the blood sample could not be
fiilly recovered, while samples with Trasylol showed greater
125recovery. Most glucagon radioimmunoassays use I—
131 131glucagon or I-glucagon. I was originally used by
Greenwood et a_l (191) for the preparation of labelled human 
growth hormone and recorded a yield of high specific radio­
activity. This method utilises chloramine-T to oxidise 
131sodium iodide. However, Marchalonis (200), in 1969,
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introduced a newer principle for the preparation of 
labelled material with radioactive iodine. The method 
depended on an enzymic system consisting of the enzyme 
lactoperoxidase and hydrogen peroxide. This method has 
been used for glucagon and other hormones by Holohan et 
al (201; and recently by Von Schenck e_fc (202). They 
both reported the improvement of their glucagon assay by 
using this system.
The methods separating free hormone from the 
antibody-bound hormone in a glucagon assay have also been 
disputed. Unger et: al^  (203) used chromatography on 
Whatman 3MM filter paper strips. This technique is still 
used as a reference method. Salt precipitation was used 
by Unger ^t a_l (204) ; however, the conditions for this method are 
so critical that the method is unsuitable as a routine assay. 
Ethanol precipitation of the bound hormone has been used by 
Heding (199). The results obtained by this method were 
comparable to those obtained from the chromatographic 
separation on Whatman 3MM paper. The use of a second 
antibody as a precipitating agent has been employed by 
Hazzard e_fc a_l (205) , the major disadvantage of this technique 
being the expense and the second period of incubation it 
requires.
Adsorption of the free hormone and separation by 
centrifugation has also been used in many assay systems.
Nonaka and Foà (205) used cellulose powder suspension 
(10% w/v) . However, this method suffers from some
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disadvantages such as incomplete adsorption. The dextran- 
coated charcoal method is, by far, the most widely used in 
glucagon assay. Leclercq-Meyer et al (207) used it in their 
assay. The main advantages of this method are that it is 
cheap, simple and easy to perform.
1.3,6 Clinical Use of Glucagon Measurement
More than fifty years have passed since its 
discovery and more than twenty years of its availability 
in pure crystalline form, yet glucagon measurement still 
has not routinely been used for clinical diagnosis. This 
is mainly due to its apparently low level in normal plasma 
and the difficulty of its assay. However, glucagonoma can 
be confirmed by measuring glucagon and if the function of 
A-cells is to be investigated, a provocative test (e.g. 
arginine) for glucagon can also be monitored.
High plasma glucagon levels have been reported in 
two other clinical areas; these are diabetes mellitus and 
renal failure. Bribery ejt (208) characterised renal 
failure by an unexplained high plasma glucagon concentrations 
and Kuku gt a3. (209) found levels as high as 500 pg/ml in 
uremic patients.
Unger e^ a_l (210) noticed an increased response of 
glucagon to arginine in diabetic patients and recently it 
was shown that diabetic patients have an exaggerated 
response of glucagon to a meal (211). But, when dealing
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with diabetic patients, the results must be treated cautiously
as glucagon antibodies may be present in the plasma (212) ,
especially in patients with prolonged insulin treatment (213).
125These antibodies may compete for I-glucagon (214). Even 
without insulin treatment, diabetic patients can produce 
glucagon antibodies, perhaps a result of autoimmunisation (215)
Familial hyperglucagonaemia can also be exposed by 
measuring glucagon since its existence has been reported 
recently (21^,217).
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CHAPTER 2
DEVELOPMENT OF GLUCAGON RADIOIMMUNOASSAY
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2.1 INTRODUCTION
Glucagon is a poor immunogen and therefore it is 
a difficult subject for immunoassay. Its low 
concentration in the blood complicates the task even 
further for routine application.
The objects of this section were:
(a) To produce an antiserum of sufficiently high 
avidity to be used routinely for glucagon radioimmunoassays 
which have sufficient sensitivity to make the assay 
clinically useful.
(b) To use this antiserum to produce experimental 
glucagon deficiency in other animals.
2.2 MATERIALS
2.2.1 For Producing Glucagon Antisera
Glucagon: (crystalline, porcine) lot no.258-V016“36,
donated by Lilly Laboratories (Eli Lilly and 
Company, Indianapolis, USA).
Glutaraldehyde EM: 25% aqueous solution (TAAB Laboratories, 
Emmer Green, Reading, UK).
Freund's adjuvant: complete and incomplete forms (DIFCO 
Laboratories, West Molesey, Surrey, UK).
Marcol 52: (Esso Petroleum Company, England).
BCG vaccine, BP, BNF: (Glaxo Laboratories Ltd., Greenford,
England).
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Pertussis: (Lister Institute, Elstree, Herts, England).
The preparation contains not more than 20,000 
million B. pertussis per 0.5 ml dose.
Sodium hydroxide "Analar": (BDH Chemicals Ltd., Poole, 
England).
Egg albumin: (BDH Chemicals Ltd., Poole, England).
2.2.2 For Glucagon lodination
The following materials were obtained from BDH 
Chemicals Ltd., Poole, England, and were of Analar grade 
unless otherwise stated:
Anhydrous sodium phosphate
Sodium dihydrogen phosphate (dihydrate)
Sodium chloride
Chloramine-T (Laboratory reagent grade)
Sodium metabisulphite (Laboratory reagent grade)
Potassium iodide
Absolute ethanol
Sodium barbiturate
Hydrochloric acid
12 5Na I carrier-free: [The Radiochemical Centre, Amersham,
UK. (Spec.Activ.) 14 yCi/yg)].
Quso-G 32 silica (Croxton and Garry Ltd., Windsor House, 
Esher, Surrey, UK).
QAE-Sephadex A25 (Pharmacia (GB) Ltd.).
Dried human albumin (Blood Products Laboratory, Lister 
Institute, Elstree, Herts,, UK).
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Thiomersalate: (Lilly Laboratories, Illinois, USA) .
Tris (hydroxymethyl)aminomethane: (Sigma Chemical Company).
Whatman chromatography paper 3 MM: (W and R Balston Ltd.,
Springfield Mill, Maidstone, Kent, UK).
2.2.3 For Glucagon Assay
Horse serum no.5 (inactivated): (Wellcome Reagents Ltd.,
Wellcome Laboratories, Beckenham, Kent, UK).
Aprotinin: (Bayer UK Ltd. or Novo Research Institute,
Novo Alle, DK-2880, Bagsvaerd, Denmark).
Charcoal (Norit GSX): (Hopkin and Williams, Chadwell
Heath, Essex, UK).
Dextran T-250: (Pharmacia (GB) Ltd.).
Glucagon standard. The World Health Organization 1st 
international standard for glucagon, porcine, 
for bioassay (69/194): (The Medical Research Council,
National Institute for Biological Standards and 
Controls,Holly Hill, Hampstead, London, UK),
Gastrin: (Medical Research Council, National Institute
for Biological Standards and Controls, Holly Hill, 
Hampstead, London, UK).
Gastric Inhibitory Polypeptide (GIP): (Dr. J. Brown,
University of British Columbia, Vancouver, British 
Columbia).
Vasoactive Intestinal Polypeptide (VIP) and Secretin: 
(Karolinska Institute, Stockholm) .,
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Assay buffer, 0.04M phosphate, pH 7.4 made up as follows:
2 3.00 g Disodium hydrogen phosphate (anhydrous)
5.97 g Sodium dihydrogen phosphate dihydrate 
1.25 g Thiomersalate
The above salts were dissolved in double-deionised 
water (which was used for preparing all other reagents) and
made up to 5 1 and the pH was checked. The buffer was
: o'
stored at 4 C and used for up to 4 months.
Pooled human plasma (PHP): heparinised human plasma 
was collected from apparently healthy volunteers to make a 
stock of about 100-150 ml. The plasma was allowed to stand 
at room temperature for about 1 hour. Aprotinin was then 
added in a ratio of 1000 K.I.U. aprotinin per ml of plasma. 
This mixture was then divided into suitable aliquots (1-5 ml) 
and stored at -20^C until used. Once thawed, the residue of 
the aliquot was discarded.
2.3 PRODUCTION OF ANTISERUM
Several methods for producing glucagon antiserum 
in rabbits and other species have previously been 
described. Unger et al (196) imminused rabbits with 
porcine glucagon emulsified in Freund’s adjuvant. Grodsky 
et ad (218) used glucagon conjugated to the carrier protein 
ovalbumin to increase the immunogenicity of the hormone. 
Subsequent methods (219,220,221) used glucagon conjugated 
with glutaraldehyde or carbodiimide to other proteins. In 
most cases Freund's adjuvant has been used as an 
emulsifier (196) but Bayol arlacel can also be used (218) .
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Both the route of administration of the immunogen 
and the length of time between the 1st (primary) 
immunisation and subsequent (boosting) immunisations 
appear to be important. Glucagon antisera have been 
produced under a variety of immunisation schemes. Unger 
et ad (196)boosted on a monthly basis whilst others, 
e.g. Grodsky et aT (218), left the animals to rest for 
a few months before boosting.
It is thus difficult to draw any conclusions from 
the literature on the ideal method or conditions for the 
best results. The following section describes the two 
methods which were used for producing a glucagon 
antiserum. The Guildford procedure was used at the 
University of Surrey to produce antisera against many 
gastrointestinal hormones. The Belfast procedure was 
used to prepare pancreatic glucagon "specific" antiserum 
(KB 89), and antiserum "cross-reacting" with gut-GDI 
(KB 57) (224) .
2.3.1 Methods
(a) Immunisation
(i) Guildford procedure
Group A animals consisted of three half-lop rabbits 
(1 male and 2 female), two months old and weighing about 
2 kg each at the beginning of the experiment. They were 
given the codes, Yl, Y2 and Y3. The following procedure
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was used for the conjugate production (sufficient for 
ten animals).
1 mg glucaton was dissolved in 0.1 ml O.OIN NaOH
followed by 4.9 ml assay phosphate buffer.
1.29 mg egg albumin was dissolved in 5 ml assay
buffer.
The above two solutions were mixed and 0.2 ml 
glutaraldehyde (1:100 v/v, diluted from the stock in 
distilled water) was added slowly with mixing. The 
mixture was left for 5 minutes and 0.5 ml of BCG vaccine 
was added.
The resultant mixture was then put into a syringe 
attached to another syringe by a double-hubbed connector.
The second syringe contained 20 ml Marcol 52: Arlacel A
(10:1 v/v) and the two liquids were mixed by passing
them back and forth between the two syringes. The 
resultant emulsion became stable after about 20-30 transfers 
The stability of the emulsion was tested by placing a drop 
on a clear water surface. If the drop stayed firm the 
emulsion could be used for injection.
■ .
A 3 ml portion of the emulsion was injected into 
each rabbit j.itradermally (i.d.), distributed over 60 sites 
in the back, which had previously been shaved (50 yl of 
emulsion per site). Immediately afterwards 0.5 ml 
Bordetella pertussis vaccine was given subcutaneously to 
each animal. B. pertussis has been used to assist the
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production of antiserum for steroid hormones in rabbits 
by Vaitukaitis et ad. (222) and by Scaramuzzi et al for 
the production of steroid hormones in sheep (223).
(ii) Belfast procedure (22 4) (modified)
Group B animals consisted of three half-lop 
rabbits (all female), 2 months old and weighing about 
2 kg each at the beginning of the experiment. These 
animals were given the codes Y4, Y5 and Y6. The 
procedure used to prepare the conjugate was as follows 
(sufficient for 5 animals).
2.5 mg glucagon was dissolved in 0.5 ml 
O.IN NaOH followed by 4.5 ml assay phosphate 
buffer;
5.0 mg egg albumin was dissolved in 5.0 ml 
assay phosphate buffer.
The two solutions were mixed and 1 ml of 1:100 
(v/v) glutaraldehyde was added dropwise with mixing.
The resultant solution was emulsified with 5 ml of 
Freund's complete adjuvant using an homogeniser until 
the emulsion was stable. Each animal received 3 ml of 
this emulsion distributed over 12 sites as follows:
2 in the forelimbs - intramuscular 
2 in the neck - subcutaneous 
4 in the back - subcutaneous 
4 in the back limbs - intramuscular
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In the Belfast procedure the molar ratio of egg 
albumin :hormone was 1:6.5. On the other hand, in the 
Guildford method, the molar ratio was 1:10.
The two procedures were started at the same time, 
all the animals being obtained from the same suppliers 
at the same time. Both procedures are summarised in 
Table 2.1.
(b) Bleeding procedure
A sample of blood (5-10 ml) from all the animals
was obtained from the marginal ear vein just before
immunisation. The blood was collected in small bottles
prewashed with normal saline (0.9% NaCl) and then left to
stand at room temperature overnight. The next day the
blood was spun at 2,500 rpm (1,900 g) and the serum was
divided into 1 ml aliquots and stored at -20°C. Another
sample was taken three weeks after immunisation.
Subsequent samples were obtained at weekly intervals and
the sera obtained from all the samples were tested for
the presence of antibodies by constructing antibody
dilution curves (see E.i). The titres were monitored
in all cases; titre being defined as the dilution of the
125antiserum at which half maximum binding of I-glucagon 
to antibody is obtained.
(c) Boosting procedure
During the course of this study the animals were 
boosted only once, 11 months after the primary immunisation.
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TABLE 2,1 IMMUNISATION PROTOCOL FOR GROUPS A AND B
Parameter Group B 
Animals 4,5,6
Group A 
Animals 1,2,3
Amount of antigen per 
animal
0.5 mg 0.1 mg
Weight of carrier 
protein per animal 
(egg albumin)
1 mg 0.129 mg
Conjugating agent 
(1% glutaraldehyde) 
ml/animal
0.2 0.02
Adjuvant Freund’s Complete Marcol 52/Arlacel A
ml/animal 1 ^ 2
Adjuvant/aqueous ratio 1:2 2:1
Route of injection 4 in the back (SC) 
2 in the neck (SC) 
6 in the limbs (IM)
60 sites in the 
back (ID)
BCG ml/animal 0.05
Secondary adjuvant 0.5 ml B-pertussis/ 
animal
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for reasons to be explained. One animal, Y5, died 30 
weeks after the primary immunisation. It was decided 
to give the remaining animals a booster injection after 
the titre of the antiserum had subsided.
The same two immunisation methods were followed 
except that one animal (Y3) was transferred from group 
A and included with the surviving two animals from 
group B. Hence the Guildford procedure for a booster 
injection was applied to Yl and Y2 only, while the 
Belfast procedure was applied to Y4, Y5 and Y3.
(i) Guildford procedure
The Guildford procedure was used in the same manner 
as before except that neither BCG nor B, pertussis were 
given.
(ii) Belfast procedure
The Belfast procedure was used as before except 
that the dose of immunogen per animal was halved.
In both methods the volume of immunogen was 3 ml.
One week later all the animals were bled. 
Subsequently they were bled weekly or fortnightly and 
the titre of the antiserum was recorded.
(d) Preparation of glucagon and gut-GLI (Belfast)
(i) Glucagon standard
This is supplied in ampoules, each containing 
1.49 I.U. (one International Unit, I.U., is approximately 
1 mg of porcine glucagon).
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The contents of one ampoule were dissolved in
14.9 ml acid-alcohol (1.5 ml conc. HCl, sp.gr. 1.180 +
75 ml absolute ethanol + 25 ml deionised water) to give
a concentrated stock solution of 100 yg/ml. This
solution was divided into small volumes (0.2-0.5 ml)
oand stored at -20 C. It was stable in this form for 
at least one year. This stock was diluted with the same 
acid-alcohol to give a daily working standard (DWS) of 
1 yg/ml concentration. This was divided into small 
volumes (0.1-0.2 ml) and stored at -20°C. It was stable 
for up to 4 months* After thawing, any remaining 
standard was discarded.
For use in the assay, 10 yl of the DWS were added 
to 4 ml of pooled human plasma aprotinin mixture (or its 
extracts). This dilution produced a standard with a 
glucagon concentration of 2,500 pg/ml. This was then 
double-diluted with the same pooled human plasma aprotinin 
(or its extracts) to give the following standard solutions 
1,250, 625, 313, 156 and 78 pg/ml. Frothing was avoided 
during the preparation of the standard solutions to avoid 
hormone damage (224).
(ii) Gut-GLI (Belfast)
Solutions of gut-GLI-Belfast were made to a 
concentration of 10,000 pg/ml by dissolving in pooled 
human plasma (PHP). Solutions of the reference human 
albumin and standard pancreatic glucagon were made up in
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in the same way. The resulting three solutions were 
double diluted serially in PHP to give solutions with 
concentrations 5,000, 2,500, 1,250, 625 and 313 pg/ml 
for the gut-GLI and the reference albumin. For standard 
glucagon, solutions containing 2,500, 1,250, 625, 313, 156 
and 78 pg/ml in PHP were made. These solutions were 
tested using three antisera: Y6PR (see E-iv), KB89 and 
KB87. Antiserum KB89 was said to be "pancreatic specific" 
and KB87 was known to "cross-react" with gut-GLI.
(e) Other methods
(i) Antibody dilution curve
Antibody dilution curves were set up by serially
diluting antisera to cover a suitable range (depending
on the antiserum, e.g. from 1:10 to 1:10,000 dilutions).
A 100 yl portion of the resulting diluted antisera was
125incubated for 24 hours with 100 yl I-glucagon and
100 yl phosphate buffer. After separation, the percentage 
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binding of  ^I-glucagon was plotted against the dilution 
of the antiserum (Fig.2.12).
(ii) Preparation of charcoal suspension for assay 
separation
The suspension was made by mixing 5 g of charcoal 
and 0.5 g dextran with 500 ml of the assay buffer to form 
a stock solution (which should be made at least 24 hours 
before use). This was prepared every 4 months. For use 
in the assay, this suspension was diluted 1/4 (v/v) with the 
assay buffer to give a final concentration of 0.25% (w/v)
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charcoal. One volume of horse serum no.5 was then added 
to 9 volumes of diluted charcoal slurry and the mixture 
stirred on a magnetic stirrer during addition to the 
assay tubes.
(iii) Collection of blood samples for glucagon assay
Blood for glucagon determinations was poured into 
an ice-cold, heparinised tube containing 10,000 KE units 
of aprotinin (for 10 ml blood) as soon as possible after 
venepuncture. The tube containing the blood sample was 
kept on ice prior to centrifugation. The plasma was 
separated within ten minutes and divided into 0.5 ml 
portions. These were stored at -20°C until required for 
assay.;
(iv) Dilution of glucagon antiserum for immunoassay
Y6PR (antiserum from animal Y5,'16th bleed (R) after 
primary immunisation) was chosen for the routine assay.
The antiserum was initially diluted 1/2000 (v/y) in the assay 
buffer and later, because of stability problems, was 
diluted 1/100 (v/v) and divided into 0.5 ml portions, 
which were freeze-dried. For use in the assay, an aliquot 
was reconstituted with 1 ml deionised water.
2.3.2 Assessment of Antisera
(a) .Titre after Primary Immunisation
The first bleed, bleed A, was collected from the 
animals 3 weeks after immunisation. The results of the
61
-o Yl 
-a Y2 
-A Y3 
■A Y4 
■O Y5 
-e Y6
bù
m
ma
1/10 1/20 1/40 1/80 1/160 1/320 1/640
Initial dilution of the antiserum
Fig. 2.1 Antibody dilution curves of the first bleed  
(three weeks) after primary immunisation.
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test on that bleed are shown in Fig.2.1. In all cases 
antibodies were present in the serum. The pre- 
immunisation bleed of all the animals was tested and no 
antibodies could be found.
The third bleed (C) collected 6 weeks after 
immunisation was tested in the same way. These bleeds 
were high titre antisera (Fig.2.2). Y5 and Y6 had the 
highest titres in their group, and were higher than the 
titre of Yl antiserum, which was the highest in its 
group. YÔ antiserum at this stage appeared to have the 
highest titre of all. Subsequent bleeds confirmed the 
superiority of Y6 antiserum in so far as the titre is 
concerned (Fig.2.3). The titre of Y3 antiserum was 
consistently the highest in its group. The progress of 
the antibody production is shown in Fig.2.3.
It became clear that animal Y6 produced the highest 
titre antisera, so bleeds of larger volume were obtained 
from the sixth bleed onwards. Of the other animals, Y5 
proved to be the second best animal in producing 
antiserum. Unfortunately, the animal died just over 
six months after the primary immunisation. The animals 
were then left to rest for a long period until antiserum 
titres had subsided, before boosting.
(b) Titre after first boost
As mentioned earlier this was the only booster 
injection given, due to the sustained high titre of some
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1/20 1/40 1/80 1/160 1/320 1/640 1/2, 560 1/10, 240
Initial dilution of the antiserum
Fig. 2. 2 Antibody dilution curves of bleed C (6 weeks after 
primary immunisation) of glucagon immunised 
animals.
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Weeks after primary immunisation
Fig. 2.3 Development of the antibodies in sera from  
glucagon immunised animals
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animals for a long period. This booster injection was 
performed 11 months after the primary injection. The 
titre of the antisera were assessed prior to boosting 
and found to be very low in Yl, Y2 and Y4, while in Y3 
it was 1/1,500 and in Y6 it was 1/7,000.
A bleed was taken one week after the boost and 
samples were obtained weekly thereafter. Fig.2.4 shows 
the development of antibodies in the serum of all 
animals. Table 2.2 summarises the results obtained after 
primary and booster injections.
(c) Specificity of the antisera
One of the dominating problems in producing a 
glucagon antiserum is the cross-reactivity of the 
antiserum with the material excreted from the gut (gut- 
GLI or N-terminal), and to a lesser extent with other gut 
hormones such as GIF, VIP, secretin and gastrin. The 
aim was to produce a specific antiserum for pancreatic 
glucagon. Hence, the main concern was cross-reactivity 
with gut-GLI, though cross-reactivity with other gut 
hormones was also checked.
Gut-GLI from two sources was obtained: The Queen's 
University of Belfast and University of Texas, Dallas, 
Texas, USA). Each of the two materials was studied to 
evaluate the cross-reactivity with Y-glucagon antisera.
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t  The animal died after this bleed
Fig. 2 .4  Post boost development of the antibodies in sera  
from glucagon immunised animals
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TABLE 2.2
Animal
Method of 
the primary 
immunisation
Highest titre 
after primary 
immunisation
Me thod o f 
first 
boosting
Highest 
titre after 
the boost
Yl A 1/900 A 1/2,900
Y2 A 1/200 A 1/280
Y3 A 1/6,000 B 1/20,000*
Y4 B 1/250 B 1/400
Y5 B 1/13/000* —
Y6 B 1/65,000 B 1/25,000
*Died while the titre was still rising
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(i) Belfast gut-GLI
The material had a molecular weight of about 12,000, 
had been isolated from porcine colon and freeze-dried with 
human albumin. The material was estimated, by the supplier, 
to contain 50 ng equivalent of GLi/mg of the freeze-dried . 
powder as measured by one of their antisera known to cross- 
react with the N-terminal portion of glucagon.
Fig.2.5 shows the behaviour of three solutions (of
gut-GLI, standard glucagon and reference albumin) against
antiserum Y6PR. It can be seen that the presence of the
reference albumin in the solutions does not affect the
125binding of the I-glucagon to the antiserum.
From the graph it may be noted that at least lO 
times as much gut-GLI, compared with pancreatic glucagon 
was required to produce similar decreases in percentage 
label binding. The same experiment was repeated using 
the cross-reacting antiserum KB57. The results are shown 
in Fig.2.6 which shows that KB57 needs twice as much 
pancreatic glucagon, compared with gut-GLI, to produce a 
similar decrease in percentage binding of the label.
Fig.2.7 shows the combined results of KB89, Y6PR and 
KB57 antisera against gut-GLI. It can be seen from the 
graph the extent to which each one reacts with the gut-GLI.
(ii) Dallas qut-extract
This material was called "gut-extract" rather 
than gut-GLI and little information about the amount of 
GLI it contains was known. Various concentrations of
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1,250 2,500 5, 000 10,000 or albumin313 625
625 1, 250 2, 500 n g /l156 3130 78
pancreatic 
glucagon
Fig. 2. 5 The behaviour of gut-GLI (Belfast), pancreatic
glucagon and reference albumin with Y6PR antiserum  
which was used at 1/40, 000 dilution
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156 313 625 1, 250 2,500 ng/L pancreatic
glucagon
313
Fig. 2. 6 The behaviour of gut-GLI (Belfast), pancreatic glucagon 
and reference albumin with KB57 antiserum which was
used at 1/420 dilution
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Fig. 2 .7  The binding of gut-GLI (Belfast) to three 
different antisera
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this material were used and the GLI content measured 
using KB57 (cross-reacting antiserum). A suitable 
range of concentrations was found in terms of pancreatic 
glucagon for the study by this procedure. Fig.2.8 
shows the results of this study, again using the three 
antisera used previously. (The only antiserum which 
showed a response to the different amounts of the material 
was KB57. In order to decrease label binding from 40% 
to 20%, 10,000 ng/ml of the material was needed. However, 
the same amount had no effect on label binding to the other 
two antisera, KB89 and Y6PR).
(iii) Other gut hormones
Y6PR was also tested against GIP, VIP, secretin 
and gastrin. The results are shown in Fig.2.9 which 
indicates the absence of cross-reactivity of Y6PR with 
these materials.
2.3.3 Discussion
(a) Immunisation and production of antisera
In this study the results of the immunisation 
technique used for Group B animals (Belfast method) were 
better than the results obtained from the Group A 
(Guildford method). However, the results are not 
conclusive, since the method employed only three animals 
and one antigen. When boosted, Y6 did not show the 
expected response compared with other animals, notably
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^  KB89 (at 1/8,000) 
#  T6PR (at 1/40, 000) 
® KB 57 (at 1/420)
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1,2500
Fig. 2. 8 The binding of Dallas gut-extract to three 
different antisera
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Y3. This observation agrees with that of Teale et al 
(225) of the necessity of leaving the animals to rest 
for a long period of time until the titre has fallen to 
a base line before boosting. Table 2.3 shows this 
point. The lower the titre before the boost, the better 
the response after the boost. This could be interpreted 
as follows. IVhen the circulating level of the antibodies 
in the animal is high and the animal is injected with 
antigen, large amounts of antigen will react with the 
antibodies thus reducing the amount of the antigen 
available for provoking the immune response. Those 
animals with low levels of circulating antibodies will 
have effectively more molecules of antigen available for 
provoking the immune response.
(b) Specificity studies
A group of closely related gastrointestinal 
polypeptides has shown no sign of cross-reactivity with 
Y6PR antiserum.
In the results section the data for Y6PR antiserum
.
were presented since it is used in glucagon radioimmuno­
assay. It was concluded that this antiserum exhibits a 
10% cross-reactivity with gut-GLI, in mass terms, which 
is similar to KB89 (characterised by the supplier as 
pancreatic glucagon specific); however, in molar terms, 
the cross-reactivity with this preparation is about 40%. 
Using the gut-extract from Dallas, KB89 and Y6PR showed 
no reactivity with this material. On the other hand.
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Table 2.3
Animal
Titre before 
the 
boost
Highest titre 
after the 
boost
Response 
(post boost titre) 
(pre-boost titre )
Y4 1/5 1/400 80
Y2 1/10 1/280 28
Yl 1/50 1/2,900 58
Y3* 1/1,600 1/20,000 12.5
Y6 1/7,000 1/25,000 3.5
*Died while the titre was still rising
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KB57 showed a greater ability to react with both materials. 
The cross-reactivity with Belfast gut-GLI was, in mass 
terms, about 50%; in molar terms, however, KB57 appears 
to recognise this preparation of gut-GLI more than 
pancreatic glucagon.
2.4 PREPARATION OF LABELLED GLUCAGON
2.4.1 Introduction
Successful labelling of antigens has been achieved 
using ^H, ^^^I, ^^^I, ^^^I or, to a lesser extent,
^^Se. While has been used for protein labelling (22 6),
radioiodine produces radiolabelled protein of higher
125 131specific activity. I is more widely used than I
because of its longer half-life (60 days compared with 8 
131days for I (22 7)) .
' ' 125Incorporation of I into a protein may be
achieved either by direct incorporation or by first 
125
incorporating I into a small organic molecule, which
is then incorporated into the protein; a technique
developed by Bolton and Hunter in 197 3 (22 8). Direct
125incorporation of I into proteins may be achieved by:
(a) using iodine monochloride (ICl) (229).
The presence of non-radioactive iodine limits the 
possibility of obtaining a high specific activity label:
(b) Using Na^^^I or where three techniques
can be used. These are: lactoperoxidase and hydrogen 
peroxide (201,230), electrolysis (231), and the
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chloramine-T (232) which is, by far, the most widely used 
for the iodination of polypeptide hormones.
In iodination, iodine may react with sulphydr.yl 
groups, histidine, tryptophan or tyrosine grou. The 
conditions of the iodinations are set up to favour the 
last group (233).
The iodination process yields a mixture of the
iodinated protein and other unwanted material such as 
125
the unreacted I and damaged iodination protein.
Removal of these materials can be achieved in several 
ways including (234): gel filtration, adsorption 
chromatography, gel electrophoresis or ion exchange.
2.4.2 Glucagon Iodination Methodology
The chloramine-T method (232) was used to prepare
t.125
I-glucagon. The iodination protocol used by 
j/rgensen and Larsen (235) was followed. Two methods 
of purification were used. They were: (a) superfine
silica powder (224) , an easy and quick method, and 
(b) QAE Sephadex A-25 (235), a more elaborate anion 
exchange method of purification.
The iodination protocol is shown below. All 
solutions were prepared freshly before iodination.
The order of addition is indicated by the step number.
The reaction was carried out in a 2 ml glass vial 
containing a small magnetic flea. The vial was clamped 
on a magnetic stirrer to ensure good mixing.
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Step No. Material Quantity Volume
yl
1 Glucagon (in O.OIN NaOH) 10 yg 25
2 Na 0.5 mCi 5
3 Buffer (0.4 M, pH 7.2) 25
4 Chloramine-T (in 0.04 M 20 yg 5
buffer, pH 7.4)
( 5 10-20 seconds interval
6 Na^S^Oj- (in 0.04 M buffer, 48 yg 20
pH 7.4)
7 KE (in 0.04 M buffer, pH 7.4) 500 yg 50
8 Tris (in 0.04 M buffer, pH 7.4) 1210 yg 5
2.4.3 Purification
(a) Silica powder
The iodination products were transferred to a 
10 ml glass tube containing 10 mg QuSO G32 superfine silica 
1,000 K,I,U, Aprotinin were added to the mixture. The 
iodination tube was washed with 3 x 500 1 0.4 M phosphate
buffer pH 7.2 and the washings were added to the silica.
The contents of the tube were vortexed for 30 seconds and 
then centrifuged for 20 minutes at 2,500 rpm (1,900 g)
O  'at 4 C. The supernatant, containing free iodine, was 
discarded. The silica was washed with 3 ml deionised 
distilled water, vortexed and then centrifuged as before 
and the supernatant was again discarded. 5 ml of acid- 
alcohol (1.5 ml concentrated HCl, 75 ml absolute alcohol 
and 25 ml distilled water) was added to the silica, 
followed by mixing for 30 seconds and centrifugation as
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before. This supernatant, containing the iodinated 
hormone, was collected and stored at -20^0.
(b) QAB-Sephadèx column
An anion exchange column of QA.E-Sephadex A25 
column was prepared by allowing 8 g of the dry gel to 
swell overnight in 0.08 M Tris buffer pH 8.5 (0.08 M 
Tris, 0.08 M NaCl in 0.02N HCl and 50 K,I,Ü. aprotinin/ 
ml). After degassing, the gel was loaded into a glass 
column (1.2 x 30 cm). The column was prewashed with 
20-30 ml of the Tris buffer containing 1% human albumin 
(which was also used for the elution). 1 ml of this 
buffer was added to the iodination products and the 
mixture was then transferred onto the column. The column 
was connected to a peristatic pump giving a flow rate of 
10 ml/hour. An automatic fraction collector was 
connected to the outlet of the column and 90 fractions 
of 2 ml were collected at 4 C.
1252.4.4 Assessment of Integrity of I-Glucagon
(a) Chromatoelectrophoresis
Chromatoelectrophoresis permits the separation of
iodinated hormone and free iodide (2 3.6) . It is used to
125 .
check the incorporation of I into the hormone before 
purification. This was used for insulin by Yalow and 
Berson (188). ,
An electrophoretic tank (Shandon) containing 0.05 M 
barbitone buffer pH 8.6 was used. A 10 yl aliquot of the
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iodination product was applied as a 1 cm line, 4 cm 
from one and of a 26 x 2 cm strip of Whatman 3 MM 
chromatography paper. Simple paper chromatography 
was allowed to proceed for 20 minutes. The whole strip 
was then saturated with the buffer. Electrophoresis was 
performed at a constant 180 volts for 70-80 minutes.
The strip was then dried, covered with transparent 
sticky tape and scanned for radioactivity using a 
Berthold thin-layer scanner. The iodinated hormone 
stayed at the origin, while the iodide moved towards 
the anode.
(b) Immunoreactivity check
Immunoreactivity of the fractions from the QAE- 
Sephadex column was assessed as follows:
Almost the same number of counts per 100 yl of 
each fraction was incubated with 100 yL of antiserum 
for twenty four hours. The percentage of counts 
bound to antibodies was then calculated.
(c) Antibody dilution and displacement curves
This determines if the labelled glucagon is 
displaced by the native glucagon. An ordinary antibody 
dilution curve, as shown in Fig.2.12 was set up. Another 
set of tubes contained the same reactants plus some 
native glucagon (usually top standard). If the label 
was not displaced, it was discarded and fresh iodination 
was followed.
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(d) Radioreceptor assay
The labelled glucagon prepared by the j/rgensen 
and Larsen method (235) was used in a glucagon receptor 
assay employing rat liver plasma membrane. Plasma 
membrane was prepared according to Ray (23 7) as modified 
by Mahmood jet al^  (23‘8) using a sucrose density gradient 
technique.
The assay tubes contained the following:
100 yg (protein equivalent) plasma membrane in 100 y 1 
0.005 M Tris buffer, pH 7.5)
100 yl Krebs-Ringer Phosphate (KRP) buffer, pH 7.5 +
1% gelatine
100 yl Glucagon standard (1-250 ng/ml reaction mixture)
100 yl Tracer (^^^I-glucagon) with not less than 10,000 cpm.
Tubes containing the above mixture were incubated
at 30 C for 45 minutes, followed by centrifugation at 3,000
orpm (2,200 g) for 30 minutes at 4 C. Supernatants were 
removed and the pellets were washed twice with KRP buffer, 
pH 7.5 containing 1% gelatine, counted and a standard 
curve was obtained. This procedure was used to test 
^^^I-glucagon prepared by the method of Goldfine ejt ajl (239) , 
which is recommended for use in receptor assay. The 
method uses less chloramine-T than the j/rgensen and 
Larsen method and purification was achieved using a 1 ml 
cellulose column.
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2,4.5 Results
125
(a) Purification of I-glucagon
(i) Silica powder
The results of purification using silica were not 
satisfactory. Either poor antibody dilution curves were 
obtained or no displacement of the tracer by unlabelled 
hormone was achieved.
(ii) QAE-Sephadex column
(a) Chromatoelectrophoresis
The results obtained from two different iodinations
as assessed by chromatoelectrophoresis are shown in 2.10.
125Preparation B shows high percentage incorporation of I 
into the hormone. Preparation A shows a low percentage 
incorporation and possibly damaged hormone (materials 
migrated from the origin).
(b) Immunoreactivity check
The immunoreactivity of the column effluent fractions 
was checked to establish the most immunoreactive fractions 
(Fig. 2.11). This also shows the elution pattern in terms 
of radioactivity.
(c) Antibody dilution curve
Fig.2.12 shows a pattern of antibody dilution curves 
of six consecutive iodinations following the J/rgensen and 
Larsen method. In all cases the label was displaceable 
by native glucagon.
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F ig .2.11 125nElution pattern of 1-glucagon following 
chromatography on QAE-sephadex A25. The 
corresponding immunoreactivities of each fraction 
are also shown
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1/4, 000 1/16, 000 1/64, 000
1/32, 000 1/128,0001/8,000
Dilution of antiserum
Fig. 2.12 Antibody dilution curve obtained using six  
consecutive preparations of ^^sj-giucagon 
by the Jorgensen and Larsen method 
#  -  @ Mean ±  SD
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(d) Radioreceptor assay
The results obtained using this assay to determine 
the best method of separation are shown in Fig.2.13.
17^
(b) Stability of I-glucagon
After the fractions from ion exchange purification
had been collected, the fractions containing the highest
radioactivity (and immunoreactivity) were pooled and
stored. Some problems were associated with the storage.
As can be seen from Fig.2.14, a loss of sensitivity
occurred when the tracer was stored frozen at -20^C for
as short a period as 24 hours, while tracer stored in liquid 
oform at -20 C did not suffer from the defect. Stabilisation 
of storage in liquid form was achieved by adding acid- 
alcohol (1.5 ml concentrated HCl + 98.5 ml absolute ethanol) 
to the pool of fractions in a ratio of 1:1 (v/v). In this 
way the solution could be kept at -20 C in a liquid state. 
However, ageing has an effect on the qulity of the tracer, 
even when stored in the liquid state at -20^0, as can be 
seen from Fig.2,15. Usually the labelled glucagon was 
discarded after 4 weeks. '
2.4.6 Discussion
An important factor in a successful immunoassay is 
125the quality of the I-hormone used. In order to provide 
suitable conditions for competition for antibody binding 
sites the radioactively labelled and native hormones
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should be of similar immunoreactivities. However, 
during the labelling procedure, some changes are 
inevitable. Ideally, these changes should not affect 
the behaviour of the hormone immunologically (or even 
biologically). For this reason, a mono-iodo-hormone 
is favourable. But, during the iodination, it is 
difficult to control the production of mono-iodo-hormone, 
and di-iodo-hormone may be produced.
125Silica purification resulted in a very poor I- 
glucagon. This is probably due to the fact that silica 
adsorbs all protein molecules, including damaged protein. 
When alcohol is added to the silica, both damaged and 
undamaged hormone is extracted, with the resulting poor 
performance of the preparation. This problem has been 
overcome by the use of an anion exchange column chromato­
graphy which separates the mono-iodo-glucagon from other 
forms. ■
■ 125 '. I-glucagon, prepared and purified by the 
JjJrgensen and Larsen method, performed well in the 
receptor assay, which is more sensitive than the immuno­
assay to changes that may occur in the hormone during 
iodination. However, changes in the quality of the 
labels with time are inevitable (Fig.2.15). This 
deterioration of the quality of the label necessitates 
the preparation of the label at least once every 4 weeks. 
This deterioration may be due to the internal radiation 
of the label itself. Freezing the label may amplify
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Glucagon standard (jag/l.)
Fig. 2.13 Comparison between two préparations of
12 5i„giucagon in a radioreceptor assay using 
rat liver plasma membrane
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Fig. 2.14 The effect of storage conditions on the stability 
of ^ 2 5j^gl-Qcagon in a normal glucagon assay
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this deterioration (240). Hence, it was necessary to
- o
keep the tracer in liquid form at -20 C which could be 
achieved by adding acid-alcohol to the aqueous solution 
of the label.
2.5 STUDIES ON GLUCAGON ASSAY
2.5.1 Assay Protocol
The assay protocol is shown in Fig.2.16. All 
solutions were cooled to 4°C before use. Total, non­
specific binding, maximum binding and zero tubes, followed 
by the tubes with the lowest concentration of antigen, were 
set up in duplicate. Each sample was assayed for non­
specific binding (NSB) as well as specific binding. After 
the addition of the standard or sample, the tubes were
shaken by hand in a rack. The unlabelled antigen was
■  ^ opre-incubated with the antiserum for 48 hours at 4 C.
The labelled glucagon was then added and the contents of
othe tubes were incubated for a further 24 hours at 4 C.
At the end of the incubation period, an ice-cooled 
suspension of dextran-coated charcoal was added to all
tubes except the totals, and the tubes left to stand at
o ■ '4 C for 10 minutes before being centrifuged for 20
minutes at 2,500 rpm (1,900 g) and 4^C.
After separation of the supernatant from the 
charcoal pellet (décantation), the charcoal pellets 
were counted. The percentage binding was calculated as 
follows :
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(a) For standards:
% I-glucagon bound =
Counts per minute (cptn) of standard NSB-cpm of standard
Mean- total counts ^
(b) For samples :
125% I-glucagon bound =
Cpm of sample MSB-cpm'of sample
Mean total counts ^
2.5.2 pH of the Assay
The original method employed 0.04M phosphate buffer,
pH 7.4, as a diluent for the assay as well as for the
125dilution of the antiserum and I-glucagon (with 2% 
horse serum added). It was also used to reconstitute 
the extracted samples and horse serum or PHP (for 
standards). This buffer was used in the new assay system, 
without the need for sample extraction.
Several phosphate buffers of the same mola rity 
were made up to cover pH range of 4-10. Fig.2.17 
illustrates standard curves at different assay pH. It 
can be seen that although the pH 7.4 buffer did not 
provide the best conditions for the highest binding of 
the zero tubes, it provided a steeper, and more 
sensitive, curve. However, over a pH range of 6-8 
there seemed to be little difference in the overall shape 
of the curves.
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O-----O pH 4. 0
A-----A pH 6. 0
Q----- 0 pH 7.4
A---A pH 8.0
G----- # pH 10.0
bC
39 78 156 313 625 1, 250 2, 5000
Glucagon (ng/l )
Fig. 2.17 Effect of pH variation on the shape of 
the standard curve of glucagon 
radioimmunoassay
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2.5.3 Sample Processing
The original method extracted plasma samples with 
acid ethanol before assay. To assess the effect of 
plasma protein on the binding of glucagon to antiserum, 
standard curves were constructed with both extracted and 
unextracted plasma. The results are shown in Fig.2.18.
The extent of the binding in the extraction procedure 
was higher than the unextracted one. This may be due 
to a non-specific "plasma" effect, which necessitates the 
use of plasma, for the standard curve, of the same species 
of the samples.
2.5.4 Incubation Time
(a) Association time
In order to optimise the incubation periods for the 
assay and to produce maximum assay sensitivity the first 
step is the determination of the association time, i.e. the 
time required to achieve maximum binding of the labelled 
antigen to the antibody. This was achieved by setting up 
several sets of zero and NSB tubes and incubating for 
various periods of time. Plotting the percentage binding 
against time gave an indication of the optimum time for 
these two reactants to reach equilibrium. The results of 
this study are shown in Fig.2.19.
(b) Sequential and equilibrium assay
The principle of radioimmunoassay depends on the 
competition between labelled and non-labelled antigens.
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Fig. 2.18 Standard curve of Y6PR with extracted and
unextracted plasma (Mean ±  8 .D . of 6 replicates)
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However, late addition of the labelled antigen 
(sequential assay) was originally introduced by Hales 
and Randle (241) for.their insulin assay and shown to 
improve the sensitivity of the assay. This system was 
also advantageous in the glucagon assay (Fig,2,20).
2,5,5 Equilibrium Constant, K Value and Scatchard Plot
The original article of Scatchard (242) 
characterised the equilibrium state of ion-protein 
reactions. This has been modified to include the 
equilibrium constant, K, which is a measure of the 
affinity of the antibody for its antigen. The application 
of Scatchard analysis to radioimmunoassay has been discussed 
by many authors (Berson and Yalow, 1959 (189); Feldman,
1972 (243); Weder et al, 1974 (244)).
Provided that a number of conditions are satisfied 
and assuming that the two forms of antigen, the labelled 
and unlabelled forms, are immunologically identical, the 
Scatchard plot provides the value of K and the number of 
binding sites n. This is achieved by plotting bound/ 
free versus the total molar concentration of antigen, .
The result (Fig,2,21) was a curve. Initial slope of the 
curve (representing the high affinity binding site) is 
equal to 1,9 x 10^ 1/m which represents the higher 
affinity constant of the antibody,
2,5,5 Assay Sensitivity
A mathematical approach to the concept of sensitivity 
in radioimmunoassay has been devised by Ekins et al (245)
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Fig. 2. 20 Effect of the late addition of the label 
(sequential assay) on the sensitivity of 
the glucagon assay .
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British Standards Institution (246). The authors defined 
sensitivity (or detection limit of an assay) in terms of 
the slope of the dose response curve, i.e. the change in 
the response metameter (antigen concentration) for a 
given change in the "dose". The detection limit of an 
assay, which can also be defined as "sensitivity", is the 
minimum amount of antigen that can be measured with 
acceptable precision. With this definition, sensitivity 
is usually estimated as the amount of standard required 
to produce a 10% decrease in the zero binding. According 
to these definitions, the dose response calculated from 
Fig.2.18 as the concentration of hormone measured at 2 SD 
(standard deviation) is equal to 122 pg/ml. From the 
same graph the 10% fall in binding from zero was produced 
by 70 pg/ml. However, practically it is difficult with 
some assays to distinguish a sample containing less than 
100 pg from zero. Hence the definition of the dose 
response could be more precise in defining the sensitivity 
of an assay.
2.5.7 Quality Control and Inter-Assay Variation
The reliance on radioimmunoassay to obtain 
important data (e.g. diagnostic purposes), raised the 
question of the quality of the results obtained using 
this technique..- Quality control is an important assessment 
of the applicability of an assay to routine clinical work. 
However, in radioimmunoassay, many problems are associated 
with the use of quality control on a large scale, e.g. 
internationally. Some of these problems are:
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1. Variation in the source and purity of antigen
2. Variation in antisera used for the same antigen
3. Differences in the characteristics of the label used
4. Antigens that are not measurable at basal level and 
are rarely elevated, e.g. glucagon, make it 
difficult to supply quality control samples.
However, local quality control has been established 
for the glucagon assay. This was achieved by giving 
healthy volunteers 1 mg glucagon and collecting blood 
samples 10 minutes afterwards. These samples were pooled 
and diluted (with PHP) to give three levels of glucagon, 
high, medium and low. The results of the study over a 
period of two weeks are shown in Table 2.4. From the 
table it can be seen that the coefficient of variation 
increases with decrease of the level of glucagon measured. 
Samples of national quality control (for United Kingdom) 
for glucagon have been assayed for a period of three 
months. The lack of sufficient data from other 
laboratories made statistical analysis inconclusive. 
Further study is necessary to evaluate the assay.
Several samples were taken from healthy fasting" 
volunteers and in most cases glucagon levels were either 
undetectable or very low.
Stimulation tests, using arginine, have also been 
performed. The results will be discussed in the third 
chapter.
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TABLE 2.4 The result of the local quality control
Assay Low level ng/l
Medium level 
ng/l
High level 
ng/l
1 97.5 438 823
2 109.0 320 750
3 117.0 250 703
4 200.0 350 1000
5 178.0 600 870
6 280.0 370 1000
7 72.0 390 730
Mean 150.5 388.3 839.4
SD 72.8 110.2 123.4 i
SEM 27.5 41.7 46.6
CV 48.4% 28.4% . 14,7%
SD = Standard deviation
SEM = Standard error of the mean
CV = Coefficient of variation
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2.5.8 Stability and Storage of Antiserum
Glucagon antiserum produced during the course of
this study has a very high titre (1/30,000). To avoid
using a very small volume (less than one 1) of the
undiluted antiserum for each assay and waste large
amounts of the antiserum, it was necessary to store some
of the antiserum in diluted form. After diluting the
antiserum in phosphate buffer to a suitable concentration
(1/2,000), aliquots of suitable size (e.g. 1, 2 or 0.5 ml)
were stored in freeze-dried form. The samples were sealed
and stored in darkness at room temperature. Freeze-
drying was completed within 24 hours. Prior to use they
were reconstituted with deionised water to give a dilution
of 1/2,000, then diluted with phosphate buffer to 1/30,000.
These vials were used for glucagon assay and to check the
125potency of preparations of I-glucagon. Over a
period of 12 months, however, a gradual decline in the
titre of the antiserum was observed (Fig.2.22). This
decline could not be attributed to the quality of the
tracer since after one year a fresh 0.5 ml of undiluted
Y5PR antiserum was diluted, divided into aliquots and
the two batches (i.e. the old freeze-dried and the
freshly diluted) were tested against the same batch of 
125I-glucagon. The results showed that while the titre, 
of the old batch was about 1/10,000 (40% binding of 
total), the fresh batch had a titre of about 1/30,000.
It was thought this decline may be due to storage of the 
antiserum after freeze-drying in too dilute a form. The 
problem of storage is to be further investigated.
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2.6 DISCUSSION
Some of the results presented in this chapter 
have already been discussed. However, there are some 
points that warrant further investigation.
Glucagon is generally regarded as a poor immunogen 
and the antiserum produced during the course of this work 
was of high titre compared with many other glucagon 
antisera reported in the literature. The best anti serum , which, 
was chosen for use in the development of the glucagon 
immunoassay (from rabbit Y6), has been reserved for radio­
immunoassay. Antisera obtained from other animals were 
used for other studies, namely, in immunocytochemistry 
study. It is intended that this type of technique be 
developed in this department using Y-series glucagon 
antisera. The immunoperoxidase method was used success­
fully to localise A-cells in the pancreas of many species 
including humans. The antiserum has been used for 
histological studies on tumours associated with 
glucagonoma (Ross, C.M.D., Personal communication). Ross 
used several glucagon antisera, including Y6PR, to study 
a 12 year old block of tumour tissue and excellent results 
were obtained using Y6PR in identifying glucagon in this 
tissue. Use has been made of the antiserum in this 
department,in performing routine radioimmunoassay. The 
main limitation is the detection limit of the assay, 
which at present is above the concentration regarded as
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the upper limit of the normal range in plasma. This 
may be due to the poor affinity of the antiserum.
The following suggestions to improve sensitivity could 
form the basis for future studies,
2.6.1 Suggestions for Future Studies
(a) The production of antiserum
It has been mentioned earlier (Table 2,3) that 
when giving animals a booster injection of an antigen, 
it must be ensured that the concentration of antibodies 
present in the circulation is at a minimum level. The 
reason for this is that a high level of circulating 
antibodies results in an increased loss of the administered 
antigens (from the booster injection). This is a natural 
reaction which could be expected to occur when antibodies 
and their antigen are brought together. This point also 
raises the question of the endogenous production of 
antigens, particularly when the administered antigen is 
similar or identical to the endogenous material. This 
means that once the immune response is provoked, the 
first antibodies produced (which may be of high affinity) 
will react with antigen produced by the animals, and 
probably disturb any feedback mechanism for the antigen, 
until an equilibrium state is reached. This is a very 
important factor in the production of antisera. The 
solution to this problem could be achieved by either 
destroying the A-cells that are responsible for the 
production of glucagon or by complete surgical removal of 
the pancreas.
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In 1966 Okuda and Groliman (247) found that acute 
administration of "Neutral red dye" to rats caused hyper- 
glycaemia and when the treatment continued, a hypoglycaemic 
state was reached. They interpreted their results as 
being due to the effect of neutral red on the A-cells of 
the pancreas. If this assumption is true, it could be 
possible to eliminate, or minimise, endogenous pancreatic 
glucagon secretion by chronic treatment with neutral red. 
Alternatively, surgical removal of the pancreas may offer 
an even more definite solution to this problem. However, 
use of either of these approaches (neutral red treatment 
or pancreatectomy) may be more advantageous if employed 
after the animals have been immunised and the titres 
have fallen. A subsequent booster injection may produce 
the desired high avidity antiserum. Close and continuous 
assessment of the glucose concentration of the animals 
would be necessary to keep them alive for the longest 
period possible.
(b) The assay and its conditions
The sensitivity of the glucagon radioimmunoassay
may be improved by studying more carefully the effect*of
using an alternative method of phase separation other
than the dextran-coated charcoal, horse serum mixture.
Recently, in this department, donkey anti-rabbit antiserum
has been employed as a means of separating the bound
125antigen from the free I-glucagon. The results 
suggest that this technique (double antibody) could be
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used for glucagon assay. An improvement in the detection 
limit has been achieved using this technique (Tsiolakis, D., 
personal communication).
(c) Alternative techniques for glucagon measurement
Alternative techniques for the measurement of 
glucagon have emerged in recent years and may be regarded 
as steps in the move away from the traditional radioimmuno­
assay. These are:
(i) Solid-phase radioimmunoassay
The system utilises an insoluble matrix to couple 
antigens and antibodies with the retention of the 
respective immunological activities. For this purpose, 
the matrix may be polymers such as insoluble poly­
saccharides or various types of plastic. Lundqvist ^t 
a 1 (248) have recently applied this technique to glucagon.
In their assay, antibodies were coupled to cyanogen 
bromide-activated, microcrystalline cellulose. The 
cellulose-bound antibodies were then used in the assay 
system. However, the assay tubes have to be mixed 
continuously for the whole of the incubation period in ’ 
order to keep the cellulose particles in suspension. 
Centrifugation of the antigen-antibody-cellulose complex 
at the end of the incubation, and counting, after 
washing, gave the amount of bound glucagon.
(ii) Two-antibody immunoradiometric assay
The original immunoradiometric assay makes use
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of labelled antibodies and a solid-phase coupled antigen.
In this system the labelled antibodies are incubated with 
the serum to be tested and after a certain time the solid 
phase coupled antigen is added, which binds the remaining, 
unreacted antibodies. Thus, the radioactivity of the 
supernatant is directly correlated with the amount of the 
particular antigen present in the serum. A two-antibody 
immunoradiometric assay has been introduced by Beck and 
Hales (249) for glucagon and other peptides. This system 
uses iodinated anti-IgG antibodies directed against the 
immunoglobulin of the species in which the anti serum to 
the hormone was raised.
However, in both methods the detection limit 
described by the authors (248,249) does not show a 
significant improvement on the conventional radioimmunoassay. 
But this does not exclude the possibility that by adjusting 
the conditions, a more sensitive and reliable assay could 
be produced.
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CHAPTER 3
STUDIES ON 2DG-INDUCED HYPERGLYCAEMIA
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Hyperglycaemia induced by 2DG has been studied by 
many workers whose work has been reviewed in Chapter One 
(1.2). The possible involvement of glucagon and/or 
nervous stimulation of the adrenal medulla in the mechanism 
of the 2DG-induced hyperglycaemia is still in doubt. It 
was, therefore, the subject of this work to study further 
these possibilities with emphasis on glucagon.
3.1 MATERIALS (for other materials see Chapter Two)
The following materials were obtained from Sigma 
Chemical Company:
2-Deoxy-d-glucose (2DG) (Grade II)
20% sterile aqueous solution of 2-deoxy-d-glucose
3,5 Diaminobenzoic acid
Norit A charcoal
Glucose-6-phosphate (G-6-P)
2-Deoxy-d-glucose-6-phosphate (2DG-6-P)
Adenosine triphosphate (ATP) (Equine muscle) 
Hexokinase (E.C.2.7.1.1) (yeast)
Glucose-6-phosphate dehydrogenase (E.C.l.1.1.49) 
(G-6-PDH) (Torula yeast type XI suspended in
2.6 M ammonium sulphate solution).
The following chemicals, and those used for the 
preparation of Krebs-Ringer-phosphate solution, were - 
obtained from BDH Chemicals Ltd., Poole, Dorset, UK and, 
unless otherwise stated, were of "Analar" grade:
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L-arginine (chromatographically homogenous) 
Perchloric acid (60%)
Phosphorus pentoxide 
Sulphuric acid 
Ethyl acetate 
Phenol 
Methanol
Potassium hydroxide 
Sodium carbonate
Nicotinamide adenine dinucleotide phosphate (NADP) 
(Enzymically assayed)
Krebs-Ringer-phosphate solution, which was used 
for the gut perfusion experiment, was prepared as follows:
(a) 0.9% sodium chloride (0.154 M)
(b) 1.15% potassium chloride (0.154 M)
(c) 1.22% calcium chloride (O.llO M)
(d) 3.82% magnesium sulphate heptahydrate (0.154 M)
(e) 17,8 g disodium hydrogen phosphate dihydrate 
+ 20 ml 1 N hydrochloric acid made up to
1 litre (O-1 M)
The above solutions were mixed just before the 
experiment in the following porportion:
100 parts of (a)
4 parts of (b)
3 parts of (c)
1 part of (d)
20 parts of (e)
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The following materials were also used:
Adrenaline (Macarthy’.s Ltd., Chesham House, Romford, Essex, UK) 
32-Deoxy-d- 1- H -glucose (S,A. =22 Curies/mmol) and 
Tritiated-n-hexadecane (The Radiochemical Centre, Amersham, UK) 
Insta gel (Universal liquid scintillation cocktail) and 
Hyamine hydroxide (Packard instrument Co. Inc., Dowers 
Grove, Illinois, USA)
Pentobarbitone sodium (Nembutal, sterile solution 60 mg/ml: 
Veterinary Products Division of Abbott Laboratories 
Ltd., Queenborough, Kent, UK)
Phenobarbitone sodium (Sagatal, sterile solution 60 mg/mlr 
May and Baker Ltd., Dagenham, UK)
Saline (sterile 0.9% solution of sodium chloride) (Travenol 
Laboratories Ltd., Thetford, UK)
Somatostatin (synthetic: Serono Institute, Rome, Italy)
Insulin (Duncan Flockhart and Co. Ltd., Birbeck Street,
London, UK)
Adrenergic blockers:
Phentolamine (Rogitine, supplied as 10 mg/ml solution:
Ciba Laboratory, Horsham, Sussex, UK)
Propranolol (Indenal, ADM 23900/75: a gift from ICI Ltd., 
Pharmaceuticals Division, Alderley Park,
Macclesfield, Cheshire, UK)
Oxprenolol (Trasicor, batch no. 5 3/75: a gift from Ciba 
Laboratory, Horsham, Sussex, UK)
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Phenoxybenzamine (Dibenylene, supplied as 100 mg/2 ml
solution: Smith Kline and French Laboratories Ltd., 
Welwyn Garden City, Herts, UK)
Tolazoline (Priscol: MacarthyVs Ltd., Chesham House,
Romford, Essex, UK)
Thymoxamine (Opilon: William R. Warne and Co. Ltl,
Eastleigh, Hants., UK)
Glucose estimation kits: GOD-PERID method (glucose oxidase) 
and HEXOKINASE method (Boehringer Mannheim GmbH, Diagnostca, 
West Germany). The buffer supplied with the latter kit was 
used for the investigation of the effect of 2DG-6-P on the 
oxidation of G-6-P.
Animals: unless otherwise stated, in the experiments 
performed in this study, male Wistar albino rats, weighing 
200-300 g, were used. These were bred in the Animal Unit 
of the University of Surrey.
3.2 METHODS
3.2.1 Measurement of 2-Deoxy-D-Glucose
The method of Blecher (250) has been used throughout 
this work with slight modifications in the sample 
preparation. The method is simplified as follows:
A 50 pi sample of blood, plasma, serum or standard 
was added to 0.5 ml 0.33 N perchloric acid in a small tube 
(LP3 type), mixed and then centrifuged at 2,500 rpm (1,900 g) 
A 50 pi portion of the resulting supernatant (A) was 
transferred into a 10 ml glass tube followed by 2.95 ml
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distilled water. 3,5-Diaminobenzoic acid dihydro­
chloride, DABA-2 HCl, was prepared from 3,5-diaminobenzoic 
acid (DABA) as follows: 5 g DABA powder was dissolved in
about 20 ml of hot distilled water; 1 g of Norit A 
charcoal was then added and the mixture was boiled and 
filtered while it was still hot. The filtrate was left 
to cool to room temperature, then concentrated hydrochloric 
acid was stirred in slowly, while cooling the container, 
until the crystalline DABA-2 HCl precipitated completely.
The crystals were then separated by filtration and dried 
under vacuum over phosphorous pentoxide at lOO^C. The
■ . . Qdried crystals had a melting point of about 235 C.
A 0.01 M solution of DABA-2 HCl in 5.0 M phosphoric 
acid was prepared by dissolving 0.225 g DABA-2 HCl in 100 ml 
5.0 M phosphoric acid.
A 3 ml aliquot of this solution was added to a lO ml
glass tube which contained the supernatant of the sample
or standard and distilled water. The resulting mixture,
consisting of 6 ml liquid, was then incubated in a
boiling water bath for 15 minutes. Following a 20-minute
operiod at 15-17 C in the dark, the samples and standards 
were measured in a fluorimeter against the reagent blank.
The excitation wavelength was 390 nm and the emission 
wavelength was 490 nm. In most experiments, samples had 
values between 0-6 mmole/litre. The standard curve was, 
therefore, set up accordingly and the value of the 
samples were obtained by direct reading from the curve.
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3.2.2 Measurement of Glucose
If the samples were from an experiment where 2DG 
had been used, it was necessary to use the hexokinase 
method for glucose estimation as the presence of 2DG did 
not interfere with the measurement. A Boehringer kit 
was used for this purpose. In other experiments another 
kit from the same supplier, and which employs glucose 
oxidase, was used. This was the GOD-PERID kit. In 
both methods the supernatant (A) used for the 2DG 
estimation was used.
The ability of 2DG and 2DG-5-P to interfere with 
the hexokinase method for glucose measurement was 
investigated. The method utilises the following reactions
(1) Glucose + ATP hexokinase ^ G-6-P + ADP
(2) G-6-P + NADP"^  G-6-PDH ^Gluconate-6-P+NADPH+h '^■     ----- P"
The optical densities at 340 nm were measured to
- , - . 
monitor the amount of NADPH + H present before and after
the addition of the enzymes, which were extracted from
yeast.
For the studies on the effect of 2DG and 2DG—6—P 
on the reactions of the method, the following procedure 
was followed:
0.2 ml sample (containing glucose or G-6-P)
2.5 ml buffer (triethanolamine 0.3 mol/1 + 
magnesium sulphate 4 mmol/1, pH =7.5)
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0.1 ml ATP (0.015 M, only if glucose was initially 
used)
0.1 ml NADP (0.012 M)
(The above concentration was made according to the leaflet 
supplied with the hexokinase kit).
The above solutions were mixed and the initial 
optical density at 340 nm was recorded ( against air. 
Then depending on the reaction under investigation, the 
first or both of the following were added:
0.02 ml G-6-PDH (125 U/ml)
0.02 ml Hexokinase (125 U/ml) (if glucose was 
initially used)
The reactants were mixed and exactly lO minutes 
later the optical density at 340 nm was measured ( ^ ) .
The changes in the optical densities (i.e. ^-  ^ )
represent the amount of NADPH + h"*" produced which is 
directly proportional to the amount of glucose or G-6-P 
present in the reaction mixture.
To study the effect of 5 mmol/1 2DG (the highest 
concentration found in plasma samples in all experiments 
performed later) and 5 mmol/1 2DG-6-P on the hexokinase 
method reactions, standard solutions of glucose and 
G-6-P were prepared and the study was made according 
to the following table:
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Set Group A Set Group B
1 Glucose (0-10.mmol/1) 4 G—6—P (O—10 mmol/l)
2 Glucose (0-10 mmol/1) + 
5 mmol/1 2DG
5 G—6—P (O—lO mmol/l) + 
5 mmol/l 2DG
3 Glucose (0-10 mmol/1) 4- 
5 mmol/1 2DG-6-P
6 G-6-P (O-lO mmol/l) + 
5 mmol/l 2DG—6—P
The standard curves obtained from sets 2 and 3 were 
not different from the standard curve obtained from set 1. 
Also curves obtained from sets 5 and 6 were the same as 
the curve of set 4. These results indicate that neither 
2DG nor 2DG-6-P, at the concentrations used, have any 
effect on yeast hexokinase and G-6-PDH used in the hexo­
kinase method for glucose. However, a simple kinetic 
study was performed to investigate the nature and extent 
of 2DG-6-P inhibition at higher concentration on the reaction
(2). Several solutions of G-6-P were prepared containing 
10-50 mM/1 (final); a solution of 500 mM (final) of 
2DG-6-P v/as also prepared. The reaction rate of each 
concentration of G-6-P at 340 nm was followed. The 
2DG-6-P solution was then added to another set of G-6-P 
solutions and again the reaction rates v/ere recorded.
The results of this study are shown in Fig.3.1. The
-6apparent Km value for the G-6-PDH (0.33 x 10 M) is 
comparable to those found by other authors (1 x 10 M) (251) .
It can be seen from the graph that the inhibition was very
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small despite the high concentration of 2DG-6-P used.
This suggests that although 2DG-6-P can competitively
inhibit reaction (2), the inhibition is of low affinity.
This is further illustrated by the relatively high Ki 
-3
value (10 M) obtained as shown in the figure, .
3.2.3 Measurement of Insulin
The estimation of insulin was generously performed 
by the staff of the Biochemistry Department, St. Luke's 
Hospital, Guildford, Surrey. The method was a double 
antibody radioimmunoassay, utilising the following:
I First antibody, obtained from Wellcome Reagents Ltd., 
Beckenham, Kent, UK, was anti-insulin guinea pig 
serum (Code RD/lO).
II Labelled insulin: obtained from the Radiochemical 
Centre, Amersham, UK (Code IM.38).
III Standard insulin: obtained from Wellcome Reagents Ltd. 
(RD 13) (human) .
IV Second antibody: Guildhay donkey anti-guinea pig 
serum was used, obtainable from the Department of 
Biochemistry, University of Surrey, Guildford, Surrey.
V Complement: obtained from Wellcome Reagents Ltd.
(Code CT02) .
3.2.4 Measurement of Glucagon
Glucagon estimation was carried out according to 
the method described in Chapter Two.
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3.2.5 Measurement of Corticosterone
The estimation of corticosterone was performed following 
the method described by Pegg and Kean (252) with the following 
modifications :
(i) For extraction, ethyl acetate was used instead 
of dichloromethane: and
(ii) Distilled water was used in place of saline/2% 
ethanol reagent.
• These modifications simplified the method and improved 
its reproducibility (J. English, personal communication).
3.2.6 Gut Perfusion with 2DG
Krebs-Ringer-phosphate solution was used alone for the 
control. The test solution contained 100 mM 2DG. In both 
cases the solution was constantly stirred at 37^C.
The rats were fasted for 16 hours before being anaes­
thetised with an intraperitoneal injection of phenobarbitone 
(60 mg/kg b.w. ) . '^Then they were deeply anaesthetised, an 
incision (2.5 inches) was made along the ventral midline.
The duodenum was ligated below the bile duct and a small slit 
made below the ligature. A plastic cannula (2.5 mm i.d.)
attached to a 20 ml plastic syringe full of Krebs solution at
■ -o' '37 C was inserted into the duodenum and held in place with a
double ligature. The distal gut was ligated above the ileo-
caecal junction and cut cephalad to the ligature. The intestinal
lumen was cleared of particulate matter by washing with the
solution in the syringe at the duodenal end. A second cannula was
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then inserted into the ileal end of the intestine and 
secured in place with a double ligature. The cannula 
leading to the duodenum end was then connected to a 
peristatic pump and solution from the reservoir was 
perfused through the gut at a rate of 6-7 ml/minute for 
30 minutes. At the end, the cannulae were disconnected 
and blood from the liver portal vein was collected (2-3 
ml) in heparinised tubes containing 3000 units cf 
aprotinin.
3.2.7 Metabolic Studies using Tritiated 2DG
In this experiment a tracer amount of tritiated 2DG 
(25 ]iCi) was mixed with 500 mg/kg body weight native 2DG 
and injected intraperitoneally. After 60 minutes blood 
was collected by cardiac puncture and the animals 
sacrificed. Samples of the following were obtained (they 
were all, except the urine, immediately frozen in liquid 
nitrogen): liver, kidney, adipose tissue, pancreas, brain 
and urine. The plasma was separated and preserved while 
the blood cells were haemolised and a sample was stored. 
These samples were then separately processed for B-
'
scintillation counting.
(a) Glycogen separation
1 g liver was added to 8 ml 30% (w/v) potassium 
hydroxide (saturated with sodium carbonate). The 
containers were then placed in a boiling water bath for
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30 minutes. They were cooled on ice, and 10 ml of 
95% ethanol (v/v) added. The mixtures were left 
on ice for 30 minutes then centrifuged at 25.00 rpm 
(1900 g) for 10 minutes. The glycogen precipitate was 
washed three times with 95% ethanol. The glycogen was 
then dissolved in 4 ml distilled water followed by the 
addition of 9 ml insta gel and counted on a B- 
scintillation counter.
(b) Treatment of Tissues for B-Scintillation Counting
A 10% (w/v) preparation of the tissue in water was 
made. A 0.4 ml portion of this preparation was placed 
in a vial and 3 ml of hyamine hydroxide was added to it.
The vials were sealed and placed in a water bath at 50^C
for 3 hours. They were cooled on ice and 0.4 ml hydrogen 
peroxide (30%, w/v) was added to them. The mixtures were 
left for 12 hours (overnight) at room temperature and 
neutralised by the addition of concentrated hydrochloric 
acid (0.25-0i3 ml). This was followed by the addition 
of 9 ml insta gel rendering the samples ready for B- 
scintillation counting.
(c) Treatment of Plasma and Urine for B-Scintillation 
Counting
These were not processed. Suitable samples (0.1-
0.5 ml) were added to 9 ml insta gel and counted.
All samples were corrected for quenching by 
ascertaining their counting efficiencies with a standardised 
tritiated n-hexadecane solution used as internal standard.
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(d) Separation of 2DG and 2DG-6-P in Urine
In order to assess the amount of native 2DG 
which was excreted in the urine, the following procedure, 
which also separates glucose and G-G-P, was followed:
Thin layer chromatography on silica precoated 
plastic plates (Camlab, Cambridge, UK) was performed.
The method is a modification of that described by Adachi 
(253). The solvent system used was ethylacetate/acetic 
acid/methanol/water (6.0:1.5:1.5:1.0, by vol.) and for 
visualisation of the spots, 3 g phenol and 5 ml 
concentrated sulphuric acid in 95 ml ethanol was used.
The plates, after being sprayed with the identification 
reagent, were heated in an oven for 15 minutes at 110°C. 
Each plate contained reference spots of 2DG, 2DG-6-P 
and a mixture of the two. The chromatograms of the urine 
sample were spread over 1 cm lengths along the plate.
The gel was scraped into a vial containing lO ml insta 
gel and then counted. The chromatograms reflected Rf 
values for 2DG, 2DG-6-P, glucose and G-6-P as shown in 
the following table.
Compound Rf value
2DG 0.55
Glucose 0.48
2DG-6-P 0.19
G-6-P Oil5
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3.3 EXPERIMENTS AND RESULTS
Several experiments were designed to investigate 
the factors which may contribute to the 2DG-induced 
hyperglycaemia. Unless otherwise stated, in all 
experiments, 500 mg/kg b.w. 2DG in saline was administered 
intraperitoneally. This dose is comparable to that used 
by other workers such as Landau et al (48), Galancino e^ 
al (55) and Hdkfelt eh a_l (47) , but much greater than is 
usually used in human subjects (average dose 50 mg/kg)
(45,52).
3.3.1 Preliminary Studies
(a) Effect of nutritional state on the hyperglycaemic 
response to 2DG and glucagon
The hyperglycaemic response to 2DG was monitored in 
three groups of rats, each consisting of six animals. One 
group of animals had free access to food, animals of the 
second group were fasted for 5 hours, and animals of the 
third group were fasted for 24 hours.
All animals were anaesthetised by intraperitoneal 
injection of Sagatal (60 mg/kg b.w.). After the animals 
had lost consciousness a 50 y1 blood sample was collected 
from the tail vein and immediately mixed with 0.5 ml of 
0.33 N perchloric acid contained in a 2.5 ml plastic tube. 
After 10 minutes, 2 ml saline containing 500 mg/kg b.w.
2DG was injected into each animal. Blood samples (50 pi) 
were collected at 10, 20, 40 and 60 minutes after the
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injection of 2DG and mixed with perchloric acid as before.
The perchloric acid-blood mixture was mixed and 
centrifuged at 1900 g for 10 minutes. The supernatant 
was used to measure glucose (hexokinase method) and 
2DG.
A similar experiment was performed using glucagon 
instead of 2DG (20 y g glucagon/kg b.w.). Only glucose 
was measured.
From Figs.3.2 and 3.3 it can be seen that the 
hyperglycaemic effect of both 2DG and glucagon depends 
on the nutritional state of the animals. Although the 
6 hours fasting group of animals showed a smaller rise 
in blood glucose concentration, the difference from the 
fed group is insignificant. Although glycogen was not 
measured these results suggest that 2DG-induced hyper­
glycaemia may also depend primarily on the glycogen 
reserve in the liver.
(b) Effect of anaesthesia on 2DG-induced hyperglycaemia
To investigate the effect of anaesthesia on 2DG- 
induced hyperglycaemia, four groups of fed rats consisting 
of six animals each were used. Two groups were 
anaesthetised, as described before, and two groups were 
injected with the same volume of saline. One group of 
anaesthetised animals was given a 2 ml saline injection 
whilst the other group was given 2DG in 2 ml saline.
The conscious groups were treated in the same way. After
30 minutes, the conscious animals were sacrificed by the
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Fig. 3. 2 Blood levels of glucose and 2-DG after an
intraperitoneal injection of 2-DG (500 mg/kg 
b .w .) in anaesthetised rats in different 
nutritional states. (Values are mean ±  
standard error of the mean, n =  6)
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Fig. 3,3 Blood glucose response to an intraperitoneal 
administration of glucagon (2 0 /ig/kg b.w . ) 
in anaesthetised rats in different nutritional 
states. (Values are mean ± standard error 
of the mean, n =  6)
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guillotine and blood was collected in heparinised tubes 
containing aprotinin (1,000 K,I.U./ml blood). Glucose,
2DG, insulin, glucagon and corticosterone were measured.
The results are shown in Table 3.1 which reveals a 
significantly higher level of insulin in both anaesthetised 
and conscious rats after 2DG compared with their saline 
treated controls. However, the glucose level was not 
significantly* different between these groups.
The lower insulin level in the anaesthetised, 2DG- 
injected group versus the conscious 2DG~injected animals 
might be attributed to the suppression of B-cells by 
pentobarbitone (255).
Because of the great variations of corticosterone 
concentration between animals, no consistent change was 
found after the administration of 2DG.
3.3.2 The Role of Glucagon in the 2DG-Induced Hyperglycaemia
The similarities between the hyperglycaemia induced 
by 2DG and glucagon with regard to different nutritional 
states suggest that glucagon secretion may be modified after 
the injection of 2DG. The following experiments were 
designed to elucidate this possibility.
(Statistical significance: for a small number of observations, 
i.e. less than 20, a non-parametric test is usually 
recommended. The Mann-Whitney U test was chosen for the 
calculation of P values for all the experiments in this thesis 
This test can also provide P values for unequal numbers of 
observation of the tested populations (254)).
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(a) Effect of an intraperitoneal injection of 2DG 
on glucagon secretion
Table 3.1 shows the effect of 2DG (500 mg/kg b.w. by 
i.p.injectionj in the four groups of rats described in the 
previous section. Plasma glucagon levels show no significant 
difference between the test and the control groups (whether 
the animals are conscious or anaesthetised).
(b) Effect of an intestinal perfusion of 2DG on 
glucagon secretion
The blood used in the previous experiments was obtained 
by cardiac puncture. It had, therefore, passed through the 
liver where any insulin and/or glucagon secreted into it might 
have been removed. In the present series of experiments, 
therefore, blood was obtained from the liver portal vein (3.2.6) 
Basal values of insulin and glucagon were higher than those 
obtained from peripheral or cardiac blood. The control group 
was infused with Krebs-Ringer solution alone and the test group 
infused with the same solution containing 100 mM 2DG.
It can be seen from Table 3.2 that while mean plasma 
glucagon concentration in the test group is not significantly 
higher than that of the control one, the mean plasma insulin 
concentration of the test group is almost twice that of the 
control value. It is possible that the insulin rise was a 
primary response to the presence of 2DG itself, or a secondary 
response to the 2DG-induced hyperglycaemia.
In order to ensure that the glucagon assay was 
sensitive enough to measure physiological changes in
134
plasma glucagon in rats, glucagon secretion was stimulated 
by arginine.
(c) Stimulation of glucagon secretion by arginine
A solution containing 500 mg/kg b.w. arginine was 
injected intraperitoneally. Peripheral blood was collected 
from the tail vein at O, 10, 20, 45 and 50 minutes and plasma 
glucagon, insulin and glucose levels measured. Glucose 
results were not significantly different from the preinjection 
values. Plasma glucagon and insulin responses are shown in 
Fig.3.4. There was a six-fold increase in the concentration 
of glucagon and an almost ten-fold increase in the insulin 
concentration.
(d) Effect of injected glucagon antiserum on 2DG- 
induced hyperglycaemia
If the 2DG-induced hyperglycaemia is mediated by 
glucagon, the presence of glucagon antibodies should 
minimise or abolish this hyperglycaemia. Glucagon anti­
serum (0.5 ml/animal, with a total binding capacity of 
approximately 20 g glucagon, calculated from Scatchard 
analysis) was injected intravenously 2 minutes prior to 
the intraperitoneal injection of 2DG solution. Normal rabbit 
serum was substituted for glucagon antiserum in a control 
group of animals. After 30 minutes cardiac blood was 
collected- The glucose results are shown in Table 3.3.
There were no significant differences between animals 
which received normal rabbit serum and those which received 
glucagon antiserum.
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TABLE 3.2 Portal venous blood concentration of glucose, 
2DG, glucagon and insulin 30 minutes after gut 
perfusion with Krebs-Ringer buffer (control) 
or 100 mM 2DG in the same buffer, in rats.
+(Values are mean - standard error of the mean)
Group 
n = 4
Blood
Glucose
mmol/l
Blood
2DG
mmol/l
Plasma
glucagon
ng/1
Plasma
insulin
mU/1
Control 5.27 - 0.28 — 578 - 215 81.5 ± 18.3
2DG *8.65 - 0.22 3.13 - 0.35 707 - 121 *156.5 - 19.9
*P <0.05
TABLE 3.3 Peripheral blood glucose, 2DG and plasma insulin 
concentrations in animals 30 minutes after 2DG 
injection into rats (previously treated with either 
0.5 ml normal rabbit serum or 0.5 ml anti-glucagon 
rabbit serum).
(Values are mean - standard error of the mean
Group 
n - 5 Serum given
Blood
glucose
mmol/l
Blood
2DG
mmol/l
Plasma
insulin
mU/1
Control 5.28 - 0.25 7.7 - 1.6
2DG Normal rabbit 9.00 - 0.6 3.95 - 0.4 *18.0 - 2.5
serum
2DG Anti-glucagon 9.01 - 0.4 4.15 - 0.2 *16.8 - 1.7
rabbit serum
*p <0.05 (v control)
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Fig. 3.4 Plasma glucagon and insulin response 
to arginine stimulation test in normal 
anaesthetised rats. (Values are mean 
+ standard error of the mean, n =  5)
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(e) Studies on glucagon-immunised rabbits
The results of the previous experiment seemed to 
indicate a lack of glucagon involvement in the mechanism 
of 2DG-induced hyperglycaemia. It was, however, felt that 
glucagon-immunised animals might provide a more reliable 
distribution of antiserum (see Chapter Two) and a greater 
capacity to absorb both exogenous and endogenous glucagon.
The three glucagon-immunised rabbits (Yl, Y2 and Y4) that 
survived after the work on the glucagon radioimmunoassay was 
completed were used for the following experiments: (Each
experiment was carried out on two separate occasions; the 
results, therefore, represent the mean of six values).
(i) Glucagon injection
Glucagon, 5 g/kg b.w. was injected into the marginal 
ear vein of the animals. Blood samples were collected 
at O, 5, 10, 20, 40 and 60 minutes after the injection for 
glucagon and insulin estimation. Control rabbits were 
obtained from the Animal Unit and were matched for age and 
breed with the glucagon-immunised ones. The results are 
shown in Fig,3.5. There are considerable differences 
between the two groups, particularly with regard to the 
plasma insulin responses. Blood glucose rises were 
only marginal in the immunised rabbits, while the 
control ones showed average increases of 2 mmol/l. Insulin 
levels in the immunised rabbits rose to twice their
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animals
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Plasma glucose and insulin response to an 
intravenous injection of 5 jag/kg b.w. 
glucagon in glucagon-immunised and non­
immunised conscious rabbits. '
[Values are mean ± standard error of the 
mean, n = 3 x 2, (three animals on two 
occasions)]
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baseline level, whereas those in the control animals rose 
approximately 6 times.
(ii) Arginine stimulation test
The same two groups of rabbits, i.e. the glucagon- 
immunised and matched ones used in the previous experiments 
were used for these experiments too. A solution containing 
500 mg/kg b.w. arginine was administered through the marginal 
ear vein and blood samples collected at O, 5, 10, 20, 40 and 
60 minutes after the injection for insulin and glucose 
estimation. The glucose concentration did not change signif­
icantly from the pre-injection value in either group. Insulin 
results are shown in Fig.3.6. They show highly significant 
differences between the glucagon-immunised and non-immunised 
rabbits.
The results of the above experiment taken:in 
conjunction with the previous one suggest that the glucagon- 
immunised animals have impaired pancreatic endocrine function. 
Moreover, since exogenous glucagon, which showed an effective 
insulinotropic activity in non-immunised animals, did not . 
exhibit a significant insulinotropic activity in the 
immunised animals,it is likely that the antibodies present 
effectively prevented access of the exogenous glucagon to 
the B-cell of the immunised animals. No insulin antibodies 
could be detected in the glucagon-immunised animals.
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Fig. 3.6 Plasma insulin response in glucagon-immunised 
and non-immunised conscious rabbits to an 
intravenous injection of 500 mg/kg b.w . arginine. 
[Values are mean ±  standard error of the mean, 
n = 3 X 2 (three animals on two occasions)]
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(iii) The effect of 2DG on glucagon-immunised and 
non-immunised rabbits
To confirm that the presence of high titre glucagon 
antibodies does not prevent 2DG-induced hyperglycaemia (see 
Table 3.3), the following experiment was carried out:
A solution containing 500 mg/kg b.w. 2DG was administ­
ered intravenously, through the marginal ear vein, of the 
unanaesthetised glucagon-immunised and control animals. Blood, 
for glucose estimation, was collected at O, 10, 20, 30, 40, 60, 
90 and 120 minutes. Mean blood glucose responses in the two 
grsoups are illustrated in Fig.3.7 and show no significant 
difference between them.
(f) Effect of somatostatin on the 2DG-induced 
hyperglycaemia
It was mentioned in the introduction that somatostatin 
(SRIF) inhibits the release of glucagon and insulin and lowers 
blood glucose labels acutely. Therefore, if glucagon were to 
contribute to production of 2DG-induced hyperglycaemia, somato­
statin should, by suppressing glucagon secretion, abolish or 
diminish the hyperglycaemia.
' '
Four groups of rats, each group comprising five animals, 
were used. After anaesthetising them with phenobarbitone 
(i.p.) the rats were treated according to the schedule 
illustrated in Fig.3.8. Somatostatin was administered 
subcutaneously (s.c.) and 2DG was administered intraperiton- 
eally (i.p.). Blood was withdrawn from the tail vein for 
glucose measurement at O, 10, 20, 40 and 60 minutes.
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Fig. 3.7 The glucose response to an intravenous injection 
of 500 mg/kg b.w . 2-DG in glucagon-immunised 
and non-immunised conscious rabbits. (Values 
are mean ± standard error of the mean n = 3x2)
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The results (Fig.3.9) show that while somatostatin 
reduced blood glucose levels in control animals, and was 
presumably effective in^inhibiting glucagon release, it did 
not significantly inhibit production of 2DG-induced 
hyperglycaemia-
3.3.3 Effect of Adrenergic Blocking Agents on 2DG-Induced
Hyperglycaemia
Apart from glucagon the other major factor implicated
in the literature in mediating 2DG-induced hyperglycaemia is
increased production, or release of catecholamines. In the 
following section adrenaline and some adrenergic blocking 
agents have been studied in connection with the mechanism of 
2DG-induced hyperglycaemia.
(a) Effect of short-term adrenergic blockade on 
adrenaline-induced hyperglycaemia in rats
Adrenaline 50 yg/kg b.w. dissolved in 50 yl of saline
was injected into the tail of rats - on some occasions alone
(as controls) and on others together with pharmacological 
doses of adrenergic blockers. In all 24 "control" animals 
and 36 "experimental" animals were studied. Groups of 6, 
rats were used in each "experimental" group which were not 
necessarily dealt with on the same day. The blockers tested 
and the doses used are shown in Table 3.4. In the main the 
doses of the various blockers were 2-3 times, on a weight 
basis, that recommended by the manufacturers for human use 
and were comparable to those used by other authors in animals 
(Table 3.4).
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■® Somatostatin + 2DG 
"O Somatostatin + Saline 
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Fig. 3. 9 Effect of somatostatin on the 2-DG induced 
hyperglycaemia.
Glucose responses to an intraperitoneal 
injection of: saline only (control), 500 mg/kg b .w  
b.w. 2-DG, somatostatin only and 2-DG + 
somatostatin (for details see Fig. 3. 8) in 
anaesthetised fed rats. (Values are mean ±  ^
standard error of the mean, n =  5)
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The rats were anaesthetised with phenobarbitone. When 
they were unconscious the blockers were given intra- 
peritoneally and 2-3 minutes later adrenaline (50 yg/kg 
b.w.) was administered via the tall vein. Blood 
samples for the glucose measurement were obtained from 
the tail vein at 0, 10, 20, 40 and 60 minutes.
The results (Fig.3.10) showed that phentolamine, 
tolazoline and oxprenoloi completely blocked the hyper- 
glycaemic action of adrenaline. Thymoxamine and,phenoxy- 
benzamine significantly increased the glucose response 
while propranolol had no effect. These variations in 
response may, in part, be due to doses of blockers used.
(b) Effect of adrenergic blockade on 2DG-induced 
hyperglycaemia in rats
(i) Short-term effect
The adrenergic blockers described in the previous 
section were used at the same dose as before. Groups of 
six anaesthetised animals were used. Soon after the 
animals became unconscious, the animals in each group 
received one of the blockers intraperitoneally; 1-3 minutes 
later 500 mg/kg b.w. 2DG solution was administered intra­
peritoneally. Blood was withdrawn from the tail vein at 
O, 10, 20, 40 and 60 minutes.
None of the adrenergic blockers inhibited 2DG-induced 
hyperglycaemia significantly. As shown in Fig.3.11 the 
blood glucose responses to 2DG with, or without, adrenergic
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Control: 
Adrenaline
Phenoxybenzamine 
(5 mg/kg b .w . )
+ Adrenaline
-^hynioxaniine (1 mg/kg 
l/b. w. ) + Adrenaline
Propranolol (10 mg/kg 
b .w .)  + Adrenaline
Oxprenolol (11 mg/kg 
b .w .) + Adrenaline
Phentolamine (10 mg/kg 
b .w .)  + Adrenaline
4 Control: Saline only
^^^olazoline (7 mg/kg 
^ b. w. ) + Adrenaline
20 40
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Fig. 3.10 Blood glucose response to an intravenous injection of 
50 jLLg/kg b.w.adrenaline in the presence of various 
adrenergic blocking agents (anaesthetised fed rats. 
Values are mean ± standard error of the mean, n for 
’’control adrenaline” = 24; n = 6 for each ’’experimental” 
groups)
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Fig. 3.11 Blood glucose response to an injection of 500
m g/kg b.w. 2-DG with and without a  or jS-adrenergic 
blockers in anaesthetised fed rats. (Values are mean 
+ standard error of the mean, n = 6)
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blockers were almost parallel. Fig.3.12 shows the 
corresponding plasma levels of 2DG.
(ii) Long-term effect
Phenoxybenzamine is a long-acting alpha adrenergic 
blocking agent: therefore it may provide complete blockade 
of the a-receptors after long periods of treatment if given 
in sufficiently high doses. The drug was administered daily 
(i.p.) at a dose of 5 mg/kg b.w. for five days followed, on 
the sixth day, by a dose of 10 mg/kg b.w. The 2DG solution 
was administered to the anaesthetised animals on the sixth 
day one hour after the last dose of blocking agent. While 
blood 2DG levels were the same as in previous experiments, 
the hyperglycaemic response was absent (Fig.3.13). The 
results suggest that phenoxybenzamine may have prevented 
the 2DG hyperglycaemic effect by blocking or-receptors. 
However, it was noted that, by the end of the experiment, 
food consumption by the test animals was lower than that 
of the control animals and they were suffering from severe 
constipation and looked very ill. Because the phenoxy­
benzamine- treated animals were consuming less food, it was 
thought that hepatic glycogens reserve may have become ‘ 
depleted and their general carbohydrate metabolism somewhat 
affected. An arginine stimulation test was carried out 
on these animals the next day [for details of the test see 
3.3.2. (c)] and the results are shown in Fig.3.14. They 
indicate a lower plasma glucagon response in the treated 
animals compared with their controls. Moreover, instead
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(Values are mean t  standard error of the mean, n=6)
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Fig. 3.13 The effect of long-term treatment with 35 m g/kg  
b.w. phenoxybenzamine (ce-blocker) on the plasma 
glucose response to 2-DG injection in 
anaesthetised rats (500 m g/kg b.w.)
(Values are mean + standard error of the mean, 
n = 5)
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of the slight (10%) increase in blood glucose concentration 
observed in the control animals, the test animals showed 
a marked decrease (60%) . Phenoxybenzamine ha s a dual 
effect. It is both a potent inhibitor of noradrenaline 
synthesis and blocks its uptake by various tissues (261).
It is; therefore, possible that diminished availability of 
noradrenaline at sympathetic nerve endings in the liver is 
at least partially responsible for the inhibition of 2DG- 
induced hyperglycaemia by phenoxybenzamine.
3.3.4 Studies on the Metabolic Fate of 2DG
As the previous work failed to elucidate the exact 
mechanism by which 2DG induces hyperglycaemia, the metabolic 
fate of injected 2DG was studied. The following invest­
igations were carried out.
(a) Distribution of tritiated 2DG following 
intraperitoneal injection in rats
Ten animals were anaesthetised and divided into two 
groups. Both groups were given the usual dose of 500 mg/ 
kg b.w. 2DG (i.p.), but the test group also received 25 yCi 
(0.186 yg) tritiated 2DG per animal. After 60 minutes,
5 ml blood was collected by cardiac puncture; the animals 
were then killed and samples of liver, kidney, adipose tissue, 
brain, pancreas and urine were collected. Blood was separated 
and both plasma and red cells were stored at -20°C.
Tissues from the animals which received only 
"cold" 2DG were used as blanks when the tissue extracts 
were counted for tritium. Urine samples were diluted
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1:100 (v/v) before counting. Other tissue extracts were 
counted after treatment as described in 3,2.7, (b).
The results of this study are recorded in Table 3.5 
More than 50% of the radioactivity was recovered from 
urine and the rest of the radioactivity were distributed 
in body tissues with slightly more in the liver and the 
blood than elsewhere.
The urine samples were fractionated by TLC using 
the technique described in 3.2,7.(d) and sprayed with 
the identification reagent. It was found that most of 
the radioactivity was in the region of 2DG (Rf =0,55) (as 
compared with a 2DG standard and a urine sample "spiked" 
with 2DG, 2DG-6-P, G-6-P and glucose were also used as 
standard).
(b) Excretion of 2DG in rats
In a separate experiment four rats were injected 
with the same quantities of 2DG as before and tritiated 
2DG (25 yCi/animal) without anaesthetic. They were left 
individually in special metabolic cages and urine was 
collected at various times. The results are shown in/ 
Table 3,6. It was observed that more than 50% of the
amount given was excreted in the urine in the first 24
hours; of this 44% appeared in the first 3 hours.
Urinary volume was high particularly in the first 3 hours, 
probably due to the diuretic effect of the hyperesmolar
solution of the 2DG given.
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TABLE 3.5 Distribution of 25 y Ci (0.186 yg)/animal 
tritiated 2DG (+ 500 mg/kg b.w. "cold"
2DG) in anaesthetised fed rats. Tissues 
were collected at 60 minutes after the 
injection of 2DG.
(Values are mean - standard error of the mean)
Tissue (n = 5) yCi/ml or g wet tissue
yC i/organ 
(mean value)
% of total 
amount giver
Liver* 0.038 + 0.002 0.456 1.824
Brain 0.065 + 0.005 0.130 0.520
Pancreas 0.053 + 0.003 0.027 0.108
Kidney 0.108 + 0.002 0.216 0.864
Plasma 0.029 + 0.002 0.319 1.276
Red blood cells 0.043 + 0.002 0.267 1.068
Urine 6.870 + 1.000 13.740 54.960
Unaccounted
for**
0.042 9.845 39.380
Total 25 100
* Glycogen was found to contain less than 0.001 Ci/g 
liver.
**Possibly distributed evenly throughout the rest of the 
body tissues.
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3.4 DISCUSSION
3.4.1 The Hyperglycaemic and Hyperinsulinaemic Effect of 2DG
The 2DG-induced hyperglycaemia was found under various 
experimental conditions, except when the animals were fasted 
for 24 hours. This indicates a need for an adequate amount 
of liver glycogen which was also necessary for glucagon- 
induced hyperglycaemia (Fig.3.2).
The high plasma insulin concentrations observed after
injection of 2DG, which in some cases preceded the hyper-
\ ■ ' 
glycaemia, may be attributable to a direct action of 2DG
on the pancreas. Hdkfelt and Hultquist (54) found that
injection of 2DG causes nuclear enlargement, degranulation
and decreased stainability of the cytoplasm of both A and
B cells of the pancreas. These authors speculated that
the release of glucagon and insulin was increased. It is,
therefore, possible that increased glucagon secretion
mediates or amplifies the 2DG-induced hyperglycaemia.
Of the hormones measured in this thesis, plasma 
insulin was the only one found to be affected by the 
injection of 2DG. However, as indicated in Chapter One 
(1.2), there are other hormones such as adrenaline and growth 
hormone which have not been studied and which may 
also be affected by 2DG injection.
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3.4.2 The Fate of 2D G after Injection
(a) Excretion
Little is known about what happens to the injected 
2DG apart from the fact that it enters body cells and is 
phosphorylated to 2DG-6-P. Experiments which employ 
tritiated 2DG were designed to provide additional data 
which might help to understand its effects. It was 
revealed, however, that large amounts (55% of total) of 
the labelled compound were excreted into the urine 
unchanged. Another amount (5.5% of total) of the 
labelled material was accounted for in the tissues that 
were tested. The rest of the material (39.4% of total) 
could have distributed among the body tissues that were 
not tested. The data also show that only a small amount 
of tritiated 2DG (1.8% of total) is incorporated into 
the liver and an even smaller amount in the glycogen (0.04% 
of total) . '
The 2DG treated rats excreted approximately 40%
more urine during the 24 hours following injection than
,
their controls (14.32 - 1.2 ml/24 hours for test animals
■ + • ■ against 10.37 - 0.7 ml/24 hours for controls). This may
have been due to the greater osmolar load resulting from
the 2DG that was excreted unchanged in the urine.
(b) Intracellular metabolism of 2DG
It has sometimes been said that the main cause of 
the 2DG-induced hyperglycaemia is the competition between 
2DG-6-P and glucose-6-P for phosphoglucoisomerase (44) ,
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with subsequent inhibition of the glycolytic pathway 
leading to partial blockage of glucose metabolism.
However, as shown in 3.2.2 the alternative energy pathway, 
the hexose,monophosphate shunt can still operate ^t the 
phosphate level) at a molar ratio of 2DG-6-P/G-6-P of less 
than 10 and a significant inhibition may occur at a 
concentration of 2DG-6-P 50 times that of G-6-P. The 
presence of 2DG (or its phosphate) in the cells of the 
central nervous system may have great importance in 
initiating the hyperglycaemia. Frohman and Nagai (57) 
found that injection of 2DG (50 mg/kg b.w.) directly into 
the ventricular fluid of dogs caused a rise in blood 
glucose, although the same dose (5 mg/kg b.w.) was 
ineffective in producing hyperglycaemia when injected 
intravenously. The concentration of 2DG locally must 
have been very high indeed. The site of the 2DG effect 
is not clear from these observations but the hypothalamus 
has been suggested (57).
3.4.3 The Relationship between Glucagon and 2DG-Induced
Hyperglycaemia
(a) Blood glucagon concentration after 2DG 
injection
Despite the evidence provided by Müller e^ aj^  (56) 
and Frohman and Nagai (57) that plasma glucagon levels 
rose after the injection of 2DG, none of the experiments 
performed in this study, using intraperitoneal injections of 
2DG into rats, showed a significant rise in glucagon levels.
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However, it should be mentioned that in both of the 
previous reports conscious dogs were used and the 2DG 
solutions were infused intravenously or intraventrically 
via a cannula.
(b) The hyperglycaemic effect of 2DG in glucagon- 
immunised animals
These animals provide an interesting "glucagon- 
deficient" model for experimental work since sufficient 
unoccupied glucagon antibody molecules are present in 
their circulation to "mop-up" additional glucagon added 
to the circulation acutely. This is shown by the 
failure of the glucagon-immunised animals to show a 
"normal" rise in blood glucose (or plasma insulin) after 
administration of exogenous glucagon.
Despite an apparent lack of glucagon effect in 
these animals, 2DG injection caused a rise in blood 
glucose similar to that observed in control animals.
These data suggest that glucagon is not necessary for 
the hyperglycaemic effect of 2DG. This view is supported 
by the failure to observe a rise in plasma glucagon in 
2DG-treated rats and the failure of somatostatin, a 
glucagon suppressor, to prevent the appearance of 2DG- 
induced hyperglycaemia,
(c) Insulin response to arginine in glucagon- 
immunised animals
The insulinotropic activity of arginine has been 
shown in many species but the exact mechanism has not as
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yet been resolved. There are two views on this matter.
One is that arginine has a direct stimulatory effect on 
the B-cells (262); the second view is that arginine 
stimulates insulin secretion indirectly by eliciting 
glucagon secretion from the A-cells (263). The present 
results from glucagon-immunised animals favour the second 
view since arginine failed to stimulate insulin in the 
glucagon-immunised animals to the same extent as in 
control animals.
3.4.4 The Relationship between the 2DG-Induced Hyperglycaemia
and Catecholamines
The results of experiments performed in this study 
concerning the possible role of adrenaline (and nor­
adrenaline) in mediation of 2DG-induced hyperglycaemia were 
equivocal. Although some adrenergic blockers, e.g. phento 1- 
amine (a), tolazoline (3) and oxprenolol (3) inhibited 
adrenaline-induced hyperglycaemia, they did not prevent 
2DG-induced hyperglycaemia. This could indicate that 
catecholamines receptors are not essential for the 
production of 2DG-induced hyperglycaemia. However,
.
results obtained from the use of adrenergic blockers should 
be treated cautiously since these drugs appear to have many 
effects on body tissues and organs (e.g. heart and liver) 
as well as interfering with carbohydrate and lipid 
metabolism (264). These effects were reflected by the 
severe constipation and general malaise found in rats
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after prolonged treatment with phenoxybenzamine. On 
the other hand complete blocking of adrenergic receptors 
may not have been attained by the simple experimental 
conditions used. Insufficient dose may be one of the 
reasons for not obtaining complete inhibition of adrenaline- 
induced hyperglycaemia and the enhanced adrenaline- 
induced hyperglycaemia observed in the presence of some 
blockers (e.g. phenoxybenzamine), might have been 
secondary to stimulated release of endogenous catechol­
amines (265) .
However, since the hyperglycaemic effect of 2DG 
was reported to be absent in autonomic denervated patients 
(52) it is likely that the integrity of the sympathetic 
nervous system is important for the hyperglycaemic effect 
of 2DG to become manifest.
3.4.5 Speculation on the 'Mechanism of 2DG-Induced
Hyperglycaemia
The present study has shown that glucagon mediation 
of 2DG-induced hyperglycaemia is unlikely. A possible 
scheme for the mechanism of the 2DG-induced hyperglycaemia 
is shown in Fig.3.15 and summarised as follows:
After the injection of 2DG into the circulation, 
it enters the cells of both the nervous system and other 
body tissues where it is converted into 2DG-6-P. The 
intracellular amount of 2DG (and its phosphate) is 
probably in equilibrium with the circulating level of 
2DG. The 2DG-6-P produced in the cells competes with
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G-6-P for phosphoglucoisomerase and since it is not further 
metabolised (?) it is likely that its effect will continue 
for a long period. Therefore, both 2DG-6-P (as it is not 
metabolisable) and G-6-P (due to the inhibition of its 
metabolising enzyme) would accumulate in the cells. This 
accumulation will result in cutting off the glucose supply 
to the cells. However, as the primary energy pathway, 
despite the presence of G-6-P, is still not operational and 
no energy is produced, the regulator cells of the autonomic 
nervous system in the hypothalamus are stimulated. This 
would result in the release of noradrenaline at nerve 
endings and adrenaline from the adrenal medulla leading in 
turn to release of glucose into the circulation providing 
there is sufficient glycogen in the liver to provide it.
Since 2DG is gradually removed from the circulation 
by the kidneys, it is possible that intracellular 2DG-6-P 
is gradually dephosphorylated and the 2DG released from 
the cells into the circulation is excreted into the urine 
leading eventually to restoration of normoglycaemia.
3.4.6 Suggestions for Future Studies
The results of the experiments carried out in the 
course of this work have clarified some aspects of 2DG- 
induced hyperglycaemia. However, a full understanding 
of the exact mechanism is still far from fulfilled. The 
following experiments might provide additional information 
on the physiological and metabolic consequences of 2DG 
administration.
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(a) Studies using 2DG-6-P
Most of the ip. vivo experiments, to date, have 
used 2DG itself. However, the theory of competitive 
inhibition by 2DG-6-P of G-6-P enzyme systems could be 
further followed by some in vivo experiments using 2DG- 
6-P. If 2DG-6-P does induce hyperglycaemia, it would 
be consistent with the view that 2DG-6-P is the primary 
hyperglycaemic metabolite. There might be, however, 
some problems with membrane transport of the phosphor y 1- 
ated metabolite into cells which would have to be 
resolved (encapsulation into liposomes might be useful).
Various species respond differently to 2DG 
injection. While 2DG injection raises plasma insulin 
levels in rats (Table 3.1) and in dogs (55), it does not 
significantly affect insulin levels in man (53) possibly 
due to over-riding inhibition of B-cells by adrenergic 
activity. Comparative studies of the effect of 2DG 
injection on the hormones involved in glucose homeostasis 
in a variety of species may produce more clues to the 
mechanism of 2DG-induced hyperglycaemia which appears to 
develop in all species so far examined (47,48,49,56).
(b) The use of hyper- and hypoglycaemic models
Hyperglycaemia induced by 2DG has so far been demon­
strated using healthy rats. Alternative means of under­
standing 2DG-induced hyperglycaemia may be achieved by 
using animal models with abnormal blood glucose levels.
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In children with idiopathic hypoglycaemia no 
increase in blood glucose level was observed after the 
injection of 2DG (50). This was apparently related to 
the absence of sensitivity of an autonomic nervous 
system or adrenal medullary response to 2DG. This 
suggests that the integrity of either the adrenal 
medulla or the autonomic nervous system as a whole is 
necessary for the production of 2DG-induced hyperglycaemia. 
Therefore, adrenalectomised and/or sympathectomised animals 
may be a useful model for further studies on the action of 
2DG on insulin secretion and glucose homeostasis.
Hyperglycaemic models, such as diabetic animals, can 
also be used to study the effects of 2DG in an environment 
of decreased insulin activity? dysfunction of the B-cells, 
and of high blood glucose levels. It would also be 
profitable to study animals immunised against insulin 
in order to ascertain whether insulin is necessary or 
not for the 2DG-induced hyperglycaemia. Pancreatect- 
omised animals would also provide an additional tool for 
the study of 2DG-induced hyperglycaemia in the absence of 
both glucagon and insulin.
168
REFERENCES
169
1. Cannon, W.B.
"Organisation for physiological homeostasis"
Physiol.Rev. _9, 1929, 399-431 (Abstract)
2. cannon, W.B.
"The wisdom of the body"
W.W. Norton and Co. Inc., N.Y. 1932
3. Gautier-Smith, P.C.
Clinical aspects of hypoglycaemia, in "Biochemical 
Aspects of Neurological Disorders" Ed. by Cumings, J.N. 
and Kremer, M. (second series)
Blackwell Scientific Publications, Oxford, 1955, pp.159-168
4. Colowick, S.P. and Kaplan, N.O.
"Carbohydrate metabolism", in "Annual Review of 
Biochemistry", Vol.20.
Ann.Rev.Inc., Stanford, California, 1951, pp.513-558.
5. Hers, H.G.
"The control of glycogen metabolism in the liver", in 
"Annual Review of Biochemistry", Vol.45.
Ann.Rev.Inc., Palo Alto, California, 1976
6. De Bodo, R.C., Steele, R., Altszuler, N., Dunn, A. and 
Bishop, J.S.
"On the hormonal regulation of carbohydrate metabolism?
14
studies with C-glucose", in "Recent Progress in 
Hormone Research" Vol.19, Ed. Pincus, G.
Academic Press, N.Y. and London, 1963, pp.445-482.
7. Marks, V.
'
"Glucose and glucose homeostasis"
Teach-In, 2, 1974, 183-193.
, pp.167-189.
170
8. Marks, V. and Turner, D.S.
"The gastrointestinal hormones with particular reference 
to their role in the regulation of insulin secretion"
Essays Med,Biochem. , _3, 1978, 109-152.
9. Daughaday, W,H., Hall, K., Raben, M.S., Salmon, W.D.,
Van Den Brande, J.L. and Van Wyk, J.J.
"Somatomedin; proposed designation for sulphation factor" 
Nature, 255, 1972, 107.
10. Froesch, E.R., Bdrgi, H., Müller, W.A., Humbel, R.E. ,
Jakob, A. and Labhart, A.
"Non suppressible insulin-like activity of human serum; 
purification, physicochemical and biological properties 
and its relation to total serum IDA" in "Recent Progress 
in Hormone Research" vol.23, ed. Pincus, G.
Academic Press, N.Y. and London, 1967, pp.555-605.
11. Froesch, E.R.
In "Recent Progress in Hormone Research" Vol. 3.0, ed.
Greep, R.O.
Academic Press, N.Y. and London, 1974, pp.295-306.
12. Tell, G.P.E., Cuatrecasas, P., Van Wyk, J.J. and 
Hintz, R.L.
"Somatomedin; inhibition of adenylate cyclase activity 
in subcellular membranes of various tissues"
Science, 180, 1973, 312-314.
13. Van Wyk, J.J., Underwood, L.E., Hintz, R.L., Clemmons, D.R., 
Viona, S.J. and Weaver, R.P.
"The somatomedins; a family of insulin like hormones 
under growth hormone control", in "Recent Progress in 
Hormone Research", Vol.30, ed, Greep, R.O.
Academic Press, N.Y. and London, 1974, pp.259-295.
171
14. Phillips, L.S and Orawski, A.T.
"Nutrition and somatomedin"
Diabetes, 26, 1977, 864-869.
15. Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., 
Rivier, J. and Guillemin, R.
"A hypothalamic polypeptide that inhibits the secretion 
of pituitary growth hormone"
Science, 17^, 1973, 77-79.
16. Siler, T.M., Vandenberg, G., Yen, S.S.C., Brazeau, P., 
Vale, W. and Guillemin, R.
"Inhibition of growth hormone release in humans by 
somatostatin"
J.din.Endocrinol.Metab., 37, 1973, 632-634.
17. Koerker, D.J., Ruch, W., Chideckel, E., Palmer, J., 
Goodner, C.J., Ensinck, J. and Gale, C.C.
"Somatostatin: hypothalamic inhibitor of the endocrine 
pancreas"
Science, 1974, 482-484.
18. Barden, N., Lavoie, M., Dupont, A., Coté, J. and 
Coté, J.P.
"Stimulation of glucagon release by addition of anti- 
somatostatin serum to islets of Langerhans in vitro" 
Endocrinology, 101, 1977, 635-638.
19. Gerich, J.E., Schultz, T.A., Lewis, S.B. and 
Karam, J.H.
"Clinical evaluation of somatostatin as a potential 
adjunct to insulin in the management of diabetes mellitus" 
Diabetologia, 13, 1977, 537-544.
172
20. Hassall, C.H., Reyle, K. and Feug, P.
"Hypoglycin A, B: biologically active peptides from 
Blighia sapida"
Nature, 17 3, 1954; 356-357.
21. Ellington, E.V., Hassall, C.H., Plimmer, J.R. and 
Seaforth, G.E.
"Amino acids and peptides. Part II The constitution 
of hypoglycin A"
J.Chem.Soc., 1959 (1), 80-85.
22. Sherratt, H.S.A.
"Hypoglycin and related hypoglycaemic compounds"
Brit.Med.Bull. 25, 1969, 250-255.
23. Milner, R.D.G. and Wirdnam, P.K.
"Hypoglycin stimulates insulin secretion"
Diabetologia, 13, 1977, 637-638.
24. Stacpoole, P.W. and Felts, J.M.
"Diisopropylammonium dichloroacetate (DIPA) and sodium 
dichloro-acetate (DCA): effect on glucose and fat 
metabolism in normal and diabetic tissue"
Metab.Clin.Exp., ID, 1970, 71-78.
25. Whitehouse, S. and Randle, P.J.
"Activation of pyruvate dehydrogenase in perfused rat 
heart by dichloroacetate"
Biochem.J., 134, 1973, 651-653.
26. Crabb, D.W., Mapes, J.P., Boersma, R*W. and Harris, R.A, 
"Effect of dichloroacetate on carbohydrate and lipid 
metabolism of isolated hepatocytes"
Arch.Biochem.Biophys., 173, 1976, 658-665.
. 173 V
27. Brov/n, J.D. , Stone, D.B. and Steele, A.A,
"Mechanism of action of antilipolytic agents"
Metabolism, 3H, 1969, 926-929.
28. Connon, J.J.
"A differential action of phenformin in normal and 
diabetic rat livers"
Diabetologia, 197 3, 47-49.
29. Fulop, M.,and Hoberman , H.D.
"Phenformin-associated metabolic acidosis"
Diabetes, 25, 1976, 292-296.
30. Holloway, P.A.H. and Alberti, K.G.M.M.
"Reversal of phenformin-induced hyperlactataemia by 
dichloroacetate in normal and diabetic rats"
Diabetologia Id, 1975, 350-351 (Abstract)
31. Bohannon, N.V. , Karam, J.H. , Lorenzi, M. , Gerich, J.E.,
Matin, S.B. and Forsham, P.H.
"Plasma glucagon suppression by phenformin in man" 
Diabetologia, 33, 1977, 503-508.
32. Frantz, A.G., Kleinberg, D.L. and Noel, G.L.
"Studies on prolactin in man", in "Recent Advances in
Hormone Research", Vol.28, ed. Astwood, E.B.
Academic Press, N.Y. and London, 1972, pp.558.
33. Cori, C.F. and Cori, G.T.
"The mechanism of epinephrine action"
J.Biol.Chem., 79, 1928, 309-355.
34. Sutherland, E.W.
"The effect of the hyperglycaemic factor and epinephrine 
on enzymes of liver and muscle"
• Ann.N.Y.Acad.Sci., 54, 1951, 693-706.
. ■ . 174
35. Mikami, S. and Oro, S.
"Glucagon deficiency induced by extirpation of alpha 
islets of the fowl pancreas"
Endocrinology, 71”, 1962, 464-47 3.
36. Leading article 
"Glucagon"
Brit.Med.J., 2, 1956, 288-289.
37. Newsholme, E.A.
"Carbohydrate metabolism ip vivo; regulation of blood 
glucose level"
Clin.Endocrinol.Metab., 5 (3), 1976, 543-578.
38. Vallance-Owen, J.
"Insulin antagonists and inhibitors", in "Advances 
in Metabolic Disorders", Vol.1, ed. Levine R. and Luft, R. 
Academic Press, N.Y. and London, 1964, pp.191-215.
39. Randle, P.J. , Gerald, P.B. , Hales, C.N. and Newsholme, E.A, 
"The glucose and fatty acid cycle. Its role in insulin 
sensitivity and the metabolic disturbances of diabetes" 
Lancet, i, 1963, 785-789.
40. Cramer, E.B. and Woodward, G.E.
"2-Deoxy-D-glucose as an antagonist of glucose in yeast 
fermenta tion"
J.Franklin Inst., 253, 1952, 354-360.
41. Woodward, G.E. and Hudson, M.T.
"The effect of 2-deoxy-D-glucose on glycolysis and 
respiration of tumor and normal tissues"
Cancer Res., 14, 1954, 599^605.
175
42. Wick, A.N. , Drury, D.R. and Mori ta, T.N.
"2-Deoxyglucose; a metabolic block for glucose"
Proc. Soc.Exp.Biol, and Med.., 1955, 579-582.
43. Kipnis, D.M. and Cori, C.F,
"Studies of tissue permeability. V. The penetration and
phosphorilation of 2-deoxyglucose in the rat diaphragm"
J.Biol.Chem., 234, 1959, 171-177.
44. Wick, A.N., Drury, D.R., Nakada, H.I. and Wolfe, J.B.
"Localization of the primary metabolic block produced 
by 2-deoxyglucose"
J.Biol.Chem., 224, 1957, 963-969.
45. Sols, A., Heredia, C.F. and Amil-Ruiz, M.
"2-Deoxyglucose as metabolic substrate and inhibitor
of glycolysis in fungi"
Biochem.Biophys.Res.Comm., 1960, 126-129.
46. Lazio, J., Harlan, W.R., Klein, R.F., Kirshner, N.,
Harvey Estes, E. and Bogdonoff, M.D.
"The effect of 2-deoxy-D-glucose infusions on lipid 
and carbohydrate metabolism in man"
J.Clin.Invest., 1961, 171-176.
47. HJkfelt, B. and Bydgeman, S.
"Increased adrenaline production following administration 
of 2-deoxy-D-glucose in the rat" -
Proc.Soc.Exp.Biol.and Med., 106, 1961, 537-539.
48. Landau, B.R. and Lubs, H.A.
"Animal responses to 2-deoxy-D-glucose administration" 
Proc.Soc.Exp.Biol.and Med.,99, 1958, 124-127.
49. Wegienka, L.C., Grasso, S.G. and Forsham, P.H.
"Estimation of adrenomedullary reserve by infusion of 
2-deoxy-D-glucose"
J.Clin.Endocrin., 26, 1966, 37-45.
176
50. Sizonenko, P.C., Paunier, L., Vallotton, M.B.,
Terraz, M. and Scholer-Markovic, D.
"Childhood hypoglycemia: plasma glucose and renin 
response to deoxyglucose for assessment of adrenal 
medulla responsiveness"
Helv.Paediat.Acta, 27 , 1972, 565-573.
51. Kruse, K. and Bartels, H.
"Die bedeutung des 2-deoxy-glucose-tests für die 
differenzierung kindlicher hypoglykâmien"
Klin.Pediat. , 3^, 1975, 308-313.
52. Brodows, R.G., Pi-Sunyer, F.X. and Campbell,R.G.
"Neural control of counter-regulatory events during 
glucopenia in man"
J.Clin.Invest., 1973, 1841-1844.
53. Goldsmith, S.J., Yalow, R.S. and Berson, S.A.
"Effects of 2-deoxy-D-glucose on insulin-secretory 
responses to intravenous glucose, glucagon, tolbutamide 
and arginine in man"
Diabetes, 19, 1970, 453-457.
54. Hôkfelt, B. and Hultguist, G.
"Stimulation of pancreatic islet cells by 2-deoxy-D- 
glucose"
Proc.Soc.Exp.Biol.and Med., 107, 1961, 66-68.
55. Galansino, G., Parmeggiani, A., Fromm, D.G., Logartz, L.J. 
and Foa, P.P.
"Studies on 2-deoxy-D-glucose-induced hyperglycemia"
Proc.Soc.Exp.Biol.and Med., 116, 1964,1005-1006.
.177
56. Müller, W.A. , Faloona, G.R. and Unger, R,H.
"The effect of experimental insulin deficiency on 
glucagon secretion"
J.Clin.Invest., 50, 1971, 1992-1999.
57. Frohman, L.A., Müller, E.E. and Cocchi, D.
"Central nervous system mediated inhibition of insulin 
secretion due to 2-DG"
Horm.Metab.Res., 1973, 21-26.
58. Frohman, L.A. and Nagai, K.
"Central nervous system mediated stimulation of 
glucagon secretion in the dog following 2-deoxyglucose" 
Metabolism, 25 (Suppl.l), 1976, 1449-1452.
59. Panerai, A.E., Olgiati, V.R., Udeschini, G., Cocchi, D., 
Pecile, A. and Müller, E.E.
"Hyperglycaemia and inhibition of insulin secretion by 
2-deoxyglucose in rats with hypothalamic lesion" 
Pharmacol.Res.Comm., 7, 1975, 133-141.
60. Lipman, R.L., Ulvedal, F., Schnure, J.J., Bradley, E.M. 
and Lecocg, F.R.
"Gluco-regulatory hormone response to 2-deoxy-D-glucose 
infusion in normal subjects at bedrest"
Metabolism, 13, 1970, 980-987.
61. Frienkel, N., Metzger, B.E., Harris, E., Robinson, S. 
and Mager, M.
"The hypothermia of hypoglycemia"
New Engl.J.Med., 287, 1972, 841-645.
62. Gough, A.L. and Keddie, N.C.
"An assessment of the reproducibility and safety of 2- 
. deoxy-D-glucose as a gastric acid stimulant in duodenal 
ulcer patients"
Gut, 16, 1975, 171-176.
178
63. Banting, F,G. and Best, C.H.
"The internal secretion of the pancreas"
J,Lab.Clin.Med. , 1_, 1922, 251-266 (Abstract)
64. Collip, J.B.
"Delayed manifestation of the physiological effects of 
insulin following administration of certain pancreatic 
extracts"
Am.J.Physiol., 63, 1923, 391-392.
65. Murlin, J.R., Clough, H.D., Gibbs, C.B.F. and Stokes, A.M. 
"Aqueous extracts of pancreas. I. Influence on the 
carbohydrate metabolism of depancreatised animals" 
J.Biol.Chem., 5^, 1923, 253-296 (Abstract)
66. Bürger, M. and Brandt, W.
"Glukagon, the hyperglucemia-inciting substance of 
the pancreas"
Zeit.Ges.Exptl.Med., 9^, 1935, 375-397.
67. Lundsgaard, E., Neilson, A.N. and 0rskov, S.L.
"The possibility of demonstrating an insulin effect 
on the isolated mammalian liver"
Skand.Arch.Physiol., ^1, 1939, 11-19.
68. Sutherland, E.W. and De Duve, C.
Origin and distribution of the hyperglycaemic glyco­
genolytic factor of the pancreas"
J.Biol.Chem., 17^, 1948, 663-674.
69. Sutherland, E.W.
In: Recent Progress in Hormone Research" Proceedings of 
the Laurentian Hormone Conference, Volume 5, 1950, p.441. 
New York and London: Academic Press.
179
70. Staub, A., Sinn, L. and Behrens, O.K.
"Purification and characterization of hyperglycaetnic- 
glycogenolytic factor"
Science, 117, 1953, 628-629.
71. Staub, A., Sinn, L. and Behrens, O.K.
"Purification and crystallization of glucagon" 
J.Biol.Chem., 214, 1955, 619-632.
72. Bromer, W.W. , Sinn, L.G. and Behrens, O.K.
"The amino acid sequence of glucagon. V. Location of 
amide groups, acid degradation studies, and summary of 
sequential evidence"
J.Am.Chem.Soc., 79, 1957, 2807-2810.
73. Bromer, W.W. , Boucher, M.E. and Koffenberger, J.E. 
"Amino acid sequence of bovine glucagon"
J.Biol.Chem., 246, 1971, 2822-2827.
74. Sundby, F. and Markussen, J.
"Isolation, crystallization and amino acid composition 
of rat glucagon"
Horm.Metab.Res. , 1971, 184-187.
75. Sundby, F. and Markussen, J.
"Rabbit glucagon: isolation, crystallization and amino 
acid composition"
Horm.Metab.Res., 4, 1972, 56.
76. Thomson, J., Kristiansen, K., Brunfeldt, K. and 
Sundby, F.
"The amino acid sequence of human glucagon"
FEBS Letters, 21, 1972, 315-319.
. .:i8o
77. Bromer, W.W.
In "Hand book of Physiology" Section 7 : Endocrinology, 
Volume 1.
American Physiological Society, Washington, DC, 1972, p.134
78. Haugen, W.P. and Lipscomb, W.N.
"The crystal and molecular structure of the hormone 
glucagon"
Acta Cryst., 185, 1969, 425 (Abstract)
79. Dockrey, G.J.
"Molecular evaluation of gut hormones: Application of 
comparative study on the regulation of digestion" 
Gastroenterology 7_2, 1977, 344-352.
80. Weinge, K.F., Wünsch, E., Biro, G., Kettl, H. and 
Mitzuno, M.
"Immunological reactivity and biological activity of 
synthetic glucagon"
Diabetologia, 1969, 97-100.
81. Lane, M.A.
"The cytological characters of areas of Langerhans"
Am. J.Anat. , 7./1907, 409-422.
82. Hartroft, W.S. and Wrenshall, G.A,
"Correlation of beta cell granulation with extractable 
insulin of the pancreas"
Diabetes, 1955, 1-7.
83. Levine, H.J. and Glenner, G.G.
"Observations on tryptophan staining of the pancreatic 
alpha cells"
J.Nat.Cancer Inst., 20, 1958, 63-90.
181
84. Baum, J., Simons, B.F, Jr., Unger, R.H. and Madison, L.L. 
"Localization of glucagon in alpha cells in the pancreatic 
islet by immunofIncrescent technics"
Diabetes, 11, 1962, 371-374.
85. Vassallo, G., Solcia? G. and Capella, C.
"Light and electron microscopic identification of several 
types of endocrine cells in the gastrointestinal mucosa of 
the cat"
Z.Zellforsch., 98, 1969, 333-356.
86. Kobayashi, K., Fujita, T. and Sasagawa, T.
"The endocrine cells of human duodenal mucosa, an electron 
microscopy study"
Arch.Histol.Jap., 31, 1970, 433-454.
87. Sutherland, E.W. , Cori, C.F. , Haynes, R. and Olsen, N.S. 
"Purification of the hyperglycemic-glycogenolytic factor 
from insulin and from gastric mucosa"
J.Biol.Chem., 180, 1949, 825-837.
88. Unger, R.H., Eisentraut, A., Sims, K., McCall, M.S. and 
Madison, L.L.
"Sites of origin of glucagon in dogs and humans"
Clinical Research, 9, 1961, 53.
89. Kenny, A.J. and Say, R.R.
"Glucagon-like activity extractable from the gastro­
intestinal tract of man and other animals"
J.Endocrinol., 2^, 1962, 1-7.
90. Samols, E., Tyler, J., Megyesi, C. and Marks, V. 
"Immunochemical glucagon in human pancreas, gut and 
plasma"
Lancet, ii, 1962, 727.
182
91. Valverde, I., Rigopoulou, D., Exton, J., Ohneda, A., 
Eisentraut, A. and Unger, RoH.
"Demonstration and characterization of a second fraction 
of glucagon-like immunoreactivity in jejunal extracts"
Am.J.Med.Sci., 255, 1968,415-420.
92. Valverde, I., Rigopoulou, D., Marco, J., Faloona, G.R. 
and Unger, R.H.
"Characterization of glucagon-like immunoreactivity (GLI)" 
Diabetes, 33, 1970, 614-623.
93. Valverde, I., Rigopoulou, D., Marco, J., Faloona, G.R. 
and Unger, R.H.
"Molecular size of extractable glucagon and glucagon-like 
immunoreactivity (GDI) in plasma"
Diabetes, 19, 1970, 624-629.
94. Murphy, R.F., Elmore, D.T. and Buchanan, K.D.
"Isolation of glucagon-like immunoreactivity of gut 
by affinity chromatography"
Biochem.J., 125, 1971, 61P-62P.
95. Murphy, R.F., Buchanan, K.D. and Elmore, D.T.
"Isolation of glucagon-like immunoreactivity of gut 
by affinity chromatography on anti-glucagon coupled 
to sepharose 4B"
Biochim.Biophys.Acta, 303, 1973, 118-127.
96. Vranic, M., Pek, S. and Kawamari, R.
"Increased immunoreactivity in plasma of totally 
depancreatized dogs"
Diabetes, 23, 1974, 905-912. .
183
97. Matsuyama, T. and Foa, P.P.
"Plasma glucose, insulin, pancreatic and enteroglucagon 
levels in normal and depancreatized dogs"
Proc.Soc.Exp.Biol.Med., 147, 1974, 97-102.
98. Mashiter, K. , Harding, P.E. , Chou, M. , Mashiter, G.D. ,
Stout, J., Diamond, D. and Field, J*B.
"Persistent pancreatic glucagon but not insulin response 
to arginine in pancreatectomized dogs"
Endocrinology, 9^, 1975, 678-693.
99. Jacobsen, H., Demandt, A., Moody, A.J. and Sundby, F, 
"Sequence analysis of porcine gut-GLI-1"
Biochim.Biophys.Acta 493, 1977, 452-459.
100- Ohneda, A., Aguilar-Parada, E., Eisentraut, A.H. and 
Unger, R.H.
"Control of pancreatic glucagon secretion by glucose" 
Diabetes, 18, 1969, 1-10.
101. Buchanan, K.D. , Vance, J.E. , Dinstl, K. and Williams, R.H. 
"Effect of blood glucose on glucagon secretion in 
anaesthetised dogs"
Diabetes, 18, 1969, 11-18.
102. Unger, R.H., Eisentraut, A.M., McCall, M.S. and 
Madison, L.I.
"Measurement of endogenous glucagon in plasma and the 
influence of blood glucose concentration upon its secretion" 
J.Clin.Invest., 41, 1962, 682-689.
184
103. Assan, R.
In."Glucagon: molecular physiology, clinical and 
therapeutic implications" Ed. Lefebvre,PoJ. and 
Unger, R.H. p.48 
Oxford: Pergamon Press, 197 2.
104. Rodbell, M., Kraus, H.M.J., Pohl, S.L. and Birnbauraer, L, 
"The glucagon-sensitive adenyl cyclase system in 
plasma membranes of rat liver"
J.Biol.Chem., 246, 1971, 1861-1871.
105. Berson, S.A., Yalow, R.S. and Volk, V.W.
131"In vivo and Jp vitro metabolism of I-insulin and 
131I-glucagon in normal and cortisone-treated rabbits"
J.Lab.Clin.Med-, 42_, 1957, 331-342.
106- Anserge, S., Bohley. P., Kirsche,H-, Langner, J. and
Hanson, H.
"Metabolism of insulin and glucagon: breakdown of 
radioiodinated insulin and glucagon in rat liver cell 
fractions"
Eur-J-Biochem., 19, 1971, 283-288.
107. Alford, P.P., Bloom, S.R. and Nabarro, J.D.N.
"Glucagon metabolism in man. Studies on the metabolic
clearance rate and the plasma acute disappearance time 
of glucagon in normal and diabetic subjects"
J.Clin.Endocrinol.Metab., 1976, 830-838.
108. Tarding, F., Nielsen, P., Pingel, M. and V/lund, A. 
"Biological and chemical properties of two glucagon 
preparations with prolonged action"
Eur.J.Pharmac., 7, 1969, 206-209.
185
109. Mirskey, I.A., Perisutti, G. and Davis, N.C.
"The destruction of glucagon, adrenocorticotropin 
and somatotropin by human blood plasma"
J.Clin.Invest., 38, 1959, 14-20.
110. Mirsky, I.A., Perisutti, G. and Davis, N.C.
"The destruction of glucagon by the blood plasma from 
various species" Endocrinology, 64, 1959, 992-1001.
111. Eisentraut, A.M., Whissen, N. and Unger, R.H. 
"Incubation damage in the radioimmunoassay for human 
plasma glucagon and its prevention with Trasylol"
Amer.J.Med.Sci., 255, 1968, 137-142.
112. Lefebvre, P.
"Perspectives actuelles sur le role physiologique 
du glucagon"
Ann.Endocrinol. , 27^ , 1966, 786 (Abstract)
113. Goldfine, I.D., Birnbaumer, L. and Roth, J.
125"Glucagon receptor in islet cells: binding of I- 
glucagon and activation of adenyl cyclase"
Diabetes, 20, 1971, 341.
114. Sutherland, E.W. and Cori, C.F.
"Influence of insulin preparations on glycogenolysis 
in liver slices"
J.Biol.Chem., 172, 1948, 737-750.
115. Sutherland, E.W. , Robison, GoA. and Butcher, R.W.
"Some aspects of the biological role of adenosine 3’,5' 
monophosphate (cyclic AMP)"
Circulation, 37, 1968, 279-306, (Abstract)
186
116. Davoren, P.R. and Sutherland, E.W.
"The cellular location of adenyl cyclase in the pigeon 
erythrocyte"
J.Biol.Chem., 238, 1963, 3016-3023.
117. Liu, Y.P. and Cheung, W.Y.
+2"Cyclic 3',5'-nucleotide phosphodiesterase Ca confers 
more helical conformation to the protein activator" 
J.Biol.Chem., 251, 1976, 4193-4198.
118. Brostorm, C.O., Corbin, J.O., King, C.A. and Krebs, E.G. 
"Interaction of the subunits of adenosine 3',5'-cyclic 
monophosphate dependent protein kinase of muscle"
Proc.Nat.Acad.Sci.USA, 6^, 1971, 2444-2447.
119. Marinetti, G.V., Ray, T.K. and Tomasi, V.
"Glucagon and epinephrine stimulation of adenyl cyclase 
in isolated rat liver plasma membrane"
Biochem,Biophys.Res.Comm., 36, 1969, 185-193.
120. Miller, L.L.
"Direct actions of insulin, glucagon and epinephrine on 
the isolated perfused rat liver"
Federation Proc., 24, 1965, 737-744.
121. Izzo, J.L. and Glasser, S.R.
"Comparative effects of glucagon, hydrocortisone and 
epinephrine on the protein metabolism of the fasting rat" 
Endocrinology, ^,1961, 189-198.
122. Exton, J.H. and Park, C.R.
"The stimulation of gluconeogenesis from lactate by 
epinephrine, glucagon and cyclic 3',5'-AMP in the 
perfused rat liver" In: Second Symposium on Catecholamines, 
4-9 July 1965, Milan, Italy.
Pharmacol.Rev., 18, 1966, 181-188.
187
123. Garcia, A., Williamson, J.R. and Cahill, G,F.
"Studies on the perfused rat liver. II. Effect of 
glucagon on gluconeogenesis"
Diabetes, 15, 1966, 188-193.
124. Bishop, J.S. and Earner, J.
"Rapid activation-inactivation of liver uridine diphosphate, 
glucose-glycogen transferase and phosphorylase by insulin 
and qlucagin in vivo"
J.Biol.Chem., 242, 1967, 1354-1356.
125. Belocopitow, E., Fernandez, M.D.C.G., Birnbaumer, L. 
and Torres, H.N.
"Factors affecting muscle glycogen synthetase activity.
IV. Comparative study of the different dependent forms 
of glycogen synthetase"
J.Biol.Chem., 242, 1967, 1227-1231.
126. Exton, J.H. and Parke, C.R.
"Glucagon and the metabolism of glucose" In: Glucagon: 
molecular physiology, clinical and therapeutic 
implications, Ed. Lefebvre, P.J. and Unger, RoH. p.77-108. 
Oxford: Pergamon Press, 1972.
127. Hagen, J.H.
"Effect of glucagon on the metabolism of adipose tissue" 
J.Biol.Chem., 2 36, 1961, 1023-1027.
128. Rodbell, M. and Jones, A.B.
"Metabolism of isolated fat cells"
J.Biol.Chem., 241, 1966, 140-142.
129. Langslow, D.R. and Hales, C.N.
"Lipolysis in chicken adipose tissue i^ vitro"
J.Endocrinol., 43, 1969, 285-294.
188
130. Mosinger, B., Kuhn, E. and Kujalona, V.
"Action of adipokinetic hormones on human adipose tissue 
in vitro" ,
J.Lab.Clin.Med., 66, 1965, 380-389.
131. Lefebvre, P. and Luyckx, A.
"Lipolytic action of glucagon vitro and in vivo"
In: Physiopathology of adipose tissue, Ed. Vague, J. p.257 
Amsterdam: Excerpta Medica Foundation, 1969.
132. Cries, F*A.
"Hormonal control of human adipose tissue metabolism 
in vitro" In: Adipose tissue regulation and metabolic 
function, Eds. Jean Renaud, B. and Hepp, D. p.167-171.
New York and London: Academic Press, 1970.
133. Marks, V.
"Glucagon"
Clinics in Endocrinology and Metabolism, /I, 1971, 829-845.
134. Langslow, D.R. and Hales, C.N.
"Bioassay of glucagon in human serum"
Lancet, i, 1970, 1151-1152.
135. Lefebvre, P.
"Glucagon and lipid metabolism" In: Glucagon: molecular 
physiology, clinical and therapeutic implications, Eds. 
Lefebvre, P.J. and Unger, R.H., p.109.
Oxford, Pergamon Press, 1972.
136. Corbin, J.D., Keely, S.L. and Park, C.R.
"The distribution of cyclic AMP-dependant protein kinases 
in adipose, cardiac and other tissues"_
J.Biol.Chem., 250, 1975, 218-225.
189
137. Khoo, J.C. and Steinberg, D.
"Reversible protein kinase activation of hormone sensitive 
lipase from chicken adipose tissue"
J.Lip.Res., 3 ,^ 1974, 602-610.
138. Weinges, K.F. and Ldffler, G.
"Glucagon-empfindliche lipolytische aktivitât im 
fettgewebe" (Glucagon-sensitive lipolytic activity 
of adipose tissue).
Klin.Wschr., 43, 1965, 175-176 (Abstract)
139. Schade, D.S. and Eaton, R*P.
"Modulation of fatty acid metabolism by glucagon in 
man. I. Effect in normal subjects"
Diabetes, 24, 1975, 502-509.
140. Bondy, P.K. and Cardillo, L.R.
"The effect of glucagon on carbohydrate metabolism in 
normal human beings"
J.Clin.Invest., 21' 1956, 494-501.
141. Bromer, W.W. and Chance, R.Eo
"Zinc glucagon depression of blood amino acid in rabbits" 
Diabetes, 18, 1969, 748-754.
142. Marliss, E.B., Aoki, T.T. and Cahill, G.F* Jr.
"Glucagon and amino acid metabolism" In: Glucagon, 
molecular physiology, clinical and therapeutic 
implications, Ed. Lefebvre, P.J. and Unger, R.H. p.123-150. 
Oxford : Pergamon Press, 197 2.
143. Mallette, LoE., Exton, JoH. and Park, C.R*
"Effect of glucagon on amino acid transport and utilization 
in the perfused rat liver"
J.Biol.Chem., 344, 1969, 5724-5728.
190
144. Samols, E., Marri, G. and Marks, V.
"Promotion of insulin secretion by glucagon"
Lancet, ii, 1965, 415-417.
145. Marks, V. and Samols, E.
"Glucose homeostasis" In: Recent Advances in 
Endocrinology, Ed. James, V.H.T. p.111-138.
Edinburgh and London: Churchill, 1968.
146. Marks, V.
"The biological significance of the insulinotropic 
effect of glucagon in man"
Acta Isotopica, 10, 1970 > 219-227.
147. Majid, P.A., Saxton, C., Dykes, J.A ,W. , Galvin, M.C. 
and Taylor, S.H.
"Autonomic control of insulin secretion and the 
treatment of heart failure"
Brit.Med.J., 4, 1970, 328-334.
148. Samols, E., Tyler, J.M. and Kajinuma, H.
"Influence of the sulfonamides on pancreatic humoral 
secretion and evidence for an insulin-glucagon feedback 
system"; In: Proceedings of the VII Congress of the 
International Diabetes Federation. International 
Congress Series no.231, p.636-655. Amsterdam:
Excerpta Medica, 1971.
149. Josefsberg, Z., Flatau, E., Doron, M. and Laron, Z.
"The influence of oral glucose loading on the insulin 
response to i.v. glucagon in children and adolescents" 
Metabolism, 25, 1976, 277-280.
191
150. Garcia, M.J. , Czerv/inski, G. , De Santis, R, , Lan, V.V. 
and Ramey, E.
"Hyperglycaemic and insulinogenic effects of intravenous 
glucagon of different blood glucose levels"
Proc.Soc.Exp.Med., 143, 1973, 707-710.
151. Scino, Y., Taminato, T., Inoue, Y., Goto, Y. , Ikeda, M. 
and Imura, H.
"Xylitol: stimulation of insulin and inhibition of 
glucagon responses to arginine in man"
J.Clin.Endocrinol.Metab., 4^, 1976, 736-743.
152. Kuo, W.N., Hodgins, D.S. and Kuo, J*F,
"Adenylate cyclase in islets of Langerhans. Isolation 
of islet and regulation of adenylate cyclase activity 
by various hormones and agents"
J.Biol.Chem., 248, 1973, 2705-2711.
153. Charles, M.A., Fanska, R., Schmid, F.G., Forsham, P*H. 
and Crodsky, G.M.
"cAMP in pancreatic islets: glucose-induced insulin release" 
Science, 179, 197 3, 569-571.
154. Malaisse, WoJ.
"IV;- Participation of adenylate cyclase system" In:
Insulin II. Ed. Hasselblatt, A. and Birchhausen" p.139 
Springer-Verlag, Berlin, Heidelberg, New York, 1975.
155. Scian, L.E., Westermann, C.D., Verdesca, A.S. and 
Hilton, J.G.
"Adrenocortical and medullary effects of glucagon" 
Am.J.Phsyiol., 199, I960, 867-870.
192
156. Mulvehill, J.B., Hui, Y.S., Barnes, L.D. , Palumbe, P.J. 
and Dousa, T.P.
"Glucagon-sensitive adenylate cyclase in human renal 
medulla"
J.Clin.Endocrinol.Metab., 43^ 1976, 380-384.
157. Kuschke, H,J., Klusmann, H. and Schoelkens, B.
"Effect of glucagon on the human sympathetic-adrenal 
system"
Klin.Wochenschr., 44, 1966, 1297-1300.
158. Siqueira-Filho, Aristarco, G., Shapps, S.G., Maher, F.T.,
Jiang, N.S. and Elveback, L.R.
"Glucagon-blood catecholamine test: use in isolated and
familial pheochromocytoma"
Arch.Intern.Med., 135, 1975, 1227-1231 (Abstract)
159. Lawrence, A.M.
"Glucagon provocative test for pheochromocytoma"
Ann.Intern.Med., 66, 1967, 1091-1096.
160. Foa, P.P., Galansino, G. and Pozza, G.
"Glucagon, a second pancreatic hormone" 
Rec.Progr.Horm.Res., 13, 1957, 473-503.
161. Samols, E., Tyler, J., Marri, G. and Marks, V. 
"Stimulation of glucagon secretion by oral glucose" 
Lancet, ii, 1965, 1257-1259.
162. Müller, W.A., Faloona, G.R., Aguilar-Paradav F. and 
Unger, R.H.
"Abnormal alpha-cell function in diabetes response 
to carbohydrate and protein ingestion"
New Engl.J.Med., 283, 1970, 109-115.
193 / .
163. Edwards, J.C., Howell, S.L. and Taylor, K.W.
"Fatty acids as regulators of glucagon secretion"
Nature, 224, 1969, 808-809.
164. Edwards, J.C. and Taylor, K.W.
"Fatty acids and the release of glucagon from isolated 
guinea-pig islets of Langerhans incubated in vitro" 
Biochim.Biophys.Acta, 215, 1970, 310-315.
165. Madison, L.L., Seyffert, W.A. Jr., Unger, R.H. and 
Barker, B.
"Effect of plasma free fatty acids on plasma glucagon 
and serum insulin concentrations"
Metabolism, 17, 1968, 301-304.
166. Gross, R. and Mialhe, P.
"Free fatty acid-glucagon feedback mechanism"
Diabetologia, 10, 1974, 277-283.
167. Assan, R., Rosselin, G. and Dolais, J.
"Glucagonemile des perfusions et ingestions d 'acides amines" 
J.Am.Diabetol. Hotel-Dieu, 7,' 1967, 25-41 (Abstract)
168. Rocha, D,, Faloona, G.R. and Unger, R.H.
"Glucagon-stimulating activity of twenty amino acids 
in dogs"
J.Clin.Invest., 51, 1972, 2346-2351.
169. Müller, W.A. , Aoki, T.T. and Cahill, G.F.
"Effect of alanine and glycine on glucagon secretion 
in postabortive and fasting obese man"
J.Clin.Endocrinol.Metab., 40, 1975, 418-425.
170. Gerich, J.E., Langlois, M., Noacco, C., Schneider, V. and 
Forsham, P.H.
"Adrenergic modulation of pancreatic glucagon secretion in ma 
J.Clin.Invest., 53, 1974, 1441-1446.
194
171. Iversen, J.
"Adrenergic receptors and the secretion of glucagon and 
insulin from the isolated perfused canine pancreas" 
J.Clin.Invest., 52, 1973, 2102-2106.
172. Gerich, J.E., Karam, J.H. and Forsham, P.H,
"Stimulation of glucagon secretion by epinephrine in man" 
J,Clin.Endocrinol.Metab., 22' 197 3,479-480.
173. Unger, R.H., Ketterer, H. , Dupre, J. and Eisentraut, A. 
"The effect of secretin, pancreozymin and gastrin on 
insulin and glucagon secretion in anesthetized dogs" 
J.Clin.Invest., 46, 1967, 630-645.
174. Santeusanio, F., Faloona, G.R. and Unger, R.H. 
"Suppressive effect of secretin upon pancreatic alpha­
cell function"
J.Clin.Invest., 51, 1972, 1743-1749.
175. Iversen, J.
"Secretion of glucagon from the isolated, perfused 
canine nancreas"
J.Clin.Invest., 50, 1971, 2123-2136.
176. Weir, G., Knowlton, S. and Martin, D.
"Somatostatin inhibition of epinephrine-induced 
glucagon secretion"
Endocrinology, 92' 1974, 1744-1746.
177. GoIdfine, I.D., Kirsteins, L. and Lawrence, AoM, 
"Excessive glucagon responses to arginine in active 
acromegaly"
Horm.Metab.Res., 4, 1972, 97-100. \
- 195
178. Seino, Y., Goto, Y., Taminato, T., Ikeda, M. and 
Imura, H.
"Plasma insulin and glucagon responses to arginine 
in patients with, thyroid dysfunction"
J.Clin.Endocrinol.Metab., 38, 1974,1136-1140.
179. Marco, J., Calle, C., Roman, D., Diaz-Fierros, M., 
Villaneuve, M.L. and Valverde, I.
"Hyperglucagonism induced by glucocorticoid treatment 
in man"
New Engl.J.Med., 288, 1973, 128-131.
180. Sokal, J.E.
"Bioassay: glucagon" In: Methods in investigative and 
diagnostic endocrinology, Ed, Berson, S.A. and Yalow, R.S. 
Vol.2B, part III, 913-918.
Amsterdam and London: North-Holland Publishing Company, 197 3
181. Staub, A. and Behrens, O.K.
"The glucagon content of crystalline insulin preparations" 
J.Clin.Investi, 33.' 1954, 1929-1933.
182. Vuylsteke, C.A. and De Duve, C.
"The assay of glucagon on isolated liver slices"
Arch.Internat.Pharmacodyn., Ill, 1957, 437-469.
183. Berthet, J., Sutherland, E.W. and Rail, T,W.
"The assay of glucagon and epinephrine with use of 
liver homogenates"
J.Biol.Chem., 229, 1957, 351-361.
184. Sokal, J.E.
"Bioassay of glucagon using the isolated perfused rat liver" 
Endocrinology, 87, 1970, 1338-1345.
■ .196
185. Tomasi, V.Koretz, S., Ray, T.K., Dannick, J. and 
Marinetti, G.V.
"Hormone action of the membrane level. II. The binding 
of epinephrine and glucagon to the rat liver plasma 
membrane"
Biochim.Biophys.Acta, 211, 1970, 31-42.
185. Giorgio, N.A., Johnson, C.B. and Blecher, M.
"Hormone receptors. III. Properties of glucagon- 
binding proteins isolated from liver plasma membranes" 
J.Biol.Chem., 249, 1974, 428-443.
187. Freychet, P.
"Interactions of polypeptide hormones with cell membrane 
specific receptors: studies with insulin and glucagon" 
Diabetologia, 12, 1976, 83-100.
188. Yalow, R.S. and Berson, S.A,
"Assay of plasma insulin in human subjects by 
immunological methods"
Nature, 184, 1959, 1648-1649.
189. Berson, S.A. and Yalow, R.S.
"Isotopic tracer in the study of diabetes"
Adv.Biol.Med.Phys. , 6./ 1958, 349-430.
190. Ekins, R.P.
"The estimation of thyroxine in human plasma by an . 
electrophoretic technique"
Clin.Chim.Acta, 1960, 453-459.
191. Greenwood, F.C., Hunter, W.M. and Glover, J.S. .
131"The preparation of I -labelled human growth 
hormone of high specific radioactivity"
Biochem.J., 89, 1963, 114-123.
197
192. Berson, S.A. and Yalow, R.S.
"Quantitative aspects of the reaction between insulin 
and insulin-binding antibody"
J.Clin.Invest., 38, 1959, 1996-2016.
193. Chard, T.
"Observations on the uses of a mathematical model in 
radioimmunoassay" In: Radioimmunoassay methods, Ed.
Kirkhara, K.E. and Hunter, W.M. p.595 
London: Churchill Livingstone, 1971.
194. Hum, B.A.L. and Landon, J.
"Antisera for radimmunoassay" In: Radioimmunoassay 
methods, Ed. Kirkham, K.E. and Hunter, W.M. P.121-142. 
London: Churchill Livingstone, 1971.
195. Yalow, R.S.
"Radioimmunoassay methodology"
Pharmac.Rev., 25, 1973, 161-178.
196. Unger, R.H., Eisentraut, A.M., McCall, M.S., Keller, S., 
Lanz, H.C. and Madison, L.L.
"Glucagon antibodies and their use for immunoassay 
for glucagon"
Proc. Soc.Exptl.Biol.Med., 102, 1959, 621-623.
197. Faloona, G.
"Radioimmunoassay: glucagon and GLI" In: Methods in 
Investigative and Diagnostic Endocrinology, Ed.
Berson, S.A. and Yalow, R.S. Vol.2B, Part III, 919-924. 
Amsterdam and London: North-Holland Publishing Company, 1973
198. Buchanan, K.D.
In "Radioimmunoassay methods" Ed. Kirkham, K.E. and 
Hunter, W.M. p.172 "
London: Churchill Livingstone, 1971.
198
199. Heding, L.G.
"Radioimmunological determination of pancreatic and 
gut glucagon in plasma"
Diabetologia, 7, 1971, 10-19.
200. MarchaIonis, J.J.
"An enzymic method for the trace iodination of immuno­
globulins and other proteins"
Biochem.J., 113, 1969, 299-305.
201. Holohan, K,N., Murphy, R.F., Buchanan, K.D. and 
Elmore, D.T.
"Enzymic iodination of polypeptide hormones for radio­
immunoassay"
Clin.Chim.Acta, 45, 1973, 153-157.
202. Von Schenck, H., Larsson, I, and Thorell, J.I.
"Improved radioiodination of glucagon with the lacto- 
peroxidase method. Influence of pH on iodine substitution" 
Clin.Chim.Acta, 69, 1976, 225-232.
203. Unger, R.H., Eisentraut, A.M., McCall, M.S. and 
Madison, L.L.
"Glucagon antibodies and an immunoassay for glucagon" 
J.Clin.Invest., 40, 1961, 1280-1289.
204 Unger, R.H., Eisentraut, A.M. and Madison, L.L.
"The effects of total starvation upon the levels of
circulating glucagon and insulin in man"
J.Clin.Invest.,42, 1963, 1031-1039.
205. Hazzard, W.R., Crockford, P.M., Buchanan, K.D.,
Vance, J.G., Chen, R. and Williams, R.H.
"A double antibody immunoassay for glucagon"
Diabetes, 17, 1968, 179-186.
199
205. Nonaka, K. and Foa, P.
"A simplified glucagon immunoassay and its use in a 
study of incubated pancreatic islets"
Proc.Soc.Exptl.Biol.Med., 130, 1968, 330-336.
207. Leclerco-Meyer, V., Miahle, P. and Malaisse, W.J. 
"Dextran-coated radioimmunoassay of glucagon"
Diabetologia, 6, 1970, 121-129.
208. Bilbrey, G.L., Faloona, G.R., White, M.G., Atkins, C., 
Hull, A.R. and Knochel, J.P,
"Hyperglucagonaemia in uremia: reversal by renal 
transplantation"
Ann, Intern.Med. , 82,' 1975, 525-528.
209. Kuku, S.F., Jaspen, J.B., Emmanouel, D.S., Zeidler, A., 
Katz, A.I. and Rubenstein, A.H.
"Heterogeneity of plasma glucagon: circulating 
components in normal subjects and patients with chronic 
renal failure”
J.Clin.Invest., 58, 1976, 742-750.
210. Unger, R.H., Aguilar-Parada, E., Müller, W.A. and 
Eisentraut, A.M.
"Studies of pancreatic alpha cell function in normal 
and diabetic subjects" .
J.Clin.Invest., 49, 1970, 837-848.
211. Gerich, J.E.
"Alpha cell function in diabetes mellitus"
Metabolism, Clinical and Experimental, 25.' 1976, 1513-1516
212. Stahl, M., Nars, P.W., Herz, G., Baumann, J.B. and 
Girard, J.
"Glucagon antibodies after long term insulin treatment 
in a diabetic child"
A 1  r\'7 n n n / i o n t r
200
213. Cresto, J., Lavine, R., Perrino, P. and Recant, L.
Letter: "Glucagon antibodies in diabetic patients"
Lancet, 2' 1974, 1155.
214. Jaspan, J.B., Kuku, S.F., Locker, J.D, Huen, A.H.J., 
Emmanouel, D.S.,-Katz, A.I. and Rubenstein, A.H. 
"Heterogeneity of plasma glucagon in man"
Metabolism, 25. (Suppl.l), 1976, 1397-1401.
215. Baba, S., Morita. S., Mizuno, N. and Okada, K.
Letter: "Auto-immunity to glucagon in a diabetic 
not on insulin"
Lancet, ii, 1976, 585.
216. Ensinck, J.W. and Palmer, J.P.
"Dominant inheritance of large molecular weight 
species of glucagon"
Metabolism, 25. (Suppl.l), 1976, 1409-1411.
217. Boden, G. and Owen, D.
"Familial hyperglucagonemia - an autosomal dominant 
disorder"
New Engl.J.Med., 296, 1977, 534-538.
218. Grodsky, G.M., Hayashida, T., Peng, C.T. and Geshwind, I.I 
"Production of glucagon antibodies and their role in 
metabolism and immunoassay of glucagon"
Proc.Soc.Exp.Biol.Med., 107, 1961, 491-494. '
219. Assan, R., Rosselin, G., Drouet, J., Dolais, J. and 
Tchobroutsky, G.
Letter: "Glucagon antibodies"
Lancet, ii, 1965, 590-591.
201
220. Grey, N., McGuigan, J.E. and Kipins, D.M.
"Neutralization of endogenous glucagon by high titre 
glucagon antiserum"
Endocrinology, 86.' 1970, 1383-1388.
221. Holst, J.J. and Aasted, B.
"Production and evaluation of glucagon antibodies for 
radioimmunoassay"
Acta Endocrinologie, 22' 1974, 715-726.
222. Vaitukaitis, J,, Robbins, J.B., Nieschlag, E. and Ross, T. 
"A method for producing specific antisera with small 
doses of immunogen"
J.Clin.Endocrinol., 33, 1971, 988-991.
223. Scaramuzzi, R.J., Corker, C.S., Young, G. and Baird, D.T. 
"Production of antisera to steroid hormones in sheep"
In; Steroid Immunoassay. Proceedings of the Fifth Tenovus 
Workshop, Cardiff, April 1974. Ed. Cameron, E.H.D.,
Hillier, S.G. and Griffiths, K., p.111-122.
Cardiff: Alpha Omega Publishing Ltd., 1975.
224. Buchanan, K.D.
Personal communication, 1975.
225. Teale, J.D., Forman, E.J., King, L.J., Piall, E.M. 
and Marks, V.
"The development of a radioimmunoassay for cannabinoids 
in blood and urine"
J.Pharm.Pharmac., 27, 1975, 465-472.
226. Collip, P.J., Kaplan, S.A., Boyle, D.C. and Shimizu, C.S.N, 
"^^C-acetyl bovine growth hormone"
J.Biol.Chem., 240, 1965, 143-147.
202
227. Holian, J.
In Radioimmunoassay Methods. Ed. Kirkham, K.E. and 
Hunter, W.M., p.64.
London: Churchill Livingstone, 1971.
228. Bolton, A.E. and Hunter, W.M.
"The labelling of proteins to high specific radioactivities
125by conjugation to a I-containing acylating agent" 
Biochem.J., 133, 1973, 529-539.
2 29. Desbuquois, B.
"lodoglucagon: preparation and characterisation"
Eur.J.Biochem., 53, 1975, 569-580.
230. Thorell, J.I. and Johansson, B.C.
"Enzymatic iodination of polypeptides with ^^^I to 
high specific activity"
Biochim.Biophys.Acta, 251, 1971, 363-369.
231. Rosa, U., Scassellati, G.A., Pennisi, F., Riccioni, N., 
Giagnoni, P. and Giordani, R.
Tj O 1
"Labelling of human fribrogen with I by electrolytic 
iodination"
Biochim.Biophys.Acta, 86, 1964, 519-526.
232. Hunter, W.M. and Greenwood, G.C.
131
"Preparation of I-labelled human growth hormone of 
high specific activity" ’
Nature, 194, 1962, 495-496.
233. Hunter, W.M.
"Radioimmunoassay" In: Handbook of Experimental Immunology, 
Vol.1, Immunochemistry, Second edition. Ed. Weir, D.M. 
p. 17.1-17.36.
Oxford: Blackwell Scientific Publications, 1973.
203
234. Hunter, W.M.
"The preparation and assessment of iodinated antigens"
In: Radioimmunoassay Methods, Ed. Kirkham, K.E. and 
Hunter, W.M. , p.43.
London: Churchill Livingstone, 1971.
235. Jorgensen, K.H. and Larsen, U.D.
125"Purification of I-glucagon by anion exchange 
chromatography"
Horm.Metab.Res., 4, 1974, 223-224.
236. Wright, A.D. and Taylor, K.W.
"Immunoassay of hormones" In: Hormones in Blood, Vol.l 
second edition. Ed. Gray, C.H. and Bacharach, A.L., p.23—45. 
London and New York: Academic Press, 1967.
237. Ray, T.K.
"A modified method for the isolation of plasma membrane 
from rat liver"
Biochim.Biophys.Acta, 196, 1970, 1-9.
238. Mahmood, Hi, Wood, P.J. and Marks, V.
1978, in press.
239. Goldfine, I,D., Roth, J. and Birnbaumer, L.
"Glucagon and receptors in S-cells"
J.Biol.Chem., 247, 1972, 1211-1218. '
240. The Radiochemical Centre Manual 
Ed. Wilson, B.
Published by The Radiochemical Centre, Amersham, 1966.
241. Hales, C.N. and Randle, P.J.
"Immunoassay of insulin with insulin-antibody precipitate" 
Biochem.J., 88, 1963, 137-146.
204
242. Scatchard, G.
"The attraction of proteins for small molecules and ions" 
Ann.N.Y.Acad.Sci., 51, 1949, 660-572.
243. Feldman, H.A.
"Mathematical theory of complex ligand-binding systems 
at equilibrium: some methods for parameter fitting" 
Anal.Biochem., 1972,317-338.
244. Weder, H.G., Schildknecht, J., Lutz, R.A. and 
Kesselring, P.
"Determination of binding parameters from Scatchard 
plots. Theoretical and practical considerations.
Eur.J.Biochem., 42, 475-481.
245. Ekins, R.P., Newman, G.B. and O'Riordan, J.L.H. 
"Theoretical aspects of 'saturation' and radioimmunoassay" 
In: Radioisotopes in medicine: in vitro studies, Ed.
Hayes, R.L., Goswitz, F.A. and Murphy, B.E.P., p.59.
U.S. Atomic Energy Commission, Oak Ridge, Tenn.,1968.
246. Ekins, R.P.
"Mathematical treatment of data" In: Radioimmunoassay 
Methods, Ed. Kirkham, K^E. and Hunter, W.M., p.607.
London: Churchill Livingstone, 1971.
247. Okuda, T. and Grollman, A.
"Action of neutral red on the secretion of glucagon 
and glucagon metabolism in the rat"
Endocrinology, 78, 1966, 195_203.
248. Lundqvist, G., Edwards, J. and Wide, L.
"A solid phase radioimmunoassay for pancreatic glucagon" 
Uppsala J.Med.Sci., 81, 1976, 65-69.
\/205 y
249. Beck, P. and Hales, C.N.
"Immunoassay of serum polypeptide hormones by using 
I-labelled anti-(immunoglobulin G) antibodies" 
Biochem.J., 145, 1975, 607-616.
250. Blecher, M.
"A fluorometric method for the determination of 2-deoxy 
D-glucose"
Anal.Biochem., 2' 1961, 30-38.
251. Scott, W.A. and Mahoney, E.
"Defects of glucose-6-phosphate and 6-phosphogluconate 
dehydrogenases in neurospore and their pleiotropic 
effects" In: Current Topics in Cellular Regulation, 
Vol.10, Ed. Horecker, B. and Stadtman, E.R.
New York, Academic Press, 1976.
252. Pegg, P.J. and Keane, P.M.
"The simultaneous estimation of plasma cortisol and 
transcortin binding characteristic by a competitive 
protein binding technique"
Steroids, 14, 1969, 705-715.
253. Adachi, S.
"Thin-layer chromatography of carbohydrates in the 
presence of bisulfite"
J.Chromatog., 17, 1965, 295-299.
254. Siegel, S.
"Non-parametric statistics"
New York: McGraw Hill, 1955.
255. Heilman, B.
"Calcium and pancreatic B-cell function" 
Biochim.Biophys.Acta, 497, 1977, 766-774.
206
256. Williams, B.J. , Griffith, W.H. and Albrecht, M.
"The protective effect of phentolamine against cardiac 
arrhythmias in the rat"
Europ.J.Pharmacol,. , 49, 1978, 7-14.
257. Abdullah, A.H., Roby, D.M. , Boeckler, W.H. and 
Riley, C.C.
"Role of dopamine in the anorexgenic effect of 
DITA; comparison with d-amphetamine"
Europ.J.Pharmacol., 4^, 1976, 39-44.
258. Lewis, G.P. and Westwick, J.
"The effect of sulphinpyrazone, sodium aspirin and 
oxprenolol on the formation of arterial platelet thrombi. 
Brit.J.Pharmac., 55, 1975, 255P-256P.
259. Birmingham, A.T., Fentem, P.H., Yates, D. and Yates, J. 
"Cardiovascular responses of the anaesthetised cat to 
lower body negative pressure"
Brit.J.Pharmac., 55, 1975, 246P.
260. Fügner, A.
"Antagonism of the drug induced behavioural sleep 
in chicks"
Arzheim.-Forsch. 1971, 1350-1352.
261. Stjdrne, L. and Lishajko, F.
"Drug-induced inhibition of noradrenaline synthesis 
in vitro in bovine splenic nerve tissue"
Brit.J.Pharmacol.Chemother., 27.' 1966, 398-404 (Abstract).
262. Christensen, H.N., Heilman, B., Lernmark, A., Schlin, J. , 
Tager, H.S., Tdljedal, I.B.
"In vitro stimulation of insulin release by non-metabolizable 
transport-specific amino acids"
Biochim.Biophys.Acta, 241, 1971, 341-348.
207
263. Milner, R.D.
"The stimulation of insulin release by essential amino 
acids from rabbit pancreas in vitro"
J.Endocrinol. , 47.' 1970, 347-356.
264. Ellis, S.
"The effects of sympathomimetic amines and adrenergic 
blocking agents on metabolism" In: Physiological 
Pharmacology, Vol.IV, ed. Root, W. and Hofmann, E.G. 
New York and London: Academic Press, 1963.
265. Hawkins, R.D. and Haist, R.E.
"The effect of adrenalectomy, dihydroergofamine, and 
dibenzyline on the sensitivity of rats to tolbutamide" 
Can.J.Biochem.Physiol-, 41, 1963, 2189-2195.
Reproduced with permission of copyright owner. Further reproduction prohibited without permission.
